gemcitabine has been researched along with Adenocarcinoma in 1486 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 37 (2.49) | 18.2507 |
| 2000's | 553 (37.21) | 29.6817 |
| 2010's | 761 (51.21) | 24.3611 |
| 2020's | 135 (9.08) | 2.80 |
| Authors | Studies |
|---|---|
| Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU | 1 |
| Bai, C; Chen, J; Chen, Y; Chong, C; Ding, Y; Gao, Y; Geng, Y; Li, J; Wang, M; Wu, L; Yu, J; Zhang, Q | 1 |
| Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q | 1 |
| Chambers, CR; Chen, A; Ghosh, S; Ha, VH; Sawyer, MB | 1 |
| Kaneyasu, T; Morimoto, K; Moriwaki, K; Nakayama, H; Shimozuma, K | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Bauer, K; Henne-Bruns, D; Manzini, G | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Li, N; Qi, Y; Yu, D; Zhan, J; Zhang, G; Zhao, Q | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Allard, J; Bonnet, M; Bouattour, M; Gagaille, MP; Laurent, L; Leclerc, V | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Chen, T; Geng, Y; Gu, Y; Li, Y; Liu, K; Sun, L; Wang, L; Wu, S; Xu, F; Xu, H; Zhao, Z; Zou, M | 1 |
| Chen, JA; Gandara, DR; Huynh, JC; Kelly, KL; Kim, EJ; Li, T; Mack, PC; Mahaffey, N; Martinez, A; Matsukuma, K; Riess, JW; Semrad, TJ; Tam, K; Wu, CY; Yu, AM | 1 |
| Cai, Z; Cao, D; Chang, C; Cheng, K; Li, R; Li, X; Lv, W; Xiong, J; Zhang, P | 1 |
| Bai, X; Chen, W; Gao, S; Huang, B; Lao, M; Liang, T; Ma, T; Que, R; Shui, Y; Wang, J; Wei, Q; Zhang, Y | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Aucoin, N; Couture, F; Du, P; Gill, S; Harb, M; Jia, S; Jonker, D; Kavan, P; Kim, CA; Knox, JJ; Ko, YJ; Lemay, F; Loree, JM; Meyers, BM; O'Callaghan, CJ; Ramjeesingh, R; Renouf, DJ; Schaeffer, DF; Tang, PA; Tehfe, M; Topham, JT; Tu, D; Welch, S | 1 |
| Bertram, M; Binninger, A; Chiabudini, M; Hegewisch-Becker, S; Hollerbach, SH; Jänicke, M; Kaiser-Osterhues, A; Kreher, S; Marschner, N; Reiser, M; von der Heyde, E; Wolf, T | 1 |
| Jusko, WJ; Kandel, ES; Lin, Q; Qian, Z; Qu, J; Rasam, SS; Serratore, A; Shen, S; Straubinger, RM | 1 |
| Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR | 1 |
| Jiang, Y; Sohal, DPS | 1 |
| Goršić, I; Kekez, D; Librenjak, N; Pleština, S; Prejac, J; Tomek Hamzić, D | 1 |
| Allen, M; Biagi, J; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Grant, RC; Hutchinson, S; Jang, GH; Kelly, D; Knox, JJ; Lam, B; Notta, F; O'Kane, GM; Perera, S; Ramjeesingh, R; Ramotar, S; Tehfe, M; Wang, Y; Wilson, J; Zhang, A; Zogopoulos, G | 1 |
| Abdiannia, M; Acharya, A; Aranha, O; Belle, JI; Bogner, SJ; Boice, N; Breden, M; Brown, A; DeNardo, DG; Gao, F; Hawkins, WG; Herndon, J; Herzog, BH; Lim, KH; Lockhart, AC; McWilliams, R; Pedersen, K; Ratner, L; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A; Yoon, HH; Zhu, M | 1 |
| Amin, MA; Der, CJ; Grierson, PM; Knoerzer, D; Kreider, B; Lim, KH; Liu, J; Park, H; Pedersen, KS; Reddy, A; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Couturier, F; Graff, V; Herrscher, H; Moussouni, M | 1 |
| Chanez, B; Dusetti, NJ; Fraunhoffer, N; Iovanna, JL; Mitry, E; Teyssedou, C | 1 |
| Balconi, F; Berardi, R; Cimbro, E; Donisi, C; Giampieri, R; Lai, E; Lupi, A; Murgia, S; Pecci, F; Persano, M; Pozzari, M; Pretta, A; Pusceddu, V; Puzzoni, M; Scartozzi, M; Spanu, D; Ziranu, P | 1 |
| Betts, C; Bridge, M; Chen, B; Cheung, A; Coussens, LM; Crocker, M; Dragomanovich, H; Fahlman, A; Fong, L; Griffith, MJ; Lerner, K; Liu, E; Lopez, CD; Marquez, J; Pener, D; Rajagopalan, B; Sinha, M; Sivagnanam, S; Solman, I; Stultz, J; Sudduth-Klinger, J; Taber, E; Tamaki, W; Tempero, M; Todd, K; Vaccaro, G; Vo, J; Ware, C; Zhang, L | 1 |
| Arlen, P; Basu Mallick, A; Beg, MS; Cleary, JM; Horick, NK; Hosein, PJ; Huffman, BM; Lacy, J; Manz, C; Mavroukakis, S; Morse, MA; Murphy, JE; Sanoff, H; Schlechter, BL; Wang-Gillam, A; Wolpin, BM; Zaki, A | 1 |
| Aprile, G; Bergamo, F; Bernardini, I; Bozzarelli, S; Cardellino, GG; Cavanna, L; Cordio, S; De Simone, I; Di Marco, MC; Ghidini, M; Giommoni, E; Macchini, M; Maiello, E; Milella, M; Orsi, G; Pinto, C; Porcu, L; Reni, M; Rulli, E; Spada, M; Torri, V | 1 |
| Gao, W; Han, D; Huang, H; Li, X; Li, Z; Liu, L; Peng, C; Yu, X; Zhang, X; Zhu, H | 1 |
| Manji, GA | 1 |
| Chen, S; Chen, Y; Dong, A; Jin, M; Li, J; Liu, Z; Peng, Z; Wang, Y; Wei, G; Wu, S; Zhu, M | 1 |
| Furuya, N; Hamada, T; Ito, T; Kato, N; Kido, M; Kohno, H; Kouno, H; Kuraoka, K; Kusunoki, R; Kuwai, T; Mizumoto, T; Sugata, S; Tamaru, Y; Yamaguchi, A | 1 |
| Bhargava, P; Das, S; Kannan, S; Ostwal, V; Ramaswamy, A; Shah, D; Shah, M; Srinivas, S; Suman, M; Trikha, M | 1 |
| Ch'ang, HJ; Chen, JS; Chen, LT; Chiu, YF; Ho, CL; Hsieh, RK; Hwang, TL; Li, CP; Liu, TW; Shan, YS | 1 |
| Fujisawa, T; Fukuma, T; Fukumura, Y; Isayama, H; Ishii, S; Ito, K; Nagahara, A; Suzuki, A; Takahashi, S; Takasaki, Y; Tomishima, K; Ushio, M; Yao, T | 1 |
| Amador, Y; Arguelles, O; Concepción, ML; Guerra, PP; Leblanch, L; Leyva, A; Martorell, B; Moret, S; Piriz, A; Rabassa, R; Rivero, G; Sánchez, L; Sánchez, Y; Saumell, Y; Valls, AR; Vasallo, AL | 1 |
| Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Chang, A; Ding, J; Feng, Y; Fu, D; Gao, C; Gao, S; Hao, J; Huang, C; Liu, J; Liu, Y; Ma, X; Ma, Y; Tang, B; Wang, H; Wang, X; Yan, J; Yang, S; Zhang, Z; Zhao, R; Zhao, T | 1 |
| Hei, Y; Hou, D; Tian, S; Wang, B; Wang, F; Wang, Y; Xu, X; Zhang, J; Zhang, Y | 1 |
| Chen, G; Cheng, H; Deng, T; Gong, P; Jiang, S; Liu, W; Ma, L; Shi, D; Zhang, X | 1 |
| Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L | 1 |
| Chen, B; Cheng, H; Deng, T; Gong, P; He, Z; Jiang, S; Liu, W; Ma, L; Shi, D; Wang, W; Yuan, J; Zhang, X | 1 |
| Bai, C; Cheng, Y; Tang, H; Wang, X; Wang, Y; Ying, J; Zhu, Z | 1 |
| Bridgewater, JA; Cubillo, A; Hédouin-Biville, F; Macarulla, T; Palmer, DH; Prager, GW; Reni, M; Seufferlein, T; Taieb, J; Teng, Z; Vermeire, A | 1 |
| Borbath, I; Bouchart, C; Closset, J; Demetter, P; Geboes, K; Moretti, L; Navez, J; Paesmans, M; Van Laethem, JL; Vandamme, T | 1 |
| Bal, M; Bhandare, M; Chaudhari, V; Chavan, N; Kataria, P; Majumdar, S; Mandavkar, S; Ostwal, V; Ramaswamy, A; Rohila, J; Shrikhande, SV; Shrirangwar, S; Swami, R | 1 |
| Berlin, J; Carrero, X; Deshpande, V; Evans, DB; Goff, LW; Kindler, HL; Merchant, N; Meyerhardt, J; Misdraji, J; Moore, M; Newman, E; O'Reilly, EM; Ou, FS; Pisters, P; Posner, MC; Sahani, D; Shi, Q; Tamm, E; Wei, AC; Wolff, RA | 1 |
| Schwartz, PB; Uboha, NV; Weber, SM | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Feng, M; Hu, Y; Liu, C; Wang, X; Xiong, G; Xu, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L; Zhou, L | 1 |
| Alekhina, O; Billadeau, DD; Ding, L; Dube, J; Dutta, SK; Giles, FJ; Kiers, S; Kozikowski, AP; Madamsetty, VS; Mazar, AP; Mukhopadhyay, D; Schmitt, DM; Ugolkov, A; Wang, E; Zhang, JS; Zhang, Y | 1 |
| Banerjee, RK; Caulfield, TR; Dutta, SK; Huang, HS; Madamsetty, VS; Mody, K; Mukhopadhyay, D; Pal, K; Thompson, JR; Wang, E; Yen, Y | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Kubo, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B | 1 |
| Bhatnagar, S; Deo, SV; Iyer, VK; Kalyan Mohanti, B; Kumar Sahoo, R; Kumar Shukla, N; Kumar, R; Kumar, S; Mishra, S; Pal Chaudhary, S; Pal, S; Pathy, S; Raina, V; Ranjan Dash, N; Sahni, P; Sharma, A; Sreenivas, V; Thulkar, S | 1 |
| Bami, H; Boldt, G; Goodman, C; Vincent, M | 1 |
| Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z | 1 |
| Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
| Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C | 1 |
| El Hassouni, B; Giovannetti, E; Immordino, B; Mantini, G; Peters, GJ | 1 |
| Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Bjånes, TK; Cros-Perrial, E; Jordheim, LP; Kamceva, T; Kotopoulis, S; Langer, A; McCormack, E; Riedel, B; Ruiz de Garibay, G; Schjøtt, J | 1 |
| Chen, L; Chen, Z; Cheng, CS; Liu, W; Meng, Z; Tang, W; Zhong, A; Zhou, L | 1 |
| Abrams, RA; Berger, AC; Corn, BW; Crane, CH; DiPetrillo, TA; Fisher, BJ; Gillin, MT; Goodman, KA; Haddock, MG; Jiang, Y; Katz, AW; Lowy, AM; Mehta, S; Philip, PA; Regine, WF; Safran, H; Seaward, SA; Song, S; Willett, CG; Winter, KA; Wu, A | 1 |
| Jia, Y; Liu, B; Ma, J; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xue, L; Yin, X | 1 |
| Aksnes, AK; Amund Eriksen, J; Dueland, S; Faluyi, O; Iversen, B; Jensen Gjertsen, T; Ma, YT; Miller, R; Møller, AS; Neoptolemos, JP; Palmer, DH; Valle, JW | 1 |
| Chen, X; Gao, M; Han, H; Hou, Y; Ji, J; Jin, Q; Kang, M; Zhang, P | 1 |
| Debnath, MC; Ganguly, S; Kazi, J; Mukhopadhyay, R; Paul, B; Sen, R | 1 |
| Dahabreh, IJ; García-Albéniz, X; Hernán, MA; Howlader, N; Logan, RW; Mariotto, AB; Petito, LC | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Buse, JB; Corty, RW; Fine, JP; Langworthy, BW; Lund, JL; Sanoff, HK | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Abu Hilal, M; Al-Sarireh, B; Alseidi, A; Bassi, C; Besselink, MG; Boggi, U; Bolm, L; Bonds, M; Dreyer, SB; Ferraro, D; Fontana, M; Fusai, GK; Halimi, A; Harris, S; Jamieson, NB; Khalil, K; Malleo, G; Mavroeidis, VK; Moekotte, AL; Mortimer, MC; Napoli, N; Primrose, JN; Roberts, KJ; Robinson, S; Salvia, R; Shablak, A; Soonawalla, Z; van Roessel, S; Wellner, UF; White, SA; Wilmink, JW; Zarantonello, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Bottinor, W; Das, S; Nunnery, S | 1 |
| Heneghan, M; Kitagawa, M; Prachalias, A; Srinivasan, P; Suzuki, K; Zen, Y | 1 |
| Chen, SY; Hsu, YH; Lin, JA; Wang, SY; Yen, GC | 1 |
| Fazio, N | 1 |
| Kelsen, DP; O'Reilly, EM; Park, W | 1 |
| Arima, K; Kanda, H; Kato, M; Kitano, G; Masui, S; Nishikawa, K; Nishikawa, T; Owa, S; Sasaki, T; Sugimura, Y; Sugino, Y; Uchida, K; Yoshio, Y | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Aly, A; Botteman, M; Chiorean, EG; Goldstein, D; Lee, CK; Louis, CU; Lu, B; Margunato-Debay, S; McGovern, D; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD | 1 |
| Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Evans, DB | 1 |
| Hines, OJ; Ye, L | 1 |
| Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q | 1 |
| Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C | 1 |
| Arshad, A; Dennison, AR; Isherwood, JD; Jones, DJL; Ng, LL; Runau, F; Sandhu, JK | 1 |
| Dash, AK; Deodhar, S; Hulce, M; North, EJ | 1 |
| Chie, EK; Jang, JY; Kim, BH; Kim, H; Kim, K; Kwon, W; Lee, KB; Lee, KH; Oh, DY | 1 |
| Bendell, J; Berlin, J; Bhargava, P; Brachmann, CB; Chaves, J; Gordon, M; Khan, SA; Liu, J; Patel, MR; Shah, MA; Sharma, S; Starodub, A; Thai, D; Wainberg, ZA; Windsor, KS; Zavodovskaya, M | 1 |
| Cui, C; Feng, Y; Hao, C; Kong, D; Su, H; Tian, X; Xue, J; Yan, L; Yao, Q; Yao, Y; Zhou, T | 1 |
| Arpicco, S; Chegaev, K; Donadelli, M; Fruttero, R; Gazzano, E; Masetto, F; Mullappilly, N; Riganti, C; Rolando, B | 1 |
| Boeck, S; Guenther, M; Haas, M; Heinemann, V; Kirchner, T; Kruger, S; Mayerle, J; Ormanns, S; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Adachi, T; Eguchi, S; Harada, H; Miyazaki, Y; Nagai, K; Sugiyama, H | 1 |
| Ito, K; Kawamoto, Y; Komatsu, Y; Nakano, S; Nakatsumi, H; Saito, R; Sakamoto, N; Yuki, S | 1 |
| Aghmesheh, M; Foroughi, J; Moulton, SE; Piper, AK; Sahin, Z; Talebian, S; Vine, KL; Wade, SJ; Wallace, GG | 1 |
| Al-Batran, SE; Aldaoud, A; Behringer, DM; Bildat, S; Blau, W; Büchner-Steudel, P; Däßler, KU; Dörfel, S; Eschenburg, H; Ettrich, TJ; Feustel, HP; Fietz, T; Forstbauer, H; Gallmeier, E; Götze, TO; Groschek, M; Hahn, L; Harich, HD; Hausen, GZ; Höffkes, HG; Hofheinz, RD; Homann, N; Jacobasch, L; Koenigsmann, M; Kretzschmar, A; Kunzmann, V; Mahlmann, S; Messmann, H; Papke, J; Pauligk, C; Peters, U; Pink, D; Reichart, A; Schaaf, M; Schlag, R; Schönherr, C; Schubert, J; Schuch, G; Schulz, H; Schwindel, U; Siegler, G; Springfeld, C; Stauch, M; Trojan, J; Uhlig, J; Vehling-Kaiser, U; Vogel, A; von Weikersthal, LF; Waibel, K; Waidmann, O; Wehmeyer, J; Weniger, J; Wierecky, J; Wolf, M; Wörns, MA; Zahn, MO | 1 |
| Benkirane-Jessel, N; Chalhoub, S; Fuhrmann, G; Hassan, S; Idoux Gillet, Y; Peluso, J; Rochel, N; Ubeaud-Sequier, G | 1 |
| Cha, J; Hsu, S; Huang, S; Jennings, E; Lee, JB | 1 |
| Armenoult, L; Arsenijevic, T; Augustin, J; Ayadi, M; Bachet, JB; Bigonnet, M; Blum, Y; Cros, J; Dahan, L; de Reyniès, A; Duconseil, P; Dusetti, NJ; Elarouci, N; Emile, JF; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Hammel, P; Iovanna, J; Moutardier, V; Nicolle, R; Puleo, F; Roques, J; Svrcek, M; Van Laethem, JL; Vanbrugghe, C | 1 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Real, FX; Siveke, JT | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Azevedo-Pouly, AC; Brekken, RA; Girard, L; Huang, H; Kantheti, HS; Layeghi-Ghalehsoukhteh, S; MacDonald, RJ; Niederstrasser, H; Ocal, O; Pal Choudhuri, S; Pashkov, V; Posner, BA; Wilkie, TM; Zolghadri, Y | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Chen, Y; Huang, C; Kong, X; Liu, C; Meng, Q; Meng, YM; Qiu, X; Su, L; Wang, M; Wong, PP; Wu, S; Zhao, X | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, SW; Im, SA; Jang, JY; Kim, JH; Kim, JS; Kim, SW; Kim, TY; Kwon, J; Lee, KH; Oh, DY | 1 |
| Choi, MH; Hong, TH; Kim, IH; Lee, IS; Lee, MA | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Hayashi, H; Ishida, M; Kamei, T; Miyazaki, K; Mizuma, M; Morikawa, T; Motoi, F; Nakagawa, K; Ohtsuka, H; Shinoto, M; Takiyama, H; Unno, M; Yamada, S | 1 |
| Hua, YQ; Li, Y; Liu, LM; Ning, ZY; Sheng, J; Shi, WD; Zhang, K | 1 |
| Philip, PA | 2 |
| Goel, A; Okada, Y; Takahashi, N; Takayama, T | 1 |
| Albores-Saavedra, J; Álvarez-Hilario, LG; Ávila-López, PA; Cedillo-Barrón, L; Guerrero, G; Hernández-Montes, G; Hernández-Rivas, R; Herrera-Goepfert, R; Montes-Gómez, AE; Nuñez-Martínez, HN; Peralta-Alvarez, CA; Recillas-Targa, F; Schnoor, M; Vargas, M; Villegas-Sepúlveda, N | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| Aoki, T; Iso, Y; Kubota, K; Matsumoto, T; Mori, S; Park, KH; Sakuraoka, Y; Shimizu, T; Shiraki, T; Yamaguchi, T | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Barrios-Anderson, A; Radhakrishnan, R; Shimanovsky, A; Yu, E | 1 |
| Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK | 1 |
| Gotoda, T; Hemmi, A; Iwatsuka, K; Kikuta, D; Moriyama, M; Nakagawara, H; Ogawa, M; Shibuya, H; Yamao, K | 1 |
| Furukawa, T; Kasuga, A; Kawano, F; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ono, Y; Ozaka, M; Sasahira, N; Sasaki, T; Takahashi, Y; Takamatsu, M; Takeda, T; Yamada, Y | 1 |
| Bae, SB; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MY; Lee, N; Lee, SC; Lee, YN; Lim, SH; Moon, JH; Park, SK; Yun, J | 1 |
| Abuelafia, AM; Bigonnet, M; Chuluyan, E; Cros, J; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Nicolle, R; Palazzo, L; Teyssedou, C | 1 |
| Akshinthala, D; Clohessy, JG; Gaglia, G; Gray, NS; Hidalgo, M; Ke, S; Kibe, S; Kim, N; Koikawa, K; Lee, TH; London, N; Lu, KP; Manz, TD; Muthuswamy, SK; Nakamura, M; Nezu, Y; Oda, Y; Ohuchida, K; Pinch, BJ; Qiu, C; Santagata, S; Sekino, N; Suizu, F; Verma, A; Wegiel, B; Wulf, GM; Zhou, XZ | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Hashimoto, K; Kim, Y; Kobayashi, S; Morimoto, O; Murakami, M; Nakahira, S; Shimizu, J; Sugimoto, K; Takahashi, H; Takeda, Y; Tanemura, M; Tomokuni, A; Tsujie, M; Yamada, D; Yamada, T; Yokoyama, S | 1 |
| Benz, D; Chen, S; Cruise, GM; Lopez-Benitez, R; Wu, X; Wu, Y | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Aguilar-Bonavides, C; Behrens, C; Çeliktas, M; Delgado, O; Dennison, JB; Dhillon, D; Do, KA; Fahrmann, JF; Gazdar, AF; Hanash, SM; Ostrin, EJ; Taguchi, A; Tanaka, I; Tripathi, SC; Villalobos, P; Wang, H | 1 |
| Berlin, J; Engebretson, A; Hong, TS; Katz, MHG; Khorana, AA; Maitra, A; Mangu, PB; Mohile, SG; Mumber, M; Schulick, R; Shapiro, M; Urba, S; Zeh, HJ | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Baechmann, S; Boeck, S; Clemens, MR; Esposito, I; Haas, M; Heinemann, V; Jung, A; Kettner, E; Kirchner, T; Kruger, S; Laubender, RP; Ormanns, S; Quietzsch, D; Remold, A; Schlitter, AM; Siveke, JT; Wenzel, P; Westphalen, CB | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Abou-Khalil, J; Rocha, FG | 1 |
| Jia, L; Li, H; Li, L; Liu, X; Sun, Y; Wu, J; Zhao, L; Zhou, W | 1 |
| Hao, YP; Sun, L; Wang, HY; Wang, L; Zhang, J; Zhu, YP; Zhuang, YP | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Buchy, E; Cayre, F; Couvreur, P; Desmaële, D; Garcia-Argote, S; Mura, S; Pieters, G; Rouquette, M; Sobot, D; Vukosavljevic, B; Windbergs, M | 1 |
| Corr, SJ; Curley, SA; Curtis, LT; Frieboes, HB; Godin, B; Ho, JC; Ware, MJ; Wu, M | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Anile, G; Banna, GL; Castaing, M; Conte, P; Dieci, MV; Guarneri, V; Lal, R; Marletta, F; Nicolosi, M; Parra, HJS; Strano, S | 1 |
| Achiwa, K; Fujita, M; Kataoka, K; Matsubara, H; Minami, Y; Naitoh, T; Urano, F; Yamada, M; Yamamoto, H | 1 |
| Carlan, SJ; Guzman, A; Holloman, C; Madruga, M; Sundharkrishnan, L | 1 |
| Sohal, DPS | 1 |
| Boggi, U; Cernusco, NLV; Coppola, M; Falcone, A; Gonnelli, A; Montrone, S; Morganti, R; Paiar, F; Panichi, M; Pasqualetti, F; Sainato, A; Vasile, E | 1 |
| Bayerl, C; Breitenstein, S; Frei, L; Staerkle, RF; Stieger, R | 1 |
| Dora, CP; Jain, S; Katiyar, SS; Kumar, P; Kushwah, V; Pillay, V; Suresh, S | 1 |
| Benes, C; Gao, P; Gray, NS; Li, F; Li, Y; Liu, F; Liu, Q; Liu, Y; Merlino, AA; Quinn, MM; Wang, X; Wong, KK | 1 |
| Abrego, J; Berim, L; Chaika, NV; Grem, J; Gunda, V; King, RJ; Lazenby, AJ; Sasson, AR; Shukla, SK; Singh, PK; Tadros, S; Vernucci, E; Yu, F | 1 |
| Adamian, Y; Brambilla, D; Gharibi, A; Hong, J; Hoover, M; Kelber, JA; La Kim, S; Lin, J; Molnar, J; Wolfenden, L | 1 |
| Anders, RA; Che, X; Chen, J; Jaffee, EM; Kleponis, J; Muth, S; Rucki, AA; Sharma, R; Xiao, Q; Zheng, L | 1 |
| Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N | 1 |
| Afgar, A; Mahmoodzadeh, H; Radfar, JE; Rajabpour, A; Rajaei, F; Teimoori-Toolabi, L | 1 |
| Gilabert, M; Raoul, JL; Rousseau, F | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Fu, XB; He, JP; Jiao, H; Li, CL; Li, W; Liao, ZY; Liu, XR; Yang, B; Yi, C; You, X; Yuan, ML; Zhao, J | 1 |
| Thomas, H | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Alvarez, R; Caruso, R; Cubillo, A; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ielpo, B; Kalivaci, D; Lazzaro, S; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Beck, J; Blaydorn, L; Bornemann-Kolatzki, K; Khemka, V; Schütz, E; Urnovitz, H; Weiss, GJ | 1 |
| Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM | 1 |
| Fushida, S; Harmon, JW; Hayashi, H; Kishimoto, K; Makino, I; Miyashita, T; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okazaki, M; Tajima, H; Takamura, H; Yamaguchi, T | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Baiu, I; Charville, GW; Visser, BC | 1 |
| Brenner, R; Capanu, M; Chen, AP; Dhani, N; Do, RK; Epstein, AS; Estrella, H; Golan, T; Kelsen, DP; Kindler, HL; Lee, JW; Lowery, MA; Maynard, H; Moore, MJ; O'Reilly, EM; Salo-Mullen, EE; Segal, A; Segal, M; Stadler, ZK; Tang, LH; Yu, KH | 1 |
| Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Egawa, S; Eguchi, H; Fujiki, F; Homma, S; Ishii, J; Ishikawa, T; Ito, K; Kanno, Y; Koido, S; Kokura, S; Kon, M; Kumanogoh, A; Morimoto, S; Morita, S; Nagano, H; Nishida, S; Oba, MS; Oka, Y; Sato, M; Shimada, H; Sugiyama, H; Unno, M; Yanagimoto, H; Yasuda, H | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Hasuo, K; Jin, Y; Kakazu, A; Komori, K; Masuda, M; Mikayama, Y; Watanabe, T | 1 |
| Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
| Ambo, Y; Ando, M; Ebata, T; Fukutomi, A; Hirano, S; Kaneoka, Y; Konishi, M; Nagino, M; Nimura, Y; Ohtsuka, M; Ozawa, F; Shimizu, Y; Tsuchiya, Y; Uesaka, K; Yamamoto, M | 1 |
| Agrawal, N; Arora, A; Baghmar, S; Bihari, C; Chattopadhyay, TK; Kumar, G; Kumar, S; Pamecha, V; Panda, D; Patidar, Y | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Hu, H; Huang, CX; Li, D; Tong, MT; Wang, J; Xing, HB; Zhai, CY | 1 |
| Gao, H; Itkin-Ansari, P; Jakubison, BL; Konieczny, SF; Liu, Y; Moser, SE; Schweickert, PG; Scully, K; Yang, Y | 1 |
| Cassoni, A; Di Benedetto, G; Fadda, MT; Raponi, I; Terenzi, V; Valentini, V | 1 |
| Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E | 1 |
| Bazin, I; Canon, JL; Cubillo, A; Hammel, P; Hidalgo, M; Macarulla, T; Manojlovic, N; Poddubskaya, E; Radenkovic, D; Raymond, E; Schueler, A; Van Cutsem, E; Verslype, C; Zhao, C | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Coe, IR; Karshafian, R; Mariglia, J; Momin, S | 1 |
| Duran, H; Ielpo, B; Quijano, Y; Vicente, E | 1 |
| Abdel-Wahab, R; Bhosale, PR; Fogelman, DR; Javle, M; Overman, MJ; Shroff, RT; Varadhachary, GR; Wang, X; Wolff, RA | 1 |
| Absil, J; Bali, MA; Chao, SL; Marechal, R; Matos, C; Metens, T; Peerboccus, BM; Pullini, S; Van Laethem, JL | 1 |
| Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
| Bernaldo de Quirós Fernández, S; Dunlop, CR; Fornari, C; Jodrell, DI; Johnson, TI; Koh, SB; Lau, A; Richards, FM; Wallez, Y; Yates, JWT | 1 |
| Fung, KP; Han, QB; Lau, CBS; Leung, PC; Leung, PS; Li, L; Pu, JX; Sun, HD; Wong, TP; Yue, GGL; Zhao, SL | 1 |
| Aly, A; Asghari, G; Beale, P; Botteman, M; Clingan, P; Ferrara, S; Harris, M; Mainwaring, P; Margunato-Debay, S; Parnis, FX; Romano, A; Young, R | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| De Haes, P; Morren, MA; Noë, E; Van Cutsem, E; Van den Oord, JJ; Verhulst, L; Verslype, C | 1 |
| Anthony, L; Desimone, P; Dineen, S; Goel, G; Hosein, PJ; Husnain, M; Kudrimoti, M; Loaiza-Bonilla, A; Peterson, SL; Pimentel, A; Pollack, T; Ratermann, K; Tzeng, CD; Westendorf-Overley, C | 1 |
| Bahra, M; Denecke, T; Jühling, A; Klein, F; Pelzer, U; Riess, H; Roemmler-Zehrer, J; Sinn, M; Striefler, J; Wislocka, L | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Ben David, G; Binenbaum, Y; Fridman, E; Gil, Z; Milman, N; Schroeder, A; Shlomi, T; Yaari, Z | 1 |
| Ciesielka, M; Homa-Mlak, I; Kozioł, P; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Bamlet, WR; Bentrem, DJ; Etheridge, AS; Glubb, D; Gordân, R; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, H; McWilliams, RR; Mulkey, F; Nakamura, Y; Neel, N; Niedzwiecki, D; Owzar, K; Petersen, GM; Ratain, MJ; Seiser, E; Sibley, AB; Talamonti, MS; Van Loon, K; Venook, AP; Yeh, JJ | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Borbath, I; Conroy, T; Malka, D | 1 |
| Han, BS; Jang, HY; Kwon, B; Sin, JI | 1 |
| Chiou, SH; Dorsch, M; Grüner, BM; Koong, AC; Kozak, MM; Kusch, E; Naranjo, S; Winslow, MM | 1 |
| Copolla, D; Goyal, G; Kim, J; Kim, R; Kommalapati, A; Mahipal, A; Neuger, A; Soares, H; Tella, SH | 1 |
| Dhir, M; Zureikat, AH | 1 |
| Arlt, A; Deisinger, F; Helm, O; Hesse, L; Kha, ML; Röcken, C; Schäfer, H; Sebens, S; Sipos, B | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Rao, M; Soni, SC; Sureka, B; Varshney, VK | 1 |
| Cao, XY; Hu, LP; Huo, YM; Jiang, SH; Jiang, YS; Li, J; Li, Q; Sun, YW; Tao, LY; Tian, GA; Wang, YH; Xiao, GG; Yang, MW; Yang, Q; Yang, XM; Zhang, XX; Zhang, YL; Zhang, ZG; Zhu, LL | 1 |
| Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Bartsch, JW; Bronsert, P; Conrad, C; Hoeppner, J; Kulemann, B; Lopatta, P; Maurer, J; Nyström, A; Oria, VO; Preca, BT; Schilling, O; Schmitz, T | 1 |
| Cai, YL; Li, J; Shen, ZP; Song, Y; Wu, XD; Zou, L | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Azumi, Y; Fujii, T; Hayasaki, A; Iizawa, Y; Isaji, S; Kato, H; Kishiwada, M; Kuriyama, N; Mizuno, S; Murata, Y; Sakurai, H; Takeuchi, T; Tanemura, A; Usui, M | 1 |
| Buyse, M; Giai, J; Maucort-Boulch, D; Péron, J | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Chang, HL; Chong, IW; Hsu, JF; Lee, YL; Li, CY; Lin, CM; Shen, YT; Wei, PJ; Yang, CJ | 1 |
| Araujo-Gutierrez, R; Bryan, NS; Fernandez-Moure, JS; Fleming, JB; Kang, Y; Kirui, D; Van Eps, JL | 1 |
| Bekaii-Saab, T | 1 |
| Bosch, R; Brú, A; Brú, I; Carmona-Güedes, S; Céspedes, MV; Pascual, E; Souto, JC | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Fujimori, N; Kakihara, D; Kimura, R; Matsuda, R; Miyasaka, Y; Mori, Y; Nakamura, M; Nakata, K; Oda, Y; Ohno, T; Ohtsuka, T | 1 |
| Arteta, B; Benedicto, A; Hernandez-Unzueta, I; Herrero, A; Márquez, J; Olaso, E; Romayor, I; Sanz, E | 1 |
| Clay, T; Das, A; Dean, A | 1 |
| Bynon, JS; Cen, P; Dinh, BC; Gonzalez, A; Mohlere, V; Thosani, NC; Wray, CJ; Zhang, S | 1 |
| Allegrini, V; Aversa, J; Ball, CG; Barrows, CE; Behrman, SW; Berger, AC; Cagigas, MN; Christein, JD; Dickson, PV; Dixon, E; Ecker, BL; Fisher, WE; Freedman-Weiss, M; Guzman-Pruneda, F; Hollis, RH; House, MG; Kent, TS; Kowalsky, SJ; Malleo, G; Salem, RR; Salvia, R; Schmidt, CR; Seykora, TF; Vollmer, CM; Zheng, R; Zureikat, AH | 1 |
| Eid, R; Haddad, FG; Hajjar, AH; Kourie, HR | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Asanuma, H; Hayashi, H; Hirata, K; Hirohashi, Y; Imai, K; Ito, YM; Kanaseki, T; Kimura, Y; Kubo, T; Kutomi, G; Miyakoshi, T; Mizuguchi, T; Murai, A; Nakae, Y; Nakatsugawa, M; Ota, Y; Sato, N; Shima, H; Sugita, O; Takemasa, I; Tokita, S; Torigoe, T; Tsukahara, T; Tsurita, G; Wada, S; Watanabe, K; Yasui, H | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Alfaro-Olea, A; Casajús-Navasal, A; Marín-Gorricho, R; Nebot-Villacampa, MJ; Uriarte-Pinto, M; Zafra-Morales, R | 1 |
| Berlin, J; Cardin, DB; Cohen, SJ; Davis, SL; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, WA; O'Neil, BH; Shahda, S; Stagg, RJ | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Bevan, P; Boeck, S; Ebert, MP; Heinemann, V; Laubender, RP; Mala, C | 1 |
| Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M | 1 |
| Blaszkowsky, LS; Chan, E; Hartford, A; Hidalgo, M; Jackson, L; Ko, YJ; Lichinitser, M; Macarulla, T; McWhirter, E; Morrison, K; O'Reilly, EM; Pezet, D; Rarick, M; Reyno, L; Ritch, P; Rocha-Lima, CM; Roman, L; Spratlin, J; Vincent, M; Wolpin, BM | 1 |
| Berzcel, L; Charabaty, A; Collins, SP; Gurka, MK; Haddad, N; Jackson, P; Jha, R; Johnson, CD; Lei, S; Ley, L; Marshall, JL; Pishvaian, MJ; Slack, R; Suy, S; Tse, G | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Bhattacharya, R; Khan, JA; Kudgus, RA; Mukherjee, P; Reid, JM; Robertson, JD; Szabolcs, A; Walden, CA | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Drebin, JA; Feldman, MD; Giantonio, BJ; Ginsberg, G; Harlacker, K; Heitjan, DF; Kochman, ML; Metz, JM; O'Dwyer, PJ; Plastaras, JP; Sohal, DP; Sun, W; Teitelbaum, UR | 1 |
| Endo, I; Hosono, K; Kobayashi, N; Kubota, K; Matsuyama, R; Mori, R; Nakajima, A; Sato, T; Taniguchi, K; Watanabe, S | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Jiang, Y; Jiao, X; Sun, S; Zheng, C | 1 |
| Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Murakami, S; Okazaki, T; Otsubo, I; Sawa, H; Shinozaki, K; Tsuchida, S; Ueno, K; Yoshida, Y | 1 |
| Agaram, N; Crooks, PA; Schmidt, CM; Stantz, K; Wu, H; Yip-Schneider, MT | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Furuse, J; Higashi, S; Ikeda, M; Inagaki, M; Kato, H; Mitsunaga, S; Ochiai, A; Ohno, I; Shimizu, S; Terao, K | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Chabot, JA; Hershman, DL; Insel, BJ; Khanna, LG; Neugut, AI; Oberstein, PE | 1 |
| Choi, MH; Kim, JS; Lim, SK; Shin, DH | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
| Maréchal, R; Van Laethem, JL | 1 |
| Artru, P; Bachet, JB; Bidard, FC; Bouché, O; Chibaudel, B; Desseigne, F; Hammel, P; Huguet, F; Louvet, C; Mathiot, C; Mineur, L; Pierga, JY | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Fleming, J; Jiang, ZQ; Katz, M; Kopetz, S; Lee, JE; Overman, MJ; Shroff, R; Varadhachary, G; Wang, H; Wang, X; Wolff, RA | 1 |
| Badola, S; Chen, L; Deng, H; Fuchs, CS; Gansert, JL; Kindler, HL; Loh, E; McCaffery, I; Patterson, SD; Suzuki, S; Tang, R; Tudor, Y | 1 |
| Behrman, SW; Chitkara, D; Kumar, N; Mahato, RI; Mittal, A | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Alongi, F; Clerici, E; Comito, T; Cozzi, L; Fogliata, A; Iftode, C; Mancosu, P; Navarria, P; Reggiori, G; Rimassa, L; Scorsetti, M; Tomatis, S; Tozzi, A; Zerbi, A | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Hamed, SS; Jusko, WJ; Straubinger, RM | 1 |
| Jarboe, J; Saif, MW | 1 |
| Saif, MW; Strimpakos, AS | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Bae, I; Cho, CH; Duong, HQ; Hong, YB; Kim, JS; Kim, YJ; Lee, HS; Seong, YS; Wang, A; Yi, YW; Zhao, W | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Contreras-Steyls, M; Estrada, D; Gallego, E; Herrera, E; López-Navarro, N; Moyano, B | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
| Abood, GJ; Bahary, N; Bartlett, DL; Krasinskas, AM; Lembersky, BC; Moser, AJ; Potter, DM; Ramanathan, RK; Shuai, Y; Smith, RP; Van Buren, G; Zeh, HJ; Zureikat, AH | 1 |
| Alvarez, R; Barbacid, M; Cubillo, A; de Vicente, E; Garcia-Garcia, E; Guerra, C; Hidalgo, M; Lopez-Casas, PP; Lopez-Rios, F; Megias, D; Muñoz, M; Musteanu, M; Plaza, C; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Tabernero, S | 1 |
| Abo, R; Bamlet, W; Brisbin, A; Carlson, E; Eckloff, BW; Ellsworth, KA; Fridley, BL; Jenkins, GD; Li, L; Moon, I; Petersen, G; Wang, L; Wieben, ED | 1 |
| Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
| Alavi, A; Beatty, GL; Brothers, A; Chiorean, EG; O'Dwyer, PJ; Saboury, B; Sun, W; Teitelbaum, UR; Torigian, DA; Troxel, AB; Vonderheide, RH | 1 |
| Amit, M; Binenbaum, Y; Gil, Z; Krelin, Y; Shabtay-Orbach, A; Weizman, N; Wong, RJ | 1 |
| Bartholin, L; Calvo, E; Cano, CE; Dusetti, N; Garcia, MN; Garcia, S; Grasso, D; Hamidi, T; Iovanna, JL; Lomberk, G; Loncle, C; Urrutia, R | 1 |
| Bahra, M; Bischoff, S; Denkert, C; Dörken, B; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Sallmon, D; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Berrevoet, F; De Bosschere, K; Ferdinande, L; Geboes, K; Hav, M; Ky, V; Laurent, S; Monsaert, E; Troisi, RI; Van Damme, N; Vanderstraeten, E | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Centeno, BA; Chellappan, SP; Lawrence, NJ; Pernazza, D; Pillai, S; Sebti, SM; Singh, S; Treviño, JG; Verma, M; Zhang, D | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Arakawa, K; Ide, M; Ishioka, NS; Itoh, H; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Ogawa, T; Ohshima, Y; Oriuchi, N; Oyama, T; Segawa, A; Shimizu, K; Sunaga, N; Sunose, Y; Takeyoshi, I; Tominaga, H; Yamaguchi, A | 1 |
| Bai, L; Jiao, SC; Li, J; Long, YY; Shi, WW; Su, D; Wang, LJ | 1 |
| Berger, W; Berta, J; Döme, B; Grusch, M; Hegedűs, B; Hoda, MA; Horváth, LZ; Kenessey, I; Keszthelyi, M; Klepetko, W; László, V; Rényi-Vámos, F; Rojkó, L; Rózsás, A; Török, S; Tóvári, J | 1 |
| Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU | 1 |
| Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Schlaich, F; Weber, KJ | 1 |
| John, P; McConnell, K; Saif, MW | 1 |
| Saif, MW | 4 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Abe, M; Azemoto, N; Furukawa, S; Hiasa, Y; Hirooka, M; Ikeda, Y; Imai, Y; Imamine, S; Inada, N; Koizumi, M; Kumagi, T; Kuroda, T; Matsuura, B; Miyaike, J; Miyake, T; Nishiyama, M; Ohno, Y; Okada, S; Onji, M; Seike, H; Shibata, N; Tanaka, Y; Tatsukawa, H; Utsunomiya, H; Yamanishi, H; Yokota, T | 1 |
| Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Maithel, SK; Pantazides, BG; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Volkan Adsay, N; Warren, MD; Yu, DS | 1 |
| Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN | 1 |
| Cleland, LG; Graf, SW; Limaye, VS | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Bauer, C; Bauernfeind, F; Conrad, C; Dauer, M; Duewell, P; Eigler, A; Endres, S; Kiefl, R; Schnurr, M; Sterzik, A | 1 |
| Etienne, E; Geny, B; Gottenberg, JE; Lannes, B; Messer, L; Meyer, A; Meyer, C; Moreau, P; Sibilia, J; Spielmann, L | 1 |
| Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME | 1 |
| Beer, DG; Bergeron, EJ; Chen, G; Giordano, TJ; Grabauskiene, S; Morgan, MA; Reddy, RM; Thomas, DG | 1 |
| Bianco, R; Bordonaro, R; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Costanzo, R; Di Maio, M; Favaretto, AG; Filipazzi, V; Gallo, C; Gridelli, C; Leo, S; Morabito, A; Perrone, F; Rossi, A; Sandomenico, C | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Butturini, G; Carter, R; Cox, T; Cunningham, D; Dervenis, C; Ghaneh, P; Goldstein, D; Izbicki, JR; Jackson, R; Karapetis, C; Lacaine, F; Lind, PA; Mayerle, J; Middleton, MR; Neoptolemos, JP; O'Reilly, D; Oláh, A; Palmer, D; Rawcliffe, CL; Robinson, BA; Sand, J; Scarfe, A; Stocken, DD; Sumpter, K; Valle, JW | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH | 1 |
| Cai, X; Cui, JJ; Huang, WY; Song, WF; Wang, L; Wang, LW | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Aoyama, F; Hiyoshi, M; Kataoka, H; Sawaguchi, A; Takahashi, N | 1 |
| Briggs, K; Curley, SA; Koshkina, NV; Palalon, F | 1 |
| Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J | 1 |
| Bierwirth, C; Binkowski, AM; Dobbelstein, M; Köpper, F | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Abdi, E; Button, P; Clarke, S; Clingan, P; Do, H; Dobrovic, A; Gregory, D; Michael, M; Nott, L; Solomon, B; White, SC; Zimet, A | 1 |
| Kondratska, K; Kondratskyi, A; Lemonnier, L; Lepage, G; Morabito, A; Prevarskaya, N; Skryma, R; Yassine, M | 1 |
| Chen, J; Li, Y; Lou, Y; Wang, LR; Zhang, GB | 1 |
| Ko, AH; Walker, EJ | 1 |
| Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Ii, N; Inoue, H; Isaji, S; Kishiwada, M; Kobayashi, M; Mizuno, S; Murata, Y; Sakurai, H; Shiraishi, T; Tabata, M; Usui, M; Yamada, T; Yamakado, K | 1 |
| Botteman, M; Ji, X; Reni, M; Solem, C; Wan, Y; Whiting, S | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Forster, T; Gebhard, MM; Gerhauser, C; Giese, N; Gladkich, J; Gross, W; Heilmann, K; Herr, I; Isayev, O; Labsch, S; Liu, L; Mattern, J; Nessling, M; Nwaeburu, CC; Rausch, V; Richter, K; Schaefer, M; Schemmer, P; Schoensiegel, F; Werner, J; Zhang, Y | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Fukutomi, A; Gansert, J; Ikeda, M; Kobayashi, Y; Okusaka, T; Shibayama, K; Takubo, T | 1 |
| Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN | 1 |
| Li, LQ; Li, Q; Li, YQ; Liang, CY; Liang, R; Liao, SN; Liao, XL; Lin, Y; Liu, ZH; Yuan, CL; Zhang, YM | 1 |
| Borazanci, E; Von Hoff, DD | 1 |
| Abou-Alfa, GK; Allen, PJ; Brennan, MF; Capanu, M; Coit, DG; DeMatteo, RP; DʼAngelica, M; Gerdes, H; Jarnagin, WR; Kingham, TP; Klimstra, DS; Kurtz, RC; LaValle, J; Lowery, MA; OʼReilly, EM; Perelshteyn, A; Reidy, DL; Schattner, M; Tang, LH; Winston, C | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Infante, JR; Kasubhai, SM; Le, N; Li, CP; Liu, Y; Oh, DY; Park, JO; Redhu, S; Scheulen, ME; Somer, BG; Steplewski, K | 1 |
| Bang, S; Chung, MJ; Park, JY; Park, SW; Song, SY | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Blum, H; Bruns, CJ; Camaj, P; Ellwart, JW; Ischenko, I; Jäckel, C; Jauch, KW; Krebs, S; Mysliwietz, J; Nelson, PJ; Niess, H; Renner, A; Zhao, Y | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Alishekevitz, D; Bril, R; Fremder, E; Gingis-Veltski, S; Hasnis, E; Karban, A; Raviv, Z; Shaked, Y; Voloshin, T | 1 |
| Abrams, TA; Allen, JN; Baran, A; Blaszkowsky, LS; Borger, DR; Clark, JW; Connolly, GC; Faris, JE; Fuchs, C; Goyal, L; Harris, DJ; Herr, M; Hezel, AF; Hyrien, O; Iafrate, AJ; Khorana, AA; Murphy, JE; Ng, K; Noel, MS; Regan, E; Ryan, DP; Sheehan, S; Yurgelun, M; Zheng, H; Zhu, AX | 1 |
| Brunner, TB; Chu, KY; Hawkins, M; Mukherjee, S; Partridge, M; Wilson, JM | 1 |
| Chen, B; Liu, LL; Lou, HZ; Pan, HM; Pan, Q; Sun, P; Weng, XC | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| Arakawa, H; Gong, J; Hayashi, K; Homma, S; Ikegami, M; Imazu, H; Ishidao, T; Ito, M; Kajihara, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Koyama, S; Misawa, T; Mori, M; Odahara, S; Ohkusa, T; Okamoto, M; Shimodaira, S; Sugiyama, H; Tajiri, H; Takakura, K; Toyama, Y; Tsukinaga, S; Uchiyama, K; Yanagisawa, S; Yoshizaki, S; Yusa, S | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Gao, XD; Ge, LH; Jin, ZY; Liang, JG; Te, MR; Wang, CL | 1 |
| DeNardo, DG; Goedegebuure, SP; Knolhoff, BL; Linehan, DC; Luo, J; Meyer, MA; Nywening, TM; Wang-Gillam, A; West, BL; Zhu, Y | 1 |
| Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P | 1 |
| Bekaii-Saab, TS; Ben-Josef, E; Dawson, LA; Griffith, KA; Herman, JM; Kim, EJ; Ringash, J; Serrano, PE; Wei, AC; Zalupski, MM | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Burns, M; Cardenes, HR; Chiorean, EG; Howard, T; Khawaja, MR; Kleyman, S; Loehrer, PJ; Nakeeb, A; Yu, Z | 1 |
| Adachi, T; Goto, A; Hirata, T; Ishimine, Y; Kasai, K; Kondo, Y; Naito, T; Yabana, T | 1 |
| Held-Warmkessel, J | 1 |
| Addanki, S; Bollu, LR; Candelaria, NR; Dey, P; Fisher, WE; Gabbi, C; Gustafsson, JÅ; Hodges, SE; Issazadeh, MA; Ittmann, MM; Jonsson, PK; Karaboga, H; Lin, CY; Lin, JZ; Liu, K; McElhany, AL; Nguyen-Vu, T; Steffensen, KR; Su, F; Vedin, LL; Wu, W; Zheng, J | 1 |
| Andriulli, A; Burbaci, FP; Cappello, F; Copetti, M; di Mola, FF; di Sebastiano, P; Fontana, A; Graziano, P; Lombardi, L; Maiello, E; Pazienza, V; Pellegrini, F; Rappa, F; Tavano, F; Vinciguerra, M | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Qiu, ZQ; Zhao, K | 1 |
| Cooper, AJ; Keshavarz, S; Lwaleed, BA; Rooprai, HK; Thani, NA | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Chao, YJ; Hsu, HP; Shan, YS; Sy, ED | 1 |
| Abel, EV; Balis, UG; Blau, JL; Craig, R; Greenson, JK; Griffith, KA; Khan, GN; Kim, EJ; Sahai, V; Simeone, DM; Takebe, N; Zalupski, MM | 1 |
| Li, HY; Li, N; Li, Q; Li, X; Shen, XH; Sun, HH; Wei, W | 1 |
| Blandino, G; Cordani, M; Di Agostino, S; Donadelli, M; Fiorini, C; Padroni, C | 1 |
| Bahra, M; Denkert, C; Dörken, B; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Hwang, IG; Jang, JS; Lee, KH; Lee, KT; Lee, MA; Lim, J; Nam, EM; Song, HS; Zang, DY | 1 |
| Alexander, DB; Fukamachi, K; Futakuchi, M; Hagiwara, Y; Hino, O; Iigo, M; Shibata, K; Suzui, M; Tsuda, H | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
| Lu, L; Xie, J; Yuan, J | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Konishi, K; Marubashi, S; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K; Yoshioka, Y | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Butler, H; John, P; Saif, MW | 1 |
| Aloia, T; Balachandran, A; Conrad, C; Cooper, AB; Evans, DB; Fleming, JB; Fogelman, D; Garg, N; Holmes, HM; Katz, MH; Lee, JE; Ngo-Huang, A; Parker, N; Petzel, M; Slack, R; Varadhachary, G; Vauthey, JN | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Huang, P; Ju, HQ; Wu, M; Yanaga, K; Zhuang, ZN | 1 |
| Cordani, M; Donadelli, M; Fiorini, C; Gotte, G; Picone, D | 1 |
| Chang, DT; Columbo, LA; Dholakia, AS; Fisher, GA; Goodman, KA; Griffith, ME; Hacker-Prietz, A; Herman, JM; Iacobuzio-Donahue, CA; Koong, AC; Laheru, DA; O'Reilly, E; Pai, JS; Pawlik, TM; Raman, SP; Rosati, LM; Sugar, EA; Wild, AT; Wolfgang, CL; Zheng, L | 1 |
| Hirano, Y; Homma, S; Ito, Z; Kajihara, M; Kan, S; Kobayashi, H; Koido, S; Matsumoto, Y; Misawa, T; Mori, M; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Takami, S; Yoshida, K | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Azevedo, S; Bach, BA; Bodoky, G; Carrato, A; Fuchs, CS; Gansert, JL; Haddad, V; Ikeda, M; Lipton, LR; Loberg, R; Melichar, B; Moore, MJ; Nemecek, R; Ohkawa, S; Okusaka, T; Peeters, M; Riess, H; Świeboda-Sadlej, A; Szczylik, C; Tjulandin, SA; Van Cutsem, E; Van Laethem, JL | 1 |
| Hirata, T; Ishikawa, O; Kawaguchi, Y; Konishi, K; Nishiyama, K; Ogawa, K; Ohigashi, H; Otani, K; Takahashi, H; Teshima, T; Tomita, Y | 1 |
| Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
| Cai, H; Gu, M; Xu, T; Xu, Z; Yu, B; Zhou, J; Zou, Q | 1 |
| El-Maraghi, RH; Goldstein, D; Hammel, P; Heinemann, V; Kunzmann, V; Lu, B; Penenberg, DN; Romano, A; Sastre, J; Scheithauer, W; Siena, S; Tabernero, J; Teixeira, L; Tortora, G; Van Laethem, JL; Von Hoff, DD; Young, R | 1 |
| Erkan, M; Esposito, I; Friess, H; Hong, X; Jäger, C; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Valkovska, N; Wu, W | 1 |
| Cao, F; Cui, Y; Li, F; Li, J; Liu, S; Sun, H | 1 |
| Bidaut, G; Borge, L; Calvo, E; Garcia, S; Gayet, O; Gouirand, V; Guillaumond, F; Guimaraes, C; Iovanna, JL; Lac, S; Lavaut, MN; Loncle, C; Nigri, J; Olivares, O; Ouaissi, M; Pinault, M; Roques, J; Servais, S; Staels, B; Tailleux, A; Tomasini, R; Vasseur, S | 1 |
| O'Reilly, EM; Yang, A | 1 |
| Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Matsumoto, T; Murakami, S; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Osawa, S; Sawada, S; Shibuya, K; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Abe, T; Egawa, S; Fukase, K; Hayashi, H; Karasawa, H; Katayose, Y; Kawaguchi, K; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naito, T; Nakagawa, K; Okada, R; Okada, T; Sakata, N; Taniguchi, H; Unno, M; Yabuuchi, S; Yoshida, H | 1 |
| Hu, Y; Xu, X; Ye, W; Ying, K; Zhang, R | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Dong, YZ; Liao, Y | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Kleespies, A; Neumann, J; Niess, H; Renz, BW; Reu, S; Schiergens, TS | 1 |
| Bousquet, C; Bousquet-Dubouch, MP; Breibach, F; Chalabi-Dchar, M; Cordelier, P; Delisle, MB; Duluc, C; Gayral, M; Martineau, Y; Mathonnet, M; Moatassim-Billah, S; Perraud, A; Pyronnet, S; Samain, R; Schmid, H; Tomasini, R | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gara, RK; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N; Zhao, H | 1 |
| Faure, R; Forestier, J; Hubault, M; Lombard-Bohas, C; Pivot, C; Walter, T | 1 |
| Boku, N; Fukutomi, A; Furukawa, M; Ikeda, M; Ishii, H; Maguchi, H; Miyazawa, M; Mizuno, N; Nishio, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Tani, M; Togashi, Y; Tsunoda, T; Ueno, H; Yamao, K; Yamaue, H | 1 |
| Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
| Chen, D; Dong, X; Hao, F; Liu, Z; Lu, X; Ni, G; Wang, M | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Rieken, S; Springfeld, C; Werner, J | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Bahary, N; Bao, P; Bartlett, DL; Boone, BA; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Moser, AJ; Normolle, DP; Singhi, AD; Wu, WC; Zeh, HJ; Zureikat, AH | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Chatzitheoklitos, E; Lambropoulou, M; Pitiakoudis, M; Polychronidis, A; Romanidis, K; Simopoulos, C; Tsaroucha, AK; Tsiaousidou, A | 1 |
| Bahra, M; Boas-Knoop, S; Denecke, T; Klein, F; Neuhaus, P; Pelzer, U; Pratschke, J; Puhl, G; Pullankavumkal, JR; Riess, H; Sinn, M | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
| Erlichman, C; Foster, NR; Kim, GP; McWilliams, RR; Pedersen, KS; Wang-Gillam, A | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Guo, XZ; Li, HY; Li, YY; Liang, C; Mukaida, N; Ni, QX; Song, Y; Sun, MH; Wang, Z; Yu, XJ | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Lin, ZQ; Luo, RJ; Wu, W; Xia, Q; Xue, P | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Hur, GY; In, KH; Kang, KH; Kim, JH; Lee, EJ; Lee, SH; Lee, SY; Min, KH; Shim, JJ; Shin, C | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Aisner, DL; Bajaj, R; Baranda, JC; Bathini, V; Berlin, J; Boles, J; Cho, JK; Cohen, DJ; Cohen, SJ; Coveler, L; Cusnir, M; Fanta, P; Fehrenbacher, L; Gomes, CL; Granfortuna, J; Jimeno, A; Ma, WW; Maguire, R; Maniar, M; McRee, AJ; Menter, AR; Messersmith, WA; Nazemzadeh, R; O'Neil, BH; Olowokure, OO; Phillip, P; Radford, J; Rarick, M; Scott, AJ; Tejani, MA; Wilhelm, F | 1 |
| Belfiore, G; Belfiore, MP; De Lucia, G; Di Gennaro, TL; Gallo, C; Ianniello, GP; Marsicano, C; Romano, F; Ronza, FM | 1 |
| Bendaoud, S; de Mestier, L; Hammel, P; Hentic, O; Lekhal, C; Neuzillet, C | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| de Prado-Otero, DS; Poves-Alvarez, R; Trueba-Arguiñarena, FJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Besse, B; Gazzah, A; Remon, J; Soria, JC | 1 |
| Gall, TM; Jiao, LR; Tsakok, M; Wasan, H | 1 |
| Aguayo, G; Bizama, C; Espinoza, JA; García, P; Leal, JL; Macanas, P; Nervi, B; Riquelme, I; Roa, JC; Viñuela, E; Weber, H | 1 |
| Abakar-Mahamat, A; André, T; Arsene, D; Ciccolini, J; Dahan, L; Deplanque, G; Desramé, J; Fein, F; François, E; Gagnière, J; Guerin-Meyer, V; Guillet, P; Guimbaud, R; Lecomte, T; Legoux, JL; Lepage, C; Montérymard, C; Seitz, JF; Serdjebi, C; Volet, J | 1 |
| Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| Ryu, JK | 1 |
| Geyer, AI; Kelly, DW; O'Reilly, EM; Sahin, IH | 1 |
| Crowder, C; Hamner, JB; Singh, G; White, M | 1 |
| Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Alejandre, MJ; Delgado, JR; Linares, A; Palomino-Morales, RJ; Perales, S; Torres, C | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Aglietta, M; Amatu, A; Aprile, G; Belli, C; Cagnazzo, C; Cereda, S; Ciuffreda, L; Fasola, G; Filippi, R; Leone, F; Marino, D; Montano, M; Nasti, G; Reni, M; Siena, S; Spadi, R | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Furukawa, H; Kofunato, Y; Koyama, Y; Kumamoto, K; Shimura, T; Takenoshita, S; Yashima, R | 1 |
| Arai, Y; Ito, A; Kaiho, Y; Kamiyama, Y; Kawamorita, N; Mitsuzuka, K; Nakagawa, H; Watanabe, M; Yamada, S | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Ferrara, S; Goldstein, D; Greeno, E; Liu, H; Lu, B; Macarulla, T; Moore, M; Pilot, R; Ramanathan, RK; Tortora, G; Von Hoff, DD | 1 |
| Amiji, M; Mattheolabakis, G; Singh, A; Xu, J | 1 |
| Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
| Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M | 1 |
| Cui, YQ; Gao, CC; Gong, BG; Jiang, H; Li, F; Liu, S; Sun, HC; Xu, PY; Xu, XL; Zheng, YM | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H | 1 |
| Cohen, SJ; Conkling, P; Hersh, E; Lee, FC; Ma, WW; Modiano, M; Nugent, F; Pascual, R; Wong, L; Zalupski, MM | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Dong, SX; Han, P; Qi, J; Ren, ZG | 1 |
| Fu, S; Ma, G; Sun, Y | 1 |
| Abbruzzese, JL; Abrams, RA; Chang, P; Crane, C; Freedman, GM; Guha, C; Hoffman, JP; Li, D; Liu, C; Moughan, J; Regine, WF; Safran, H; Winter, KA | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Doherty, M; Hedley, D; Knox, JJ; McNamara, MG; Mian, M; Serra, S | 1 |
| Baldwin, GS; He, H; Lowy, AM; Nikfarjam, M; Patel, O; Yeo, D | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Arena, FP; Bathini, VG; Chiorean, EG; Clingan, PR; Goldstein, D; Infante, JR; Ko, A; Kunzmann, V; Lu, B; Mainwaring, PN; McGovern, D; Muldoon, RT; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD; Wood, TE | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 1 |
| Broussolle, C; Gerfaud-Valentin, M; Guillet, M; Noel, A; Pouteil-Noble, C; Rogier, T; Sève, P; Taleb, A | 1 |
| Chan, KW; Chen, H; Li, Y; Liu, G; Luo, L; McMahon, MT; van Zijl, PC; Vogelstein, B; Xu, J; Yadav, NN; Zhou, S | 1 |
| Bockhorn, M; Brockmöller, J; Gaedcke, J; Ghadimi, BM; Güngör, C; Hackert, T; Hank, T; Haubrock, M; Izbicki, JR; Johnsen, SA; Lüske, CM; Pflüger, R; Rapp, J; Roppel, S; Schaudinn, A; Schirmer, MA; Strobel, O; Werner, J; Zimmer, C | 1 |
| Afghani, R; Azarhoush, R; Hajimohammadi, A; Kazemi-Nejad, V; Rezapour Esfahani, M; Yari, B | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Assadi, RK; Dholakia, AS; Ellsworth, SG; Ford, E; Grossman, SA; Hacker-Prietz, A; Herman, JM; Jaffee, EM; Laheru, DA; Lu, Y; Moningi, S; Pawlik, TM; Rosati, LM; Saeed, AM; Tran, PT; Weiss, MJ; Wild, AT; Wolfgang, CL; Ye, X | 1 |
| Cherubini, G; Halldén, G; Lemoine, NR; Pantelidou, C | 1 |
| He, J; Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Alvarez, R; Caruso, R; Diaz, E; Duran, H; Fabra, I; Ferri, V; Hidalgo, M; Ielpo, B; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Ahn, DW; Chai, JW; Chun, JY; Kim, YA; Lee, JM; Shin, K | 1 |
| Donahue, TR; Gifford, JB; Hill, R; Hindoyan, A; Huang, W; Wu, H; Zeleniak, AE | 1 |
| Epperla, N; Strouse, C | 1 |
| Besselink, MG; Boerma, D; Bonsing, BA; Busch, OR; de Hingh, IH; de Vos-Geelen, J; Dohmen, MA; Erdmann, JI; Festen, S; Groothuis, KB; Klaase, JM; Molenaar, IQ; Patijn, GA; Punt, CJ; Rasch, CR; Suker, M; Ten Tije, AJ; van der Harst, E; van der Kolk, MB; van Eijck, CH; van Tienhoven, G; Versteijne, E; Zwinderman, AH | 1 |
| Dutta, R; Karaca, M; Mahato, RI; Ozsoy, Y | 1 |
| Chen, Y; Li, C; Liu, X; Wang, X; Yang, X; Zhou, G | 1 |
| Ai, J; Algül, H; Barenboim, M; Campbell, A; Demir, IE; Diakopoulos, KN; Doglioni, C; Görgülü, K; Hagemann, T; Jodrell, D; Karpathaki, AP; Kurkowski, MU; Lesina, M; Neesse, A; Protti, MP; Rose-John, S; Ruess, D; Sansom, O; Schmid, RM; Song, L; Wörmann, SM | 1 |
| Li, D; O'Reilly, EM | 1 |
| Ahn, HK; Cho, EK; Choi, SJ; Hong, J; Kim, YS; Lee, JH; Park, I; Park, J; Shin, DB; Shin, YJ; Sym, SJ | 1 |
| Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Daley, D; Engle, D; Giao Ly, NN; Greco, SH; Hajdu, C; Hundeyin, M; Mani, VR; Miller, G; Ochi, A; Pansari, M; Pergamo, M; Rendon, M; Seifert, L; Tippens, D; Tiwari, S; Torres-Hernandez, A; Werba, G; Zambirinis, CP | 1 |
| Frank, H; Kitzwögerer, M; Moser, M; Wiedemann, D | 1 |
| Arumugam, P; Bapiro, TE; Carapuça, EF; Delvecchio, FR; Feig, C; Gemenetzidis, E; Grose, RP; Kocher, HM; Lemoine, NR; Richards, FM; Williams, MD; Wilson, AS | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Beesetti, S; Bhoopalan, H; Biswal, J; Chidambaram, S; Jagadeeshan, S; Jeyaraman, J; Malathi, R; Mavuluri, J; Nair, AS; Pitani, RS; Raghavan, S; Rayala, SK; Singhal, M; Subramanian, A; Sundaram, S; Surabhi, RP; Tentu, S; Venkatraman, G | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Bachet, JB; Pernot, S; Portal, A; Taieb, J | 1 |
| Wang, BZ; Yu, ZG | 1 |
| Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D | 1 |
| Buchsbaum, DJ; Christein, JD; Cooper, SJ; Davis, NS; Gertz, J; Greeno, EW; Grizzle, WE; Heslin, MJ; Johnston, BE; Kirby, MK; Myers, RM; Oliver, PG; Posey, JA; Ramaker, RC; Sexton, KC; Vickers, SM | 1 |
| Goda, Y; Hara, H; Irie, K; Kobayashi, S; Morimoto, M; Moriya, S; Ohkawa, S; Okusaka, T; Tanaka, M; Tezuka, S; Ueno, M | 1 |
| Basson, MD; Ito, H; Ono, H | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Amitani, H; Inui, T; Kubo, K; Kuchiike, D; Mette, M; Nishikata, T; Uto, Y | 1 |
| Agle, S; Bhutiani, N; Li, S; Li, Y; Martin, RC | 1 |
| Bang, S; Chung, JB; Chung, MJ; Lee, HS; Lee, YI; Moon, do C; Park, JY; Park, SW; Song, SY | 1 |
| Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S | 1 |
| Camphausen, K; Griffith, KA; Kim, EJ; Ruch, JM; Sahai, V; Savage, JE; Simeone, DM; Zalupski, MM; Zhen, DB | 1 |
| Albert, AC; Bürtin, F; Graffunder, J; Jaster, R; Kumstel, S; Müller, S; Radecke, T; Schönrogge, M; Shih, HY; Vollmar, B; Zechner, D; Zhang, X | 1 |
| Fernando, M; Goldstein, D; Ritchie, GE | 1 |
| Adsay, V; Brutcher, E; Chen, Z; El-Rayes, B; Ethun, CG; Kooby, DA; Maithel, SK; Postlewait, LM; Sarmiento, JM; Staley, CA | 1 |
| Chen, ZN; Fu, ZG; Jiang, JL; Li, L; Meng, Y; Wu, B; Wu, XQ; Xu, BQ; Xu, L | 1 |
| Coyne, CP; Narayanan, L | 1 |
| Chang, X; Dai, M; Shi, N; Xing, C; Zhao, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Bahary, N; Hogg, ME; Poruk, KE; Steve, J; Weiss, MJ; Wolfgang, CL; Wright, GP; Zeh, HJ; Zenati, MS; Zuriekat, AH | 1 |
| Gharios, J; Kattan, J; Kourie, HR | 1 |
| He, J; Liu, L; Xiang, Z; Xiao, H; Xiao, J | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY | 1 |
| Bachet, JB; Calomme, A; Demetter, P; Drouillard, A; Maréchal, R; Ouazzani, S; Puleo, F; Van Laethem, JL; Verset, G | 1 |
| Andley, M; Maharshi, V; Nagar, P; Rehan, HS | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Chen, QD; Ge, X; Jiang, BH; Lin, Y; Liu, LZ; Lu, Y; Shi, ZM; Wang, M; Wen, Y | 1 |
| Álamo, P; Allavena, P; Avilés, P; Céspedes, MV; Cuevas, C; Gallardo, A; Galmarini, CM; Guillén, MJ; Hidalgo, M; López-Casas, PP; Mangues, R; Sarno, F | 1 |
| Ferrara, S; Goldstein, D; Kunzmann, V; Liu, H; Lu, B; Ramanathan, RK; Renschler, MF; Von Hoff, DD | 1 |
| An, Y; Duan, J; Fan, S; Li, X; Pan, Y; Tie, L; Wang, X; Xiaokaiti, Y; Yang, H; Ye, M | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
| Cabezuelo, B; de la Vara Inesta, L; Illescas, ML; Jimeno García, L; López Rubio, ME; Lucas Guillén, E; Martinez Díaz, M; Mateo Bosch, E; Morales Albuja, ME; Rodado Martínez, R | 1 |
| Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Azad, A; D'Costa, Z; Diana, A; Dushek, O; Fokas, E; Jones, K; Kruger, P; Liu, S; McKenna, WG; Muschel, RJ; Sansom, OJ; Yin Lim, S | 1 |
| Amponsah, PS; Bauer, N; Fan, P; Fellenberg, J; Gladkich, J; Herr, I; Zhao, Z | 1 |
| Arigami, T; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Mori, S; Natsugoe, S; Sakoda, M; Shinchi, H; Uchikado, Y; Ueno, S; Uenosono, Y | 1 |
| Park, K | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
| Alarcón Cano, D; Andrade G, A; Barajas, O; Butte, JM; Caglevic, C; Calderillo Ruiz, G; Carballido, M; Cuartero, V; De La Fuente, H; de la Torre, M; Díaz Romero, C; Gallardo, J; González M, P; Hoefler, S; Kon Jara, X; Lembach, H; Lingua, A; Lobatón, J; Mahave, M; Marsiglia, H; Mas López, L; Montenegro B, P; Morillas G, L; Moscoso, Y; Müller, B; O'Connor, JM; Padilla Rosciano, A; Pérez Encalada, V; Roa, JC; Roca, E; Rolfo, C; Schwartsmann, G; Solé, S; Torres, J; Ubillos, L; Yepes, A | 1 |
| Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
| Alis, H; Dagoglu, N; Gonenc, M; Karabulut, M; Karabulut, S; Serilmez, M; Tas, F; Usul Afsar, Ç | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Kawamoto, K; Mori, M; Noda, T; Ueno, G; Wada, H; Yamada, D | 1 |
| Fukada, T; Hasegawa, A; Isozaki, M; Kametaka, H; Makino, H; Seike, K | 1 |
| Fukuda, S; Harada, T; Hiraki, S; Kanesada, K; Tada, K | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Hosomi, S; Ishikawa, A; Miyamoto, M; Tanigawa, T | 1 |
| Aoki, T; Hasegawa, K; Hoshikawa, M; Kakimi, K; Kokudo, N; Matsushita, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hasegawa, S; Kawamoto, K; Kishimoto, T; Mikamori, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Wada, H; Yamada, D | 1 |
| Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Bendell, J; Benson, AB; Dong, H; Hecht, JR; Kudrik, F; Vyushkov, D; Wainberg, ZA | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Avan, A; Funel, N; Giovannetti, E; Gomez, VE; Griffioen, AW; Leon, LG; Rovithi, M; Verheul, HM; Wurdinger, T | 1 |
| Agelaki, S; Agelidou, A; Boukovinas, I; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, A; Mavroudis, D; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Ceballos, J; García-Foncillas, J; Pérez-Gracia, JL; Santisteban, M; Vivas, I | 1 |
| Vikram, B | 1 |
| Fujita, T | 1 |
| Carbó, N; Casado, FJ; García-Manteiga, J; Mazo, A; Mercadé, E; Pastor-Anglada, M; Pérez-Torras, S | 1 |
| Jiang, JX; Liu, WS; Qin, RY; Shen, M; Shi, CJ; Tian, R; Wang, M; Yan, HJ | 1 |
| Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Crane, CH; Evans, DB; Ho, L; Lano, EA; Lee, JE; Lenzi, R; Pisters, PW; Staerkel, GA; Sun, CC; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Abbruzzese, JL; Abdalla, E; Bhosale, PR; Crane, CH; Das, P; Evans, DB; Ho, L; Krishnan, S; Lee, JE; Lee, JH; Pisters, PW; Ross, WA; Staerkel, GA; Sun, CC; Tamm, EP; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA; Xiong, H | 1 |
| Drebin, JA; Hawkins, WG; Hull, M; Linehan, DC; Malyapa, RS; Myerson, RJ; Picus, J; Strasberg, SM; Tan, BR; Tan, MC; Trinkaus, K | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Auroux, J; Brunetti, F; Delchier, JC; Fabre-Guillevin, E; Locher, C; Piedbois, P; Zelek, L | 1 |
| Cereda, S; Reni, M | 1 |
| Corsini, MM; Iott, MJ; Miller, RC | 1 |
| Dabanaka, K; Hanazaki, K; Kobayashi, M; Kohsaki, T; Maeda, H; Nishimori, I; Nishioka, A; Ogawa, Y; Okabayashi, T; Onishi, S; Sugimoto, T; Yamashita, K | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Ioka, T; Kanemitsu, Y; Mizuno, N; Nakaizumi, A; Nakamura, T; Salem, AA; Sawaki, A; Takahashi, K; Tanaka, S; Ueda, R; Yamao, K | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Aerts, R; Bielen, D; Budiharto, T; Ectors, N; Goethals, L; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Vanbeckevoort, D; Verslype, C | 1 |
| Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP; Wong, D | 1 |
| Ardman, B; Fidias, P; Heist, RS; Huberman, M; Lynch, TJ; Sequist, LV; Temel, JS | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V; Wang, H | 1 |
| Donahue, B; Hiotis, SP; Hochster, HS; Marti, JL; Newman, E; Ryan, T | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bird, B; Janku, F | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O | 1 |
| Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K | 1 |
| Saif, MW; Wasif, N | 1 |
| Knisely, J; Ramos, J; Saif, MW | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Abbruzzese, JL; Amos, CI; Chen, J; Evans, DB; Frazier, ML; Killary, AM; Li, D; Sen, S | 1 |
| Twombly, R | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Izuishi, K; Kakinoki, K; Maeba, T; Okamoto, Y; Okano, K; Suzuki, Y; Usuki, H; Wakabayashi, H | 1 |
| Bae, SH; Eun, JR; Hyun, MS; Jang, BI; Kim, MK; Kim, TN; Lee, KH; Lee, SA; Ryoo, HM | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Adamson, DJ; Ali, CW; Highley, MS; Kaye, TF; Polignano, FM; Tait, IS | 1 |
| Bhure, U; Clavien, PA; Hany, TF; Heinrich, S; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, HJ; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Becker, J; Bharthuar, A; Deeb, G; Egloff, L; George, M; Iyer, RV; Lohr, JW | 1 |
| López-Tarruella, S; Rivera, F; Salcedo, M; Vega-Villegas, ME | 1 |
| Imada, H; Korogi, Y; Morioka, T; Nakano, K; Narisada, H; Ohguri, T; Yahara, K | 1 |
| Abrams, RA; Leslie, WT; Mahon, B; Shah, A; Shah, AP; Strauss, JB | 1 |
| Alonso, G; Alvarez, E; Amenedo, M; Fernández, I; Fírvida, JL; Huidobro, G; Lázaro, M; Mel, JR; Rubio, JC; Vázquez, F; Vázquez, S | 1 |
| Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT | 1 |
| Akashi, K; Arita, S; Baba, E; Hirano, G; Isobe, T; Kusaba, H; Makiyama, A; Nakano, S; Qin, B; Shibata, Y; Uchino, K | 1 |
| Aho, U; Andersson, R; Nilsson, BI; Pastor-Anglada, M; Peters, GJ; Rasch, W; Sandvold, ML | 1 |
| Bazan-Perkins, B; Candelaria, M; Cantú, D; Cetina, L; Coronel, J; Dueñas-González, A; Flores, V; Garcia-Arias, A; Gonzalez, A; Rivera, L | 1 |
| Haviland, D; Kemeny, N; Patel, D; Tse, AN; Wu, N | 1 |
| Davies, D; Halldén, G; Leitner, S; Lemoine, NR; Miranda, E; Oberg, D; Sweeney, K | 1 |
| Lluís, F | 1 |
| Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ | 1 |
| Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Clark, JW; Goulart, BH; Grenon, N; Lauwers, GY; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J | 1 |
| Bekaii-Saab, TS; Fortune, BE; Kosuri, KV; Li, X; Thomas, JP; Weatherby, LM | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL; Young, J | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; Mach, RH; McDunn, JE; Simon, PO; Vangveravong, S | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS | 1 |
| Ardizzoni, A; Bartolotti, M; Gelsomino, F; Tiseo, M | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Jacobs, MJ; Saidi, RF | 1 |
| Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Unger, C; Ziroli, V | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; McDunn, JE; Simon, PO | 1 |
| Barthet, M; Calvo, EL; Dagorn, JC; Delpero, JR; Iovanna, JL; Legoffic, A | 1 |
| Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM | 1 |
| Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM | 1 |
| Chun, SG; Yee, NS; Zhou, W | 1 |
| Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Ece, F; Hanta, I; Hasturk, S; Hatabay, N; Karatasli, M | 1 |
| Dalgleish, AG; Liu, WM; Nizar, S | 1 |
| Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tsakalaki, E | 1 |
| Frumovitz, M; Han, LY; Rashid, A; Ricks, AM | 1 |
| Freeman, JW; Giles, FJ; Wang, Y | 1 |
| Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Borbath, I; Boterberg, T; de Hemptinne, B; Demols, A; Hendlisz, A; Laurent, S; Mahin, C; Monsaert, E; Peeters, M; Polus, M; Scalliet, P; Van Laethem, JL | 1 |
| Alexandrescu, DT; Dasanu, CA; Herzog, TJ | 1 |
| Arakawa, T; Ashida, R; Hirakawa, K; Mizuno, N; Nakata, B; Sawaki, A; Shigekawa, M; Yamao, K | 1 |
| Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V | 1 |
| Abe, T; Ikeda, K; Koeda, K; Minakawa, Y; Nitta, H; Obuchi, T; Otsuka, K; Sasaki, A; Shimooki, O; Wakabayashi, G | 1 |
| Akita, H; Bepler, G; Doki, Y; Dono, K; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Takemasa, I; Zheng, Z | 1 |
| Estephan, F; Esteva, FJ; Frye, DK; Ibrahim, NK; Mejia, JA; Valero, V | 1 |
| Eguchi, H; Gotoh, K; Ishikawa, O; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H; Yamada, T; Yano, M | 1 |
| Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F | 1 |
| Choi, DW; Choi, SH; Heo, JS; Lee, HG; You, DD | 1 |
| Bang, S; Hong, SP; Park, S; Song, SY; Wen, J | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Lin, XB; Wang, FH; Xu, RH | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Bakshandeh-Bath, A; Homann, N; Peters, SO; Stölting, S; Stoltz, AS; Wagner, T | 1 |
| Antman, KA; Chabot, JA; Chen, C; Fine, RL; Grann, VR; Kumah, CK; Tsai, WY | 1 |
| Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT | 1 |
| Chen, Y; Smith, BJ | 1 |
| Esau, C; Lee, EJ; Park, JK; Schmittgen, TD | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Kaley, K; Peccerillo, J; Saadati, H; Saif, MW; Schilsky, ML | 1 |
| Baulieux, J; Bossard, N; de la Roche, E; Gamondes, JP; Geriniere, L; Guibert, B; Mulsant, P; Remontet, L; Souquet, PJ; Thibout, Y; Tiffet, O; Tronc, F | 1 |
| Ikeda, H; Mouri, H; Nakanuma, Y; Ohtsubo, K; Tsuchiyama, T; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y | 1 |
| Bechi, P; Cipriani, G; Grifoni, R; Molinara, E; Neri, B; Pantaleo, P; Pantalone, D; Rangan, S; Taddei, A; Tonelli, P; Valeri, A; Vannini, A | 1 |
| Mackenzie, RP; McCollum, AD | 1 |
| Manegold, C; Martins, RG; Parikh, P; Scagliotti, GV; Simms, L; Sugarman, KP; Syrigos, KN; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
| Barthet, M; Calvo, E; Cano, C; Closa, D; Dagorn, JC; Delpero, JR; Ferrés-Masó, M; Folch-Puy, E; Iovanna, J; Legoffic, A | 1 |
| Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
| Cellini, F; Cesario, A; Ciresa, M; D'Angelillo, RM; Fiore, M; Granone, P; Greco, C; Mineo, TC; Paleari, L; Pompeo, E; Ramella, S; Trodella, L | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Boselli, S; Catania, C; Danesi, R; de Braud, F; De Pas, T; Giovannetti, E; Manzotti, M; Minocci, D; Noberasco, C; Pelosi, G; Radice, D; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Boeck, S; Boettcher, HD; Bruns, CJ; Fietkau, R; Flentje, M; Heinemann, V; Herbst, M; Hinke, A; Miethe, S; Ostermaier, S; Rau, HG; Sauer, R; Scholten, T; Wilkowski, R | 1 |
| Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Capelozzi, VL; Galvão, FH; Pestana, JO | 1 |
| Aggarwal, BB; Anand, P; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Pandey, MK; Sethi, G | 1 |
| Matsuda, A; Matsushita, A; Matsutani, T; Sasajima, K; Uchida, E; Yokoyama, T | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Clark, WF; Robinson, A | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Liu, B; Qu, Y; Xiao, W; Yang, Y | 1 |
| Abbruzzese, JL; Javle, M; Li, D; Okazaki, T; Tanaka, M | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Katayose, Y; Nakagawa, K; Okaue, A; Rikiyama, T; Unno, M | 1 |
| Doki, Y; Eguchi, H; Hatano, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Ohmura, Y; Takeda, Y; Takiuchi, D; Tanemura, M; Tomokuni, A | 1 |
| Funamizu, N; Gocho, T; Kamata, Y; Manome, Y; Misawa, T; Okamoto, A; Uwagawa, T; Yanaga, K | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C | 1 |
| Lillemoe, KD; Nakeeb, A; Simianu, VV; Zyromski, NJ | 1 |
| Ceraulo, D; Cereda, S; Fugazza, C; Mazza, E; Reni, M; Rognone, A; Villa, E | 1 |
| Abdel Wahab, M; Dorgham, Y; Hamouda, W; Yosry, A | 1 |
| Aprile, G; Berardi, R; Cereda, S; Cordio, S; Falconi, M; Mambrini, A; Milella, M; Pasetto, LM; Passardi, A; Pederzoli, P; Reni, M; Rognone, A; Sartori, N; Tronconi, MC | 2 |
| Cheung-Lau, G; Dawson, DW; Dawson, NA; Farrell, J; Guha, C; Hines, OJ; Horvath, S; Kurdistani, SK; Manuyakorn, A; Paulus, R; Reber, H; Seligson, DB; Tze, S | 1 |
| Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S | 1 |
| Chen, R; Liu, E; Liu, X; Niu, J; Niu, W; Peng, C; Wang, J; Xu, K; Zhang, Z | 1 |
| Lee, JS; Orlando, M; Park, K; Scagliotti, G; Simms, L; Yang, CH | 1 |
| Christians, K; Evans, DB; Lal, A | 1 |
| Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T | 1 |
| Aldrighetti, L; Cereda, S; Nicoletti, R; Passoni, P; Reni, M; Viganò, MG; Villa, E | 1 |
| Cercueil, JP; Chauffert, B; Ghiringhelli, F; Guiu, B; Guiu, S; Ladoire, S; Ortega-Deballon, P; Vincent, J | 1 |
| Chen, ZH; Cheng, H; Dong, S; Guo, AL; Huang, Y; Wang, Z; Wu, YL; Xie, Z; Yan, HH; Zhang, XC | 1 |
| Batra, SK; Chakraborty, S; Johansson, SL; Mimeault, M; Momi, N; Senapati, S | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 1 |
| Garber, K | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Mehta, SP | 1 |
| Kato, Y; Katori, M; Koga, R; Kokudo, N; Saiura, A; Sakamoto, Y; Seki, M; Yamaguchi, T; Yamamoto, J | 1 |
| Dumontet, C; Hage-Sleiman, R; Herveau, S; Laurier, JF; Matera, EL | 1 |
| Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S | 1 |
| Aviram, A; Escalon, E; Melnick, SJ; Ramachandran, C; Resek, AP | 1 |
| Chakerian, P; Kaley, K; Lamb, L; Saif, MW | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| Bock, PR; Friedel, WE; Matthes, H; Zänker, KS | 1 |
| Alpaugh, RK; Astsaturov, IA; Burtness, BA; Cheng, JD; Cohen, SJ; McLaughlin, S; Meropol, NJ; Rogatko, A; Watson, JC; Weiner, LM; Xu, Z | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Benson, AB; Catalano, PJ; Cooper, H; Harris, W; Hoffman, J; Landry, J; Staley, C; Talamonti, M; Xu, N | 1 |
| Doroshow, JH; Kummar, S; Speranza, G | 1 |
| Arumugarajah, S; Canman, CE; Davis, MA; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Normolle, DP; Parsels, JD; Parsels, LA; Simeone, DM; Zabludoff, SD; Zhao, L | 1 |
| Bifulco, G; Carlomagno, C; De Placido, S; Insabato, L; Lauria, R | 1 |
| Baker, JH; Buczkowski, AK; Cham, KK; Chang, CW; Chu, EM; Chung, SW; Flexman, JA; Kozlowski, P; Minchinton, AI; Ng, SS; Owen, DA; Reinsberg, SA; Scudamore, CH; Takhar, KS; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Chaudhary, RT; Li, G; Saikumar, J | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Christein, J; Eloubeidi, M; Frolov, A; Greeno, E; Jhala, N; Keene, K; Oster, R; Posey, J; Russo, S; Varadarajulu, S; Vickers, SM; Wood, T | 1 |
| Kadish, SP; McDade, TP; Piperdi, B; Piperdi, M; Shim, JK; Sullivan, ME; Tseng, JF; Whalen, GF | 1 |
| Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J | 1 |
| Benedetti, J; Blanke, CD; Flynn, PJ; Goldman, B; Lippman, SM; Millwood, B; Moinpour, CM; O'Reilly, EM; Philip, PA; Redman, MW; Rowland, KM; Seay, TE; Vaught, NL; Wong, RP | 1 |
| Abbruzzese, JL; Atkins, JN; Benedetti, J; Blanke, CD; Corless, CL; Fenoglio-Preiser, CM; Flynn, PJ; Goldman, B; Khorana, AA; Mirtsching, BC; O'Reilly, EM; Philip, PA; Rivkin, SE; Rowland, KM; Wong, R | 1 |
| Hirano, K; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Ashley, S; Brunetto, AT; Carden, CP; Faria, AL; Myerson, J; O'Brien, ME; Popat, S | 1 |
| Cariati, A | 1 |
| Hou, J; Ji, Y; Jin, DY; Lou, WH; Niu, GM; Wang, DS | 1 |
| Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
| Fournier, CC; James, JS; Picus, J; Suresh, R; Tan, BR; Trinkhaus, K; Williams, KJ | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Fässler-Weibel, P; Gartner, V | 1 |
| Drukker, L; Epstein, A; Gabizon, A; Isacson, R; Keinan, A; Kelsen, D; Lowery, M; O'Reilly, EM; Rachkiman, M; Reissman, P; Rosengarten, O; Segal, A; Shah, MA; Smyth, E | 1 |
| Hasegawa, Y; Imaizumi, K; Kondo, M; Shimokata, K; Shindo, J; Suzuki, R; Taniguchi, H; Usami, N; Yamamoto, M; Yokoi, K | 1 |
| Hashimoto, H; Obara, K; Oshika, Y; Shimizu, E; Tanaka, Y | 1 |
| Brody, JR; Cozzitorto, JA; Freydin, B; Gonye, G; Grenda, D; Kennedy, EP; Richards, NG; Rittenhouse, DW; Rui, H; Witkiewicz, AK; Yeo, CJ | 1 |
| Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
| Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN | 1 |
| Van Dyke, T | 1 |
| Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K | 1 |
| Cardenes, HR; Chiorean, EG; Helft, P; Howard, TJ; Johnson, CS; Loehrer, PJ; Moore, AM; Stephens, AW; Tai, DF; Vinson, J; Yu, M | 1 |
| Clément-Duchêne, C; Colevas, AD; Ganjoo, K; Krupitskaya, Y; Kumar, A; Lavori, P; McMillan, A; Padda, S; Pedro-Salcedo, MS; Wakelee, HA; Zhao, G; Zhou, L | 1 |
| Backer, JM; Backer, MV; Buhr, HJ; Hotz, B; Hotz, HG | 1 |
| Fujita, H; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Gupta, P; Khanna, AK; Khanna, R; Singh, S | 1 |
| Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Diamond, DJ; Ellenhorn, JD; Ishizaki, H; Manuel, ER; Song, GY; Srivastava, T; Sun, S | 1 |
| Horneber, M | 1 |
| Meier, JJ; Ritter, PR; Schmidt, WE; Tischoff, I; Uhl, W | 1 |
| Christos, P; Espinoza-Delgado, I; Hamel, N; Kaubish, A; Lane, ME; Matulich, D; Ocean, AJ; Siegel, A; Sparano, JA; Sung, M; Ward, MM; Yen, Y | 1 |
| Cao, L; Liu, D; Que, R; Wang, G; Wang, L; Xie, D; Yu, J | 1 |
| Badmaev, V; Bar-Sela, G; Epelbaum, R; Schaffer, M; Vizel, B | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Ayuso, D; Becht, C; Culine, S; Huguet, H; Iborra, F; Pouessel, D; Rebillard, X | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Meriggi, F; Zaniboni, A | 1 |
| Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T | 1 |
| Chewaproug, D; Khanmoradi, K; Kung, SC; Melin, A; Ortiz, J; Pontinen, T; Varadi, G; Zaki, R | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Blessing, JA; Hoffman, JS; Lachance, JA; Miller, DS; Moore, KN; Rotmensch, J; Spirtos, NM; Tait, DL | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| d'Adhemar, C; Kelly, ME; Kinsella, J; Ridgway, PF; Swan, N | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K | 1 |
| Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T | 1 |
| Arpicco, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Franchini, M; Palmieri, M; Scarpa, A; Zaniboni, T | 1 |
| Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E | 1 |
| Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Jiang, J; Kim, R; Lai, KK; Liu, X; Rybicki, LA; Tan, A; Wang, Y | 1 |
| Fukuda, S; Guo, Z; Kathuria, H; Milani, M; Mitra, R; Pelus, LM; Potter, DA; Rizzardi, A; Rodriguez, M; Schmechel, S; Skalnik, DG; Srirangam, A | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Abrams, RA; Benson, AB; Hoffman, JP; Konski, AA; Lustig, R; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morita, S; Morizane, C; Nakachi, K; Okusaka, T; Tanaka, K; Ueno, H | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS | 1 |
| Baldi, A; Bazzano, S; D'Anna, S; Orlando, F; Palmieri, A; Tenaglia, S; Valentinis, L | 1 |
| Angeli, I; Calamai, G; Catania, C; Danesi, R; De Braud, F; De Pas, TM; Giovannetti, E; Milani, A; Noberasco, C; Pelosi, G; Radice, D; Russo, F; Spitaleri, G; Toffalorio, F | 1 |
| Gill, S; Kim, C; Owen, D | 1 |
| Coban, I; El-Rayes, BF; Kauh, JS; Kneuertz, PJ; Kooby, DA; Maithel, SK; Sarmiento, J; Staley, CA; Volkan Adsay, N | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Chang, BW; Saif, MW | 1 |
| Dimou, AT; Saif, MW; Syrigos, KN | 1 |
| Chen, C; Cubas, R; Li, M; Yao, Q; Zhang, S | 1 |
| Bigand, C; Couvreur, P; Hajri, A; Parmentier, C; Reddy, LH; Réjiba, S | 1 |
| Hu, J; Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC; Zhao, G | 1 |
| Buettner, GR; Cullen, JJ; Spitz, DR | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Abacioğlu, U; Atasoy, BM; Cağlar, H; Cıngı, A; Dane, F; Turhal, NS; Uçüncü Kefelı, A; Yeğen, C | 1 |
| Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Gnant, M; Goetzinger, P; Koelblinger, C; Kuehrer, I; Sahora, K; Schindl, M | 1 |
| Chang, DT; Christman-Skieller, C; Chun, CL; Columbo, LA; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Hsu, A; Kim, J; Koong, AC; Kunz, PL; Maxim, PG; Norton, J; Quon, A; Schellenberg, D; Van Dam, J; Xing, L | 1 |
| Ciombor, KK; Ferrell, A; Flores, A; Levi, J; Lopes, G; Macintyre, J; Merchan, JR; Ribeiro, A; Rocha-Lima, CM; Sleeman, D | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Avital, I; Davis, JL; Langan, RC; Levy, E; Pandalai, P; Ripley, RT; Steinberg, SM; Toomey, MA; Walker, M | 1 |
| Bennouna, J; Favrel, S; Lemarie, E; Pinel, MC; Pouget, JC; Senellart, H; Tourani, JM; Tournoux-Facon, C | 1 |
| Appelbaum, L; Goldberg, Y; Hubert, A; Kadouri, L; Peretz, T; Sagi, M; Sonnenblick, A | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Ballal, S; Dicke, K; Gurtler, J; Katz, T; Kayaleh, O; Keaton, M; Ko, AH; Lenz, HJ; Rowinsky, EK; Youssoufian, H | 1 |
| Bornschein, J; Kuester, D; Mönkemüller, K | 1 |
| Cho, JH; Kim, CS; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES; Yi, HG | 1 |
| Blackstock, AW; Fuchs, CS; Goldberg, RM; Hollis, D; Mamon, HJ; Mayer, RJ; Niedzwiecki, D; Tan, BR; Tepper, JE | 1 |
| Alvero, AB; Brown, DM; Husband, AJ; Kim, KH; McKernan, R; Mor, G; Saif, MW; Thompson, JA; Tytler, EM; Wang, X; Whiting, A | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Benninger, K; Carson, WE; Chaudhury, AR; Guenterberg, K; Guttridge, DC; Jaime-Ramirez, AC; Khan, M; Kondadasula, SV; Kreiner, M; Kuppusamy, P; La Perle, KM; Lesinski, GB; Mundy-Bosse, BL; Young, G | 1 |
| Hashimoto, S; Hirai, Y; Kawago, M; Naito, K; Nakamura, R; Nishiguchi, H; Ohta, F; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Fleming, JB; Haque, W; Hobbs, BD; Javle, MM; Krishnan, S; Lee, JE; Safran, H; Staerkel, GA; Varadhachary, GR; Wolff, RA; Yordy, JS | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Makrilia, N; Saif, MW; Syrigos, KN | 1 |
| Abbruzzese, JL; Budillon, A; Carbone, C; Chiao, PJ; Ling, J; Melisi, D; Moccia, T; Paradiso, G; Xia, Q | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Hawkes, EA; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Chen, X; Hormigo, A; Liu, A; O'Reilly, E; Pentsova, E; Rosenblum, M | 1 |
| Lowery, MA; O'Reilly, EM | 1 |
| Bachellier, P; Berrevoet, F; Clavien, PA; Delpero, JR; Dufour, P; Heinrich, S; Lang, H; Laurent, S; Lesurtel, M; Moehler, M; Pestalozzi, B; Raoul, JL; Rogiers, X; Weber, A | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 1 |
| Dosch, J; Hynes, M; Li, C; Pasca di Magliano, M; Sarkar, B; Simeone, DM; Welling, TH; Wu, JJ | 1 |
| Chen, ZW; Cheng, BJ; Jian, H; Lu, S; Xu, YH; Ye, XY; Zhou, Z | 1 |
| Lagerstedt, E; Mäenpää, J; Seppänen, J; Staff, S | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Harder, J; Hartmann, A; Hollerbach, S; Kullmann, F; Kutscheidt, A; Messmann, H; Stöhr, R; Trojan, J; Troppmann, M | 1 |
| Akaike, M; Kameda, Y; Mikayama, H; Miyagi, Y; Morinaga, S; Nakamura, Y; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Brody, JR; Witkiewicz, AK; Yeo, CJ | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Alberts, SR; Benson, AB; Brell, JM; Cardenes, H; Cella, D; Crane, CH; Feng, Y; Flynn, P; Loehrer, PJ; Ramanathan, RK; Wagner, L | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Bae, I; Duong, HQ; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Assmann, G; Bader, DC; Bruns, C; Buchner, D; De Toni, EN; Gallmeier, E; Göke, B; Guo, Y; Jung, A; Kirchner, T; Laubender, RP; Ochs, S; Palagyi, A; Schäfer, C; Seeliger, H; Ziesch, A | 1 |
| Andriulli, A; Bassi, C; Botteri, E; Festa, V; Koch, M; Maisonneuve, P; Sebastiano, PD; Valvano, MR | 1 |
| Hirokawa, N; Ito, Y; Karasawa, K; Kokubo, M; Nemoto, K; Nishimura, Y; Ogawa, K; Ogo, E; Onishi, H; Saito, T; Shibuya, H; Shibuya, K | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH | 1 |
| Balasubramaniam, A; Cho, J; Kennedy, MA; Lewis, KB; Sheriff, S; Tinch, SL; Watanabe, M | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Hamada, T; Isaji, S; Kishiwada, M; Mizuno, S; Ohsawa, I; Sakurai, H; Tabata, M; Usui, M | 1 |
| Bahra, M; Boas-Knoop, S; Esendik, U; Hartmann, W; Heppner, F; Kamphues, C; Koch, A; Lippert, S; Neuhaus, P; Pietsch, T; Schüller, U; Waha, A | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T | 1 |
| Ben-Josef, E; Lawrence, TS | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Cox, NL; Evans, P; Friedman, P; Giacomini, KM; Glubb, D; Goldberg, RM; Hollis, D; Hurwitz, H; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; Li, L; McLeod, HL; Mushiroda, T; Nakamura, Y; Owzar, K; Ratain, MJ; Schilsky, RL; Wang, L; Zembutsu, H | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Inoue, K; Kamata, M; Kitade, H; Kwon, AH; Matsui, Y; Ohe, C; Sakaida, N; Satoi, S; Tanigawa, N; Toyokawa, H; Uemura, Y; Yamamoto, T; Yanagimoto, H | 1 |
| Lee, M; Yee, NS; Yee, RK; Zhou, W | 1 |
| Lau, PC; Ng, WT; Yu, SC; Zheng, SF | 1 |
| Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC | 1 |
| Cormier, Y; Gitlitz, B; Gleave, ME; Hao, D; Laskin, JJ; Lee, C; Murray, N; Nemunaitis, J; Nicholas, G; Nugent, F; Pressnail, B; Sanborn, R; Stephenson, J; Ung, Y; Vincent, M | 1 |
| Kikuchi, I; Kurosumi, M; Nishida, K; Nishimura, Y; Sakai, H; Sakamoto, H; Tanaka, Y; Yatsuoka, T | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Egawa, N; Hanada, K; Hijioka, S; Hirose, Y; Ikari, T; Ikeda, T; Ishii, H; Itoi, T; Kimura, Y; Maetani, I; Matsumura, Y; Mouri, H; Nakajima, T; Ohoka, S; Okabe, Y; Omuro, Y; Ozaka, M; Sofuni, A; Suyama, M; Tani, M; Watanabe, R | 1 |
| Abdalla, EK; Balachandran, A; Crane, CH; Fleming, JB; Fogelman, DR; Katz, MH; Lee, JE; Pisters, PW; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wolff, RA; Xiao, L | 1 |
| Chen, D; Jiao, X; Liang, J; Niu, M; Zhang, D; Zhang, K | 1 |
| Algin, E; Balakan, O; Benekli, M; Buyukberber, S; Colak, D; Dane, F; Dikiltas, M; Durnali, AG; Elkiran, ET; Geredeli, C; Goksel, G; Gumus, M; Harputoglu, H; Helvaci, K; Inal, A; Isikdogan, A; Kaplan, MA; Kos, FT; Kucukoner, M; Ozdemir, N; Ozkan, M; Uncu, D; Unek, IT; Yildiz, R | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Ishikawa, O; Katayama, K; Kawada, N; Nagata, S; Nakamura, S; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Brody, JR; Holdbrook, T; Leiby, BE; Littman, SJ; Pequignot, E; Valsecchi, ME; Witkiewicz, AK; Yeo, CJ | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Chalasani, P; Jolivet, J; Kurtin, S; Mahadevan, D; Pretzinger, C; Ramanathan, RK; Rensvold, D; Von Hoff, DD; Weiss, GJ | 1 |
| Wolff, RA | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Lee, SC; Ling, W; Sachdeva, P; Wong, AS; Zee, YK | 1 |
| Akasbi, Y; Arifi, S; Boutayeb, F; El Idrissi, M; El Mesbahi, O; El Mrini, A; Shimi, M | 1 |
| Cheewakriangkrai, C; Manopunya, M; Suprasert, P | 1 |
| Alexander, A; Anlauf, M; Knoefel, WT; Rehders, A; Riediger, R; Schmitt, M | 1 |
| Borg, M; Goldstein, D; Halkett, G; Kneebone, A; Reece, W; Short, M; Spry, N; Zissiadis, Y | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Hadley, S; Khan, G; Lawrence, T; Leslie, W; Normolle, D; Schipper, M; Simeone, DM; Sonnenday, C; Ten-Haken, R; Zalupski, MM | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M | 1 |
| Chen, LH; Leung, PS; Liang, J; Lin, ZX; Liu, L; Zhao, M | 1 |
| Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW | 1 |
| Barth, RJ; Colacchio, TA; Davis, TH; Gardner, TB; Gordon, SR; Korc, M; MacKenzie, TA; McGowan, MM; Pipas, JM; Preis, M; Ripple, GH; Smith, KD; Srivastava, A; Suriawinata, AA; Sutton, JE; Tarczewski, SM; Tsapakos, MJ; Tsongalis, GJ; Zaki, BI | 1 |
| Duchêne, B; Hebbar, M; Jonckheere, N; Leteurtre, E; Skrypek, N; van Seuningen, I | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Sudo, T; Sueda, T; Uemura, K | 1 |
| Li, G; Li, W; Qu, X; Sun, C; Xue, X; Zhao, C | 1 |
| El-Rayes, BF; Zafar, SF | 1 |
| Auriemma, A; Bassi, C; Boz, G; Cantore, M; Frigerio, I; Giardino, A; Girelli, R; Mambrini, A; Orlandi, M; Salvia, R | 1 |
| Comans, EF; Hartemink, KJ; Paul, MA; Phernambucq, EC; Postmus, PE; Senan, S; Smit, EF | 1 |
| Barlev, A; Bray, S; Butt, Z; Cella, D; Fuchs, CS; Kindler, HL; Oglesby, A | 1 |
| Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH | 1 |
| Hampole, H; Singh, A | 1 |
| Bray, SL; Chan, D; Feigal, EG; Fuchs, CS; Galimi, F; Garbo, LE; Garon, EB; Hei, Y; Kindler, HL; Kocs, DM; Loh, E; McGreivy, J; Richards, DA; Rocha-Lima, CM; Safran, H; Stephenson, JJ | 1 |
| Bae, I; Duong, HQ; Hwang, JS; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Costello, E; Greenhalf, W; Neoptolemos, JP | 1 |
| Jiang, J; Jiang, W; Kim, R; Liu, X; Wang, Y; Xie, H | 1 |
| Gupta, MK; Madabhavi, I; Rastogi, M; Revannasiddaiah, S | 1 |
| Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Aglietta, M; Campanella, D; Capussotti, L; Colombi, F; Gabriele, P; Gatti, M; Leone, F; Massucco, P; Regge, D; Sperti, E | 1 |
| Chang, DZ; Cohen, L; Garrett, CR; Huo, Y; Liu, L; Meng, Z; Ng, CS; Shen, Y; Spelman, AR; Yang, P; Zhao, Q | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Cox, TF; Dervenis, C; Ghaneh, P; Glimelius, B; Halloran, CM; Lacaine, F; Lerch, MM; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Smith, D; Tebbutt, NC; Valle, JW; Verbeke, CS | 1 |
| Bauer, TM; Bekaii-Saab, T; El-Rayes, BF; Hammad, N; Li, X; Philip, PA; Shields, AF; Zalupski, MM | 1 |
| Frampton, AE; Jiao, LR; Krell, J; Stebbing, J | 1 |
| Goedegebuure, P; Hawkins, WG; Hornick, JR; Lockhart, AC; Mitchem, JB; Picus, J; Plambeck-Suess, S; Simon, PO; Sorscher, S; Suresh, R; Tan, B; Wang-Gillam, A | 1 |
| Bachet, JB; Demetter, P; Maréchal, R; Salmon, I; Van Laethem, JL; Verset, L | 1 |
| O'Reilly, EM | 1 |
| Li, D; Liu, M; Lou, Y; Ren, Y; Sun, X; Zhang, C; Zhou, J | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Berk, V; Buyukberber, S; Ciltas, A; Colak, D; Dane, F; Gumus, M; Inal, A; Isikdogan, A; Kos, FT; Ozdemir, NY; Ozkan, M; Unek, IT; Yildiz, R | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Bourgaux, C; Couvreur, P; Desmaële, D; Lepeltier, E; Lepêtre, S; Maksimenko, A; Mougin, J; Mura, S; Sliwinski, E; Zouhiri, F | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Bersani, S; Dalla Pozza, E; Dando, I; De Laurenzi, V; De Marco, M; di Mola, FF; di Sebastiano, P; Dijk, F; Donadelli, M; Fontana, A; Franco, R; Medema, JP; Palaia, R; Palmieri, M; Pezzilli, R; Rosati, A; Scarpa, A; Scognamiglio, G; Tavano, F; Turco, MC; Welling, L | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Barcenas, J; Bohac, GC; Conlon, K; Davis, M; Deng, Y; Lamzabi, I; Leslie, W; Li, Y; Plate, JM; Watkins, L | 1 |
| Barrière, J; Falk, AT; Ghalloussi, H; Otto, J; Poudenx, M | 1 |
| Cho, JH; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES | 1 |
| Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Behrman, SW; Chitkara, D; Kumar, V; Mahato, RI; Singh, S | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Aiura, K; Itano, O; Kitagawa, Y; Matsuda, S; Suzuki, K; Takeuchi, O; Umezawa, K | 1 |
| Jiang, W; Liu, X; Xiao, SY; Xie, H | 1 |
| Albarello, L; Balzano, G; Braga, M; Capretti, G; Castoldi, R; Cereda, S; Di Carlo, V; Doglioni, C; Pecorelli, N; Reni, M | 1 |
| Al-Wadei, HA; Banerjee, J; Schuller, HM | 1 |
| Deng, HX; Liang, SF; Nie, CL; Wei, YQ; Yuan, Z; Zhao, XY | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Krug, S; Michl, P | 1 |
| Alfieri, S; Antinori, A; Balducci, M; Crucitti, A; D'Agostino, GR; Deodato, F; Ippolito, E; Luzi, S; Macchia, G; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Cella, D; Ko, AH | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Knox, JJ; Zhu, AX | 1 |
| Chiorean, EG; Hardacre, JM; Krishnamurthi, S; Lenz, HJ; Mulcahy, M; Obel, J; Rocha-Lima, CS; Safran, H; Small, W; Talamonti, M | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Uemura, K | 1 |
| Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Khan, G; Lawrence, TS; Leslie, W; Schipper, M; Vainshtein, JM; Zalupski, MM | 1 |
| Ashida, R; Ioka, T; Katayama, K; Kobayashi, N; Takakura, R; Tanaka, S; Taniai, H | 1 |
| Ito, R; Kitamura, H; Miyake, R; Nojiri, T; Okui, N; Saito, R; Son, K; Toyama, Y; Usuba, T; Yanaga, K; Yoshida, S | 1 |
| Centeno, BA; Chellappan, SP; Fulp, WJ; Kunigal, S; Pillai, S; Singh, S; Treviño, JG | 1 |
| Huang, H; Jiao, Z; Kong, X; Li, L; Liu, Z; Xu, M; Xu, P; Zhang, Y | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Borghero, Y; Cassina, JC; Gabrielli, M; Galindo, J; Garrido, M; Guerra, JF; Jarufe, N; Madrid, J; Martínez, J; Roa, JC; Zoroquiain, P | 1 |
| Berg, DJ; Bodeker, KL; Buettner, GR; Cullen, JJ; Drisko, J; Du, J; Halfdanarson, TR; Levine, M; Roberts, LJ; van't Erve, TJ; Wagner, BA; Welsh, JL; Yee, NS; Zehr, PS | 1 |
| Arpicco, S; Beghelli, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Scarpa, A; Scupoli, MT; Zoratti, E | 1 |
| Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Haba, T; Hyougotani, A; Katoh, K; Koyama, H; Miyazawa, M; Muramatsu, A; Ozawa, K | 1 |
| Grassin, F; Guigay, J; L'Her, P; Margery, J; Morel, V; Vaylet, F | 1 |
| Chanona, G; De La Garza, J; Duenas-Gonzalez, A; Gonzalez-Enciso, A; Guadarrama, R; Lopez-Graniel, C; Mohar, A; Mota, A; Rivera, L | 1 |
| Au, SK; Chan, TM; Cheung, FY; Chiu, CY; Foo, W; Kwok, CH; Lau, WH; Law, CK; Ngan, RK; Tse, KC; Yau, S; Yiu, HH | 1 |
| Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G | 1 |
| Armand, JP; Faivre, S; Kayitalire, L; Le Chevalier, T; Lhommé, C; Lokiec, F; Monnerat, C; Novello, S; Pautier, P; Raymond, E; Ruffié, P; Taieb, J | 1 |
| Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U | 1 |
| Epelbaum, R; Faraggi, D; Gaitini, D; Kuten, A; Mizrahi, S; Nasrallah, S; Rosenblatt, E | 1 |
| Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE | 1 |
| Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A | 1 |
| Azria, D; Prost, P; Ychou, M | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Culine, S | 1 |
| Clippe, C; Ligneau, B; Trillet-Lenoir, V | 1 |
| Mornex, F | 1 |
| Edmonds, MR; Ma, BB; Pond, GR; Siu, LL; Tannock, IF | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 1 |
| Hirai, I; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Antolak, JA; Charnsangavej, C; Crane, CH; Evans, DB; Forster, KM; Janjan, NA; Lenzi, R; Papagikos, MA; Pisters, PW; Rosen, II; Wolff, RA | 1 |
| Boxberger, F; Brueckl, V; Brueckl, WM; Hahn, EG; Hautmann, M; Hohenberger, W; Jüngert, B; Wein, A | 1 |
| Alonso, V; Antón, A; Artal-Cortés, A; Ceballos, C; Corral, M; Herrero, A; Martínez-Trufero, J; Maurel, J; Puértolas, T | 1 |
| Abbruzzese, JL; Bedford, R; Freeman, SM; Hecht, JR; Kirn, DH; Lahoti, S; Reid, TR; Soetikno, RM | 1 |
| Chanona, G; de la Garza, J; Dueñas-González, A; Gomez, E; González, A; López-Graniel, C; Mohar, A; Rivera, L; Trejo-Becerril, C | 1 |
| Abbruzzese, JL | 2 |
| Borsellino, N; Caruso, M; Colucci, G; Durini, E; Galetta, D; Gebbia, N; Gebbia, V; Loizzi, M; Pandolfo, G; Pezzella, G; Rinaldi, M; Tirrito, ML; Valdesi, M; Valenza, R; Varvara, F; Verderame, F | 1 |
| Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ | 1 |
| Adachi, Y; Fujita, Y; Fujiwara, M; Horiki, N; Imoto, I; Maruyama, M; Sasaki, H; Shimomura, M; Suzuki, K; Suzuki, Y; Tanaka, T; Tanigawa, K | 1 |
| Abramoff, R; Gansl, RC; Hoff, PM; Katz, A; Machado, MC; Saad, ED; Simon, SD; Tabacof, J; Wajsbrot, D | 1 |
| Chávez-Blanco, A; Dueñas-González, A; García-López, P; González-Fierro, A; Lizano-Soberon, M; Mariscal, I; Pérez-Cárdenas, E; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Treviño-Cuevas, H; Wegman-Ostrosky, T | 1 |
| el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V | 1 |
| De Bruijn, EA; Friedel, G; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 2 |
| Fitch, TR; Geeraerts, LH; Ghosh, C; Goldberg, RM; Haddock, MG; Keppen, MD; Martenson, JA; Pitot, HC; Sargent, DJ; Vigliotti, AP | 1 |
| Albrecht, P; Elmer, A; Kortsik, C | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Chen, MC; Chen, YM; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Aziz, Z; Malik, IA; Sethuraman, G; Zaidi, SH | 1 |
| Arlt, A; Fölsch, UR; Gehrz, A; Kruse, ML; Müerköster, S; Schäfer, H; Vorndamm, J | 1 |
| Yeo, CJ | 1 |
| Closon, MT; Closset, J; Collette, M; Demols, A; Gastelblum, P; Gay, F; Gelin, M; Houbiers, G; Houtte, PV; Polus, M; Van Laethem, JL | 1 |
| Bland, KI; Bonner, JA; Buchsbaum, DJ; Huang, ZQ; Raisch, KP; Vickers, SM | 1 |
| Araki, J; Nishio, K; Oda, T; Watanabe, M | 1 |
| Hitsuda, Y; Kawasaki, Y; Koshohbu, T; Matsumoto, S; Nakatani, S; Shimizu, E; Yasuda, K | 1 |
| Calvanese, A; Ceciarini, F; Cerretani, D; Correale, P; Di Palma, T; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Neri, A; Pellegrini, M; Petrioli, R; Pinto, E; Pozzessere, D; Sabatino, M | 1 |
| Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N | 1 |
| Adsay, V; Day, J; El-Rayes, BF; Heilbrun, LK; Jain, V; Philip, PA; Shields, AF; Vaishampayan, U; Zalupski, MM | 1 |
| Lawrence, TS; Shewach, DS | 1 |
| Abbruzzese, J; Hainsworth, J; Hochster, H; Lenzi, R; Plunkett, W; Ruiz Van Haperen, V; Tempero, M | 1 |
| Crane, CH; Janjan, NA; Mason, K; Milas, L | 1 |
| Claude, L; Mornex, F | 1 |
| Aikawa, I; Matsuda, T; Taniguchi, F; Tsuda, T | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
| Colwell, B; Dagenais, M; Dancey, J; Eisenberg, PD; Fields, A; Greenberg, B; Hagan, K; Hamm, J; Humphrey, R; Moore, MJ; Ottaway, J; Seymour, L; Tu, D; Zee, B | 1 |
| Ferenczi, E; Gergely-Farnos, E; Kovács, G; Magyar, P; Ostoros, G; Strausz, J; Szondy, K | 1 |
| Haller, DG | 1 |
| Hirokawa, S; Masaki, T; Miyakawa, K; Ohkawa, S; Tamai, S; Tarao, K | 1 |
| Boezen, HM; de Leede, GP; de Vries, EG; Eppinga, P; Erjavec, Z; Groen, HJ; Kramer, H; Strijbos, JH; Van Putten, JW; Wachters, FM | 1 |
| De Boeck, G; De Bruijn, E; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F | 1 |
| Lambiase, L; Li, J; Monteiro, C; Robinson, K; Schiff, M | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Sauerbruch, T; Schlie, C; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Haller, D; Sun, W | 1 |
| Bhargava, P; Jani, CR; O'Donnell, JL; Rocha Lima, CM; Savarese, DM; Stuart, KE | 1 |
| Genet, D; Labourey, JL; Ly, K; Martin, J; Szelag, JC; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Kennedy, AW; Khuntia, D; Markman, M; Schwartz, BM | 1 |
| Bai, YR; Chen, Y; Guo, WJ; Lu, DQ; Wu, GH; Wu, XD; Yao, Y; Zhou, RH | 1 |
| Arii, S; Baba, H; Endo, M | 1 |
| Barceló, R; Ferreiro, J; Fuente, N; López-Vivanco, G; Mañé, JM; Muñoz, A; Pérez-Hoyos, T; Rubio, I; Viteri, A | 1 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 1 |
| Eckel, F; Erdmann, J; Lersch, C; Mayr, M; Schmelz, R | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Berardi, R; Carle, F; Cellerino, R; Lippe, P; Menichetti, ET; Nacciarriti, D; Piga, A; Porfiri, E; Scartozzi, M; Silva, RR; Tummarello, D | 1 |
| Calley, C; Fata, F; Ganjoo, KN; Loehrer, PJ; Picus, J; Schneider, BP; Seitz, DE; Stoner, C | 1 |
| Ashley, SW; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 3 |
| Dianzani, C; La Cesa, A; Landi, D; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Balzarini, P; Bonora, A; Ennas, MG; Grigolato, P; Moore, PS; Sartoris, S; Scarpa, A; Sorio, C; Tecchio, C | 1 |
| Abbruzzese, JL; Benedetti, JK; Chansky, K; Macdonald, JS; Pluenneke, RE; Urba, SG; VanVeldhuizen, PJ | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Van Bochove, A; Van Groeningen, CJ | 1 |
| Behrens, P; Lee, KM; Märten, A; Mühlradt, PF; Sauerbruch, T; Schmidt, J; Schmidt, T; Schmidt-Wolf, IG; Schneider, C; Tiemann, K; Uhlinsky, V; Ziske, C | 1 |
| Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K | 1 |
| De Lange, SM; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Snijders, JF; Van Bochove, A; van Groeningen, CJ | 1 |
| Campione, A; Diciolla, F; Gotti, G; Luzzi, L; Voltolini, L | 1 |
| Beraldi, E; English, JC; Evans, K; Fazli, L; Gleave, ME; July, LV; So, A | 1 |
| Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY | 1 |
| Abbruzzese, JL; McConkey, D; Pino, SM; Xiong, HQ | 2 |
| Bagajevas, A; Cesas, A | 1 |
| Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL | 1 |
| Bansal, R; Friedlander, PA; Kemeny, N; Posner, J; Schwartz, L; Wagman, R | 1 |
| Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L | 1 |
| Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V | 1 |
| Chen, LT; Chen, SC; Chuang, WL; Su, YC; Wu, WC | 1 |
| Ferson, PF; Friberg, D; Gooding, WE; Kassem, B; Keenan, R; Landreneau, RJ; Levitt, ML; Lindberg, CA; Miketic, LM; Ponas, RS; Sabatine, JM; Tarasoff, P; Trenn, MR; Whiteside, TL; Yousem, SA | 1 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Waseem, T; Whang, EE | 2 |
| Dong, M; Feng, FY; Fu, M; Liang, X; Lin, C; Lu, HY; Wu, M; Zha, YY; Zhang, XY | 1 |
| Cerretani, D; Cetta, F; Clerici, M; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Savelli, V | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Katsuki, S; Machida, T; Mezawa, S; Murakami, K; Sato, T; Takanashi, K | 1 |
| Chahine, GY; Dagher, JE; Farhat, FS; Ghosn, MG; Kattan, JG; Mokaddem, WT; Nasr, FL; Tueni, EA | 1 |
| Ikehara, M; Noda, K; Oshita, F; Saitoh, H; Suzuki, R; Yamada, K | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Allen, AM; Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Simone, D; Zalupski, MM | 1 |
| Alakavuklar, M; Coker, A; Oztop, I; Sagol, O; Tarhan, O; Yaren, A; Yavuzsen, T; Yilmaz, U | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Chen, J; Deng, HX; Ding, ZY; Fu, CH; Gao, ZN; He, QM; Kan, B; Li, HL; Li, J; Li, Q; Liu, J; Luo, Y; Mao, YQ; Su, JM; Tan, GH; Tian, L; Wang, L; Wei, YQ; Wen, YJ; Wu, Y; Xiao, F; Xie, XJ; Yang, L; Yi, T; Zhao, X; Zou, CH | 1 |
| Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
| André, T; Avenin, D; de Gramont, A; Gayet, B; Hannoun, L; Houry, S; Lotz, JP; Louvet, C; Maindrault-Goebel, F; Paye, F; Provent, S; Rosmorduc, O; Selle, F; Tournigand, C | 1 |
| Bojko, P; Hense, J; Moritz, T; Müller, S; Nowrousian, MR; Schütt, P; Seeber, S | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Blackstock, AW; Hollis, DR; Mayer, RJ; Niedwiecki, D; Tempero, MA; Tepper, JE | 1 |
| Cooper, H; Eisenberg, BL; Freedman, G; Hoffman, JP; Meropol, NJ; Pingpank, JF; Ross, EA; Sasson, AR; Wetherington, RW | 1 |
| Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Hong, YS; Kang, JH; Lee, KS; Lee, MA; Woo, IS | 1 |
| Freiha, F; Morgan, K; Srinivas, S | 1 |
| Cass, C; Dabbagh, L; Dumontet, C; Glubrecht, D; Lai, R; Mackey, JR; Sangha, R; Spratlin, J; Young, JD | 1 |
| Barauskas, G; Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Guan, ZZ; Li, N; Pan, ZK; Xu, F; Zhang, L; Zhang, Y | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Hawkins, AE; Huang, ZQ; Khazaeli, MB; Kraus, MH; Vickers, SM | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Blessing, J; Cohn, DE; Schilder, RJ | 1 |
| Alberts, SR; Erlichman, C; Fitch, TR; Foster, NR; Moore, DF; Nair, S; Rowland, KM; Schroeder, M; Steen, PD; Tschetter, LK | 1 |
| Biswas, S; Corrie, PG; Nik, S | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Nishimoto, H; Ohara, T; Shimada, K | 1 |
| Fujii, Y; Yoneto, T; Yoshikawa, K | 1 |
| Claude, L; Flandin, I; Khodri, M; Kubas, A; Mazeron, R; Mornex, F; Partensky, C; Wautot, V | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Jin-Kim, H; Kim, JS; Kim, SH; Kim, YH; Kwon, HC; Oh, SY; Park, JS | 1 |
| Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C | 1 |
| Inoue, S; Kitamura, M; Maeshiro, T; Matsuo, S; Miyamoto, S; Ohkubo, T; Ohmura, T; Tanaka, S; Umekita, N | 1 |
| Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y | 1 |
| Bograd, S; Harris, JE; Plate, AE; Plate, JM; Shott, S | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Kangasniemi, L; Raki, M; Ranki, T; Ristimaki, A; Sarkioja, M | 1 |
| Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C | 1 |
| Aitini, E; André, T; de Gramont, A; Ducreux, M; Faroux, R; Hammel, P; Labianca, R; Lepere, C; Lledo, G; Louvet, C; Taïeb, J; Zampino, MG; Zaniboni, A | 1 |
| Aldrighetti, L; Balzano, G; Bonetto, E; Bordonaro, R; Cordio, S; Di Carlo, V; Galli, L; Luppi, G; Milandri, C; Nicoletti, R; Oliani, C; Passardi, A; Passoni, P; Reni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Smith, JP; Verderame, MF; Zagon, IS | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; von Delius, S | 1 |
| Brachtel, EF; Brugge, WR; Fernandez-del Castillo, C; Ryan, DP; Sahani, D; Willett, CG | 1 |
| Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE; Vermorken, JB | 1 |
| Calbó, J; Capellà, G; Cascalló, M; Fillat, C; Mazo, A; Pastor-Anglada, M | 1 |
| Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A | 1 |
| Balzano, G; Bonetto, E; Di Carlo, V; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 1 |
| Chak, K; Chan, AT; Lam, KC; Lee, C; Mok, TS; Wong, H; Yeo, W; Yim, AP; Zee, B; Zhang, L | 1 |
| Abratt, R; Bertetto, O; Burillon, JP; Gatzemeier, U; Hui, R; Krzakowski, M; Macha, HN; Mattson, K; Parlier, Y; Pawel, JV; Pouget, JC; Reiterer, P; Szczesna, A; Tan, EH; Wernli, M | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Boterberg, T; Closon, MT; Closset, J; Demols, A; Gay, F; Honoré, P; Peeters, M; Polus, M; Van Houtte, P; Van Laethem, JL | 1 |
| Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Bajardi, E; Caraglia, M; Carli, AF; Cicero, G; Correale, P; Del Prete, S; Francini, G; Fulfaro, F; Gebbia, N; Greco, E; Intrivici, C; Marsili, S; Vuolo, G | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Bria, E; Carboni, F; Carlini, P; Cognetti, F; Di Cosimo, S; Ettorre, GM; Gelibter, A; Giannarelli, D; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Dumontet, C; Galmarini, CM; Guittet, O; Jordheim, LP; Lepoivre, M | 1 |
| Caca, K; Kronberg, J; Mossner, J; Schoppmeyer, K; Tannapfel, A; Wittekind, C | 1 |
| Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP | 1 |
| Alenda-González, C; Campos-Mollo, E; Moya-Moya, MA; Pérez-González, LE | 1 |
| Funakoshi, A; Ishii, H; Ohkawa, S; Okusaka, T; Saito, H; Saito, S; Tsuyuguchi, T; Yamao, K | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L | 1 |
| Berlin, JD | 1 |
| Ko, AH; Tempero, MA | 2 |
| Fujisaki, S; Kayashima, S; Nemoto, N; Oimuna, T; Takashina, M; Takayama, T; Tomita, R | 1 |
| Barth, RJ; Bettmann, MA; Cates, JM; Colacchio, TA; Cole, BF; Gordon, SR; Marshall, JF; McDonnell, CE; Meyer, LP; Perez, RP; Pipas, JM; Redfield, N; Ripple, GH; Suriawinata, AA; Sutton, JE; Tsapakos, MJ; Zaki, B | 1 |
| Dachman, A; Friberg, G; Karrison, T; Kindler, HL; Kozloff, M; Locker, G; Nattam, S; Singh, DA; Stadler, WM; Taber, DA; Vokes, EE | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Hirata, N; Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R; Yabu, K | 1 |
| Bepler, G; Cantor, A; Nwogu, C; Ramnath, N; Robinson, L; Sharma, A; Sommers, E | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Doi, R; Fujimoto, K; Ito, D; Kami, K; Kawaguchi, Y; Koizumi, M; Mori, T; Toyoda, E | 1 |
| Airoldi, M; Cattel, L; Milla, P; Passera, R; Pedani, F; Zanon, C | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 2 |
| Hyodo, M; Koizumi, M; Kurihara, K; Nagai, H; Sata, N; Shimura, K; Tsukahara, M; Yasuda, Y; Yoshizawa, K | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Ahn, YM; Cho, EH; Cho, KH; Choi, IS; Choi, JW; Kim, BS; Nam, SH; Roh, YH; Song, YB | 1 |
| Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KT; Park, JO; Park, K; Park, YS | 1 |
| Baron, D; Kluger, Y; Mayo, A | 1 |
| Julka, PK; Puri, T; Rath, GK | 1 |
| Abe, Y; Fujisawa, N; Fujisawa, T; Fujita, K; Inamori, M; Kawamura, H; Kirikoshi, H; Kobayashi, N; Kubota, K; Nakajima, A; Saito, S; Sakaguchi, T; Shimamura, T; Takahashi, H; Yoneda, M | 1 |
| Cho, EK; Heo, DS; Jung, KH; Kim, JH; Kim, SY; Kim, YH; Lim, HY; Park, BJ; Park, K; Ryoo, BY; Suh, CW | 1 |
| Kitano, M; Kudo, M; Nakai, T; Ohyanagi, H; Sakamoto, H; Suetomi, Y; Takeyama, Y; Yasuda, C | 1 |
| De Greef, K; Hendriks, JM; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Haye, S; Kalthoff, H; Kapischke, M; Kremer, B; Kruse, ML; Sipos, B; Tepel, J | 1 |
| Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ | 1 |
| Booker, AJ; Christensen, LA; Finch, RA; Vasquez, KM | 1 |
| Graeven, U; Killing, B; Kremer, B; Rojo, F; Schmiegel, W; Südhoff, T; Tillner, J; Unal, C; Weber, D | 1 |
| López Jiménez, A; Maestu Maiques, I; Oltra Ferrando, A; Pérez-Fidalgo, JA | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Ausania, F; Borzomati, D; Caricato, M; Coppola, R; Garberini, A; Rabitti, C; Tonini, G | 1 |
| Boehm, KA; Clark, M; Dasse, KD; Grove, W; Gulyas, S; Krishnamurthi, SS; Macdonald, K; Richards, DA; Rosemurgy, A; Wagener, DJ; Waterhouse, DM | 1 |
| Asadpour, B; Breuer, C; Buell, U; Eble, MJ; Fischedik, K; Gagel, B; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Skobel, E; Stanzel, S; Zimny, M | 1 |
| Bonomi, P; Chen, R; Christiansen, NP; McCleod, M; Mintzer, DM; Monberg, MJ; Obasaju, CK; Treat, J; Ye, Z | 1 |
| Badalamenti, G; Cicero, G; Di Leo, R; Fulfaro, F; Gebbia, N; Gulotta, G; Russo, A; Santangelo, D; Tomasello, G; Valerio, MR; Verderame, F | 1 |
| Laurie, SA; Licitra, L | 1 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Mulholland, MW; Newman, EA; Simeone, DM | 1 |
| Carrato Mena, A; Gallego Plazas, J; Guillén Ponce, C; Maciá Escalante, S; Martínez Ortiz, MJ; Rodríguez Lescure, A | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F | 1 |
| Barzon, L; Cartei, G; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
| Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A | 2 |
| Adam, R; Bellin, MF; Bralet, MP; Guettier, C; Paule, B | 1 |
| Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C | 1 |
| Eichler, K; Hammerstingl, R; Heller, M; Hochmuth, K; Jacob, U; Scheller, A; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Aikawa, I; Matsuda, T; Minato, H; Nomura, H; Taniguchi, F; Tsuda, T | 1 |
| Blackstock, AW; Case, LD; Descos, L; Kachnic, LA; Levine, EA; Limentani, SA; Melin, SA; Mishra, G; Mornex, F; Partensky, C; Tepper, JE | 1 |
| Neoptolemos, JP; Smith, DB | 1 |
| Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Greer, K; McGinness, J | 1 |
| Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N | 1 |
| Kaira, K; Mori, M | 1 |
| Li, M; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhang, Z | 1 |
| Funahashi, H; Manabe, T; Okada, Y; Sawai, H; Takeyama, H; Tanaka, M; Yamamoto, M | 1 |
| Geissler, M; Harder, J; Henss, H; Kummer, O; Lohrmann, C; Opitz, O; Otto, F; Riecken, B; Usadel, H | 1 |
| Tu, LF; Wang, LH; Wang, XF; Zhou, JY | 1 |
| Behrens, R; Buechner-Steudel, P; Fleig, WE; Kleber, G; Kuss, O; Lindig, U; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Chatani, K; Kametani, T; Masuda, S; Shibata, K; Takase, M | 1 |
| Boku, N; Fukutomi, A; Yoshino, T | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Baum, U; Brunner, TB; Grabenbauer, GG; Lambrecht, U; Sauer, R | 1 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Karapetis, CS; Keefe, DM; Koczwara, B; Kotasek, D; Moldovan, S; Olver, IN; Parnis, FX; Patterson, WK; Pittman, KB; Price, TJ; Yeend, SJ | 1 |
| Aikou, T; Kitazono, M; Kubo, F; Maemura, K; Noma, H; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H | 1 |
| Chan, M; Feller, E; Gold, R; Mega, A; Squire, S | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Bang, S; Chung, JB; Jeon, TJ; Kim, MH; Park, JY; Park, SW; Song, SY | 1 |
| Becht, C; Culine, S; de Champfleur, NM; Pouessel, D; Vieillot, S | 1 |
| Ciruelos, E; Colomer, R; Cortés-Funes, H; Hornedo, J; Llombart-Cussac, A; Mayordomo, JI; Ojeda, B; Rifà, J; Tusquets, I; Vicente, D | 1 |
| Siefker-Radtke, A | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| Imamura, F; Uchida, J; Ueno, K; Yoshimura, M | 1 |
| Buettner, H; Kaur, H; Marks, RS; Salomao, DR | 1 |
| Zalatnai, A | 1 |
| Atmatzidis, K; Chrysogelou, E; Harlaftis, N; Livanis, J; Moschidis, A; Moschidis, E; Mourelatos, D; Papageorgiou, A; Tsalis, K; Tsavdaridis, D | 1 |
| Lahans, T | 1 |
| Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ | 1 |
| Danenberg, PV; Endo, I; Fujii, Y; Ichikawa, Y; Ishikawa, T; Matsuyama, R; Mori, R; Shimada, H; Taniguchi, K; Togo, S; Ueda, M | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS | 1 |
| Akahori, T; Azuma, M; Enomoto, K; Hamada, K; Kanehiro, H; Kubo, A; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Yagita, H | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Bramhall, SR; Buckels, JA; Hassan, AB; Hewitt, H; Johnson, PJ; Markham, CE; Palmer, DH; Stocken, DD | 1 |
| Onodera, R; Sato, T; Seki, Y; Shimizu, K; Tai, H | 1 |
| Alberts, SR; Chari, ST; Gores, GJ; Kendrick, ML; Kim, GP; Martenson, JA; Roberts, LR; Rosen, CB | 1 |
| Barbera, S; Carozza, F; Ceribelli, A; Ciardiello, F; Cognetti, F; Daniele, B; Di Maio, M; Favaretto, A; Galetta, D; Gallo, C; Gamucci, T; Gebbia, V; Gridelli, C; Maione, P; Morabito, A; Perrone, F; Rosetti, F; Rossi, A; Testa, A | 1 |
| Iishi, H; Ioka, T; Ishikawa, O; Koizumi, M; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Tanaka, E; Uehara, H; Yamazaki, H | 1 |
| Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Beghelli, S; Bonora, A; Budillon, A; Caraglia, M; Costanzo, C; Dandrea, M; Donadelli, M; Palmieri, M; Piacentini, P; Scarpa, A; Scupoli, MT | 1 |
| Cereda, S; Galli, L; Reni, M | 1 |
| Alberts, SR; Camoriano, JK; Foster, NR; Haddock, MG; Hauge, MD; Martenson, JA; Moore, DF; Schaefer, PL; Stella, PJ; Swaminathan, R; Tenglin, RC | 1 |
| Lowenfels, AB; Maisonneuve, P | 1 |
| Hirte, H; Johnson, C; Low, J; Mackenzie, MJ; Moore, MJ; Pond, G; Saltman, D | 1 |
| Joensuu, T; Kärkkäinen, P; Kivilaakso, E; Kiviluoto, T; Mustonen, H; Vento, P | 1 |
| Bhargava, P; Blaszkowsky, L; Earle, CC; Fuchs, CS; Kulke, MH; Lehman, N; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Bouffard, DY; Cass, CE; Clarke, ML; Damaraju, VL; Gourdeau, H; Grey, M; Leblond, L; Mackey, JR; Wong, CK | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Chen, GY; Hong, X; Lu, L; Wang, M; Yang, ZY; Zhang, CH | 1 |
| Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Achiwa, H; Eimoto, T; Muramatsu, H; Oguri, T; Ozasa, H; Sato, S; Shimizu, S; Ueda, R; Yamazaki, H | 1 |
| Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF | 1 |
| Abou-Alfa, GK; O'Reilly, EM | 1 |
| Hagihara, A; Ikeda, M; Morizane, C; Ogura, T; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD | 1 |
| Guo, SS; Jiang, ZM; Liang, HL; Xie, DR; Yang, Q | 1 |
| Dillmann, S; Henne-Bruns, D; Keller, F; Klug, F; Mayer, JM; Stracke, S; Tuncyurek, P | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Fujii, N; Takemura, N; Tanaka, T | 1 |
| Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E | 1 |
| Hashmi, S; Saif, MW | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Aderka, D; Ashkenazy-Voghera, M; Ben-Yosef, R; Greif, J; Lev-Ari, S; Starr, A; Vexler, A | 1 |
| Babcock, TA; Dekoj, TR; Espat, NJ; Garrean, S; Hering, J; Razzak, A; Saied, A; Trevino, J | 1 |
| Emori, Y; Eta, R; Hamano, H; Iino, Y; Kawasaki, D; Takei, M; Tanaka, T; Watson, SA; Yoshinaga, K | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR | 1 |
| Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Bützow, R; Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Raki, M; Särkioja, M | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A | 1 |
| Fukuyama, T; Hachiya, Y; Hirano, Y; Ishikawa, N; Maeyama, R; Morimatsu, K; Sako, T; Tamura, T | 1 |
| Hashimoto, Y; Kato, T; Kohri, K; Okada, S; Takahashi, S; Tozawa, K | 1 |
| Alexander, HR; Bartlett, DL; Dedrick, RL; Egorin, MJ; Gamblin, TC; Herscher, LL; Lagattuta, TF; Libutti, SK; Russo, A; Zuhowski, EG | 1 |
| Dixon, J; Holcomb, B; Kennard, J; Mahomed, J; Matos, JM; Schmidt, CM; Sebolt-Leopold, J; Shanmugam, R; Yip-Schneider, MT | 1 |
| Arnoletti, JP; Ben-Josef, E; Bhargava, P; Casper, ES; Kim, P; Malafa, MP; Nakakura, EK; Shibata, S; Talamonti, M; Tempero, M; Wang, H; Willett, C | 1 |
| Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ | 1 |
| Iguch, M; Kiba, T; Motoo, Y; Nishio, K; Saitou, Y; Takahashi, Y; Yamaguchi, K | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Berardi, R; Cantore, M; Cascinu, S; Cereda, S; Ferrari, VD; Grisanti, S; Mambrini, A; Mazza, E; Pasetto, L; Reni, M | 1 |
| Braguer, D; Cournede, A; Dahan, L; Duluc, M; Laquiere, A; Laugier, R; Ressiot, E; Ries, P; Seitz, JF | 1 |
| Benson, AB; Small, W; Wahl, AO; Wisinski, KB | 1 |
| Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J | 1 |
| Boeck, S; Heinemann, V | 2 |
| Amos, KD; Arumugam, T; Evans, DB; Hwang, RF; Ji, B; Logsdon, CD; Moore, T; Ramachandran, V; Rivera, A | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Arseneau, J; Caprioni, F; Corringham, R; De Boer, C; DeWitte, M; Friess, H; Lu, JD; Malfertheiner, P; Mantovani, G; Prabhakar, U; Qi, M; Richel, D; Ritch, P; Robinson, D; Van Cutsem, E; Von Hoff, D; Wiedenmann, B; Zhong, B | 1 |
| Jing, Q; Rougcheng, L; Xinyu, Q | 1 |
| Dai, C; Du, Q; Gardner, K; Guo, X; Jacobs, JL; Jiang, K; Li, H; Li, QQ; Miao, Y; Qian, Z; Sun, G; Xu, Z; You, Y; Yu, C; Yuan, D; Zhang, X; Zhu, Y | 1 |
| Attia, S; Eickhoff, J; Erlichman, C; Heun, J; Holen, KD; Huang, W; Kolesar, J; Laheru, D; Mahoney, MR; Pitot, HC | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Dong, K; Li, B; Lin, F; Shen, JJ; Wang, R; Wang, X; Wei, SH; Zhang, HZ; Zhang, Q | 1 |
| Fujii, M; Fukatsu, H; Harada, R; Ishida, E; Kawamoto, H; Kurihara, N; Mizuno, O; Nakanishi, T; Ogawa, T; Okada, H; Sakaguchi, K; Tsutsumi, K | 1 |
| Afchain, P; André, T; Balosso, J; Dupuis, O; Huguet, F; Lledo, G; Louvet, C; Mineur, L; Moureau-Zabotto, L; Phélip, JM; Touboul, E; Vendrely, V | 1 |
| Gallick, GE; Kim, MP | 1 |
| Liau, SS; Whang, E | 1 |
| Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA | 1 |
| Arvanitaki, M; De Maertelaere, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Ames, MM; Bhattacharya, R; Buhrow, SA; Dutta, S; Katarya, A; Lau, JS; Muders, M; Mukherjee, P; Mukhopadhyay, D; Patra, CR; Reid, JM; Safgren, SL; Wang, E; Wang, S; Yaszemski, MJ | 1 |
| Chen, XJ; Qu, X; Xiao, W; Zhou, SY | 1 |
| Arvanitaki, M; de Maertelaer, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Banerjee, TK; Bromund, JL; Chen, R; Dowell, JE; Dudek, AZ; Larson, T; McCleod, MJ; Monberg, MJ; Obasaju, CK; Pandya, KJ; Schneider, DJ | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Alvarez, I; Burris, H; Chow, S; Dragovich, T; Gordon, M; Green, S; Loehrer, P; Obregon, Y; Stratton, S; Von Hoff, DD | 1 |
| Chang, S; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Greco, R; Koong, AC; Kuo, T; Lee, F; Norton, J; Quon, A; Schellenberg, D; Yang, GP | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
| Boukovinas, I; Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Mendez, P; Rosell, R; Souglakos, J; Stathopoulos, E; Taron, M; Tripaki, M | 1 |
| Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Cheng, AL; Hsu, C; Hu, FC; Huang, TC; Kuo, SH; Lin, CC; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Cerny, T; D'Addario, G; Demmer, R; Früh, M; Gillessen, S | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Bauerfeind, P; Clavien, PA; Heinrich, S; Knuth, A; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Hasegawa, Y; Hida, T; Horio, Y; Osada, H; Sekido, Y; Shimizu, J; Shimokata, K; Takahashi, T; Yatabe, Y | 1 |
| Cloud, G; Davidson, S; deShazo, M; Kuo, KL; Leggas, M; Li, M; Rinehart, J; Robert, F; Wang, H; Zhang, R | 1 |
| Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Brown, TD; Casper, ES; Flombaum, CD; Green, MR; Heelan, RT; Kelsen, DP; Tarassoff, PG; Trochanowski, B | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Haberkorn, U; Kahn, B; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Aamdal, S; Eppelbaum, R; Franklin, H; Sessa, C; Smyth, JF; Sulkes, A; Ten Bokkel Huinink, W; Vermorken, J; Wanders, J; Wolff, I | 1 |
| Christman, K; Kelsen, D; Saltz, L; Tarassoff, PG | 1 |
| Burkes, R; Cormier, Y; Crump, M; Feld, R; Schulz, M; Shepherd, FA; Strack, T | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Andersen, JS; Brown, TD; Burris, HA; Casper, ES; Cripps, MC; Green, MR; Moore, MJ; Portenoy, RK; Rothenberg, ML; Storniolo, AM; Tarassoff, PG; Von Hoff, DD | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Taguchi, T; Takada, Y | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Brix, G; Doll, J; Gerlach, L; Haberkorn, U; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Rosenberg, L | 1 |
| Michael, M; Moore, M | 1 |
| Eichinger, S; Gisslinger, H; Hattey, E; Knöbl, P; Mitterbauer, GJ; Mitterbauer, M; Speiser, W; Weltermann, A | 1 |
| Brand, R; Capadano, M; Tempero, M | 1 |
| Adsay, V; Al-Katib, A; Joshi, U; Majumdar, AP; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Nori, D; Parikh, S | 1 |
| Blaszkowsky, L | 1 |
| John, WJ; Mohiuddin, M; Regine, WF | 1 |
| Miller, V; Vander Els, NJ | 1 |
| Glimelius, B | 1 |
| Chovan, L; Janko, C; Jassem, J; Kanitz, E; Krejcy, K; Krzakowski, M; Magyar, P; Pawlicki, M; Pesek, M; Petruzelka, L; Zatloukal, P | 1 |
| Cascinu, S; Catalano, G; Graziano, F | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Ali, N; Li, Y; Sarkar, FH; Singh, B | 1 |
| Hara, N; Kurita, Y; Matsui, K; Nakai, Y; Niitani, H; Ohhashi, Y; Yokoyama, A | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Belotti, G; Cantù, A; Ciotti, R; D'Amico, A; Facchi, E; Gatti, C | 1 |
| Bailey, RD; Blaskovich, MA; Hamilton, AD; Knowles, D; Ohkanda, J; Qian, Y; Sebti, SM; Sun, J | 1 |
| Bauer, J; Kreil, A; Scheithauer, W | 1 |
| Brunet, R; Fonck, M | 1 |
| Adsay, V; Al-Katib, AM; Li, Y; Mohamed, AN; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| König, P; Kühr, T; Lhotta, K; Rumpelt, HJ; Thaler, J; Wöll, E | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA | 1 |
| André, T; Balosso, J | 1 |
| Davis, JR; Fernandes, C; Zalcberg, JR | 1 |
| Bauer, J; Bernhard, J; Borner, M; Fey, MF; Hanselmann, S; Hering, F; Hürny, C; Jacky, E; Maibach, R; Morant, R; Thürlimann, B; Trinkler, F; Zulian, G | 1 |
| Asna, N; Greif, Y; Inbar, M; Mann, A; Merimsky, O; Paz, J; Schwartz, Y; Wigler, N | 1 |
| Giaccone, G; Golding, RP; Linskens, RK; van Groeningen, CJ | 1 |
| Blitzer, JB; Evans, SS; Forsthoff, C; Link, JS; Nagourney, RA | 1 |
| Flórez, A; Peteiro, C; Rosón, E; Sánchez-Aguilar, D; Toribio, J | 1 |
| Abbate, A; Campisi, C; Di Cosimo, S; Di Sciascio, G; Gravante, G; Patti, G; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Depisch, D; Funovics, J; Greul, R; Haider, K; Kornek, GV; Krauss, G; Kwasny, W; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Au, E | 1 |
| Demeaux, H; Dilhuydy, MS; Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF | 1 |
| Czerniak, PM; Devenny, JJ; Gravallese, EM; Kerr, JS; Longtine, J; Slee, AM; Wexler, EJ; Wong, MK | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Altavista, P; Ceciarelli, F; Cividalli, A; Cruciani, G; Livdi, E; Mauro, F; Tirindelli Danesi, D | 1 |
| Eckel, F; Erdmann, J; Lersch, C; Schmidt, B; Schulte-Frohlinde, E | 1 |
| Geffen, DB; Horowitz, J | 1 |
| Johansson, M; Karlsson, A; Zheng, X | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Beauchamp, RD; Benson, AB; Berlin, J; Catalano, PJ; Talamonti, MS; Vaughn, DJ; Whittington, R | 1 |
| Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG | 1 |
| Chow, S; Hedley, DW; Tsao, MS | 1 |
| Arita, K; Daido, K; Nakamura, K; Ohashi, N | 1 |
| Einhorn, LH; Kindler, HL; Kraut, M; Masters, G; Mitchell, E; Nicol, S; Raghavan, D; Sandler, AB | 1 |
| Brodowicz, T; Függer, R; Jakesz, R; Köstler, WJ; Steger, GG; Teleky, B; Tomek, S; Vaclavik, I; Wolfram, RM; Zielinski, CC | 1 |
| Abruzzo, F; Di Leo, R; Mandina, P; Scarpulla, M; Verderame, F | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP | 1 |
| Bomans, P; Demedts, MG; Nackaerts, KL; Vansteenkiste, JF; Verbeken, EK | 1 |
| Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H | 1 |
| Löhr, JM | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE | 1 |
| Gajra, A; Graziano, SL; Kirshner, J; Mehdi, SA; Newman, N | 1 |
| Klausner, JY; Kluger, Y; Michowitz, M; Schreiber, L; Soffer, D; Sorid, D | 1 |
| Ahumada, M; Cortés, C; Gallardo, J; Rubio, B | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Kokawa, Y; Matsuyama, K; Naito, Y; Nakamura, T; Oura, S; Sakurai, T; Tanino, H; Yoshimasu, T | 1 |
| Chanona, J; De la Garza, J; Dueñas-Gonzalez, A; Florentino, R; Gonzalez, A; Guadarrama, R; Hinojosa, LM; Lopez-Graniel, C; Maldonado, V; Meléndez, J; Mohar, A; Mota, A; Muñoz, D; Reyes, M; Robles, E; Solorza, G | 1 |
| Bramham, J; Burris, HA; Calvert, SW; Greco, FA; Hainsworth, JD; Scullin, DC; Willcutt, NT | 1 |
| Fine, RL; Sherman, WH | 1 |
| Crane, CH; Evans, DB; Wolff, RA | 1 |
| André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F | 1 |
| Ibrahim, SM; Koczan, D; Löhr, M; Müller, P; Ringel, B; Ringel, J; Schmidt, C; Thiesen, HJ | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 2 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Bowry, C; Bramhall, SR; Brown, PD; Buckels, JA; Rosemurgy, A | 1 |
| Barth, RJ; Colacchio, TA; Lewis, LD; McDonnell, C; Meyer, LP; Mitchell, SE; Perez, RP; Pipas, JM; Rathmann, J; Vera-Gimon, R; Wagman, RS | 1 |
| Abbruzzese, JL; Charnsangavej, C; Evans, DB; Gravel, DM; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Wolff, RA | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, A | 1 |
| Pützer, BM; Rödicker, F; Stiewe, T; Zimmermann, S | 1 |
| Colston, KW; Dalgleish, AG; Pettersson, F | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Shureiqi, I; Smith, DC; Strawderman, M; Zalupski, MM | 1 |
| Jassem, J; Krawczyk, K; Krzakowski, M; Lis, J; Miracki, K; Mozejko-Pastewka, B; Ramlau, R; Roszkowski, K; Szczesna, A; Słomiński, JM | 1 |
| Hribaschek, A; Kasper, U; Lippert, H; Meyer, F; Ridwelski, K | 1 |
| Blumenthal, R; Cardillo, TM; Gold, DV; Ying, Z | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Buscail, L; Escourrou, J; Faure, P; Moreau, J; Pages, P | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Clarke, ML; Dumontet, C; Falette, N; Galmarini, CM; Mackey, JR; Puisieux, A | 1 |
| Fukuda, M; Kato, K; Kawasaki, Y; Kobayashi, K; Miyata, M; Saito, S; Shimizu, E; Yano, S | 1 |
| Baraona, FJ; Kett, DH; Rosado, MF; Schein, RM; Sridhar, KS | 1 |
| André, T; Bleiberg, H; Bouleuc, C; Cvitkovic, E; de Gramont, A; Flesch, M; Gamelin, E; Hammel, P; Lledo, G; Louvet, C | 1 |
| Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT | 1 |
| Beger, HG; Cammerer, G; Gansauge, F; Gansauge, S; Leder, G; Muehling, B; Pressmar, J; Ramadani, M; Stecker, K | 1 |
| Biglietto, M; Cigolari, S; Colucci, G; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Rabitti, P; Testa, A; Uomo, G | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Delclos, M; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, AB | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ryan, DP; Willett, CG | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
| Abbruzzese, JL; Daugherty, K; Moore, DF; Pazdur, R; Tarassoff, P | 1 |
109 review(s) available for gemcitabine and Adenocarcinoma
| Article | Year |
|---|---|
Pancreatic Adenocarcinoma Management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Metastatic pancreatic ductal adenocarcinoma followed by a fatal diffuse large B-cell lymphoma: A rare case report and literature review.
Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Lymphadenopathy; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms | 2023 |
Gemcitabine-induced pseudocellulitis: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Myositis; Paclitaxel; Pancreatic Neoplasms | 2021 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Surgical strategies and novel therapies for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Veins | 2017 |
A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2017 |
How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Frailty; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy | 2017 |
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Scleroderma, Localized | 2018 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Signal Transduction; Time Factors; Treatment Outcome | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2014 |
[Gallbladder cancer with elevated serum α-fetoprotein, α-fetoprotein-L3, and human chorionic gonadotropin levels].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged | 2014 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chi-Square Distribution; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Infusions, Parenteral; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Time Factors | 2014 |
[Pancreatic adenocarcinoma: 10 years of progress].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Precancerous Conditions | 2015 |
Pancreatic cancer: current management and treatment strategies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2015 |
[Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2015 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Pancreatic Neoplasms; Retrospective Studies; Rituximab | 2017 |
Pancreatic carcinoma masked as fever of unknown origin: A case report and comprehensive review of literature.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fever of Unknown Origin; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Cause of Death; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Evidence-Based Medicine; Gemcitabine; Humans; Oncology Nursing; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Postoperative Care; Practice Guidelines as Topic; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Treatment Outcome | 2008 |
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Management of a patient with borderline resectable pancreatic cancer. Case report and review.
Topics: Adenocarcinoma; Adult; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2009 |
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease Management; Gemcitabine; Glutamates; Guanine; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Palliative Care; Pemetrexed; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking | 2009 |
Novel agents for the treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Risk Factors; Survival Rate | 2009 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Adenocarcinoma of the small bowel: changes in the landscape?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Intestine, Small; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Gemox: a widely useful therapy against solid tumors-review and personal experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2010 |
Cutaneous metastasis of pancreatic adenocarcinoma after kidney transplant: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Kidney Transplantation; Pancreatic Neoplasms; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Topics: Adenocarcinoma; Antineoplastic Agents; Chicago; Congresses as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Medical Oncology; Models, Biological; Pancreatic Neoplasms; Societies, Medical; United States | 2011 |
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity | 2011 |
Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Premedication; Survival Rate; Treatment Outcome | 2012 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy | 2012 |
Soft-tissue metastasis revealing a pancreatic adenocarcinoma: one case report and a review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Soft Tissue Neoplasms; Thigh | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines | 2014 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; CD40 Antigens; Computational Biology; Deoxycytidine; Drug Therapy, Combination; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Gene Rearrangement; Hedgehog Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2012 |
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; ROC Curve; Treatment Outcome | 2013 |
Molecular changes in pancreatic cancer: implications for molecular targeting therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, CXCR4 | 2012 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Europe; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and urogenital tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Germinoma; Hematologic Diseases; Humans; Kidney Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Patient Selection; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms; Vinblastine | 2002 |
[Role of gemcitabine in the treatment of other malignant tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
[Combined gemcitabine and radiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasms; Neoplasms, Experimental; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Tumor Cells, Cultured | 2002 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
[Gemcitabine treatment of pancreatic cancer peritonitis].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritonitis | 2003 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasm Proteins; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; United States | 2003 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Dramatic improvement of psoriasis with gemcitabine monotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Psoriasis; T-Lymphocytes | 2003 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase Inhibitors; Deoxycytidine; Farnesyltranstransferase; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Matrix Metalloproteinase Inhibitors; Oligonucleotides, Antisense; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome | 2004 |
[Combined treatment of esophageal cancer: a review].
Topics: Adenocarcinoma; Alcohol Drinking; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diet; Dihematoporphyrin Ether; Esophageal Neoplasms; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Palliative Care; Photochemotherapy; Platinum Compounds; Postoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Taxoids; Time Factors | 2004 |
Gemcitabine-related radiation recall preferentially involves internal tissue and organs.
Topics: Adenocarcinoma; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Myositis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Radiation Injuries; Risk Assessment; Steroids | 2004 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense | 2004 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
Treatment of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2005 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Adjuvant treatment strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholangiopancreatography, Endoscopic Retrograde; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Diagnostic Imaging; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Hematuria; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Factors; Umbilicus; Urachal Cyst; Urachus; Urinary Bladder Neoplasms | 2006 |
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Hormone Antagonists; Hormones; Humans; Pancreatic Neoplasms; Prognosis | 2007 |
Treatment options for hepatobiliary and pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Ethanol; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neutropenia; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
Topics: Adenocarcinoma; Algorithms; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholestasis; Deoxycytidine; Disease Management; Drainage; Gastric Outlet Obstruction; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Radiotherapy, Adjuvant; Treatment Outcome | 2007 |
The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis; Treatment Failure | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Forecasting; Gemcitabine; Hormone Antagonists; Humans; Pancreatic Neoplasms; Somatostatin; Tamoxifen | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evaluation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Safety; Survival Rate; Treatment Outcome | 1997 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mitomycin; Neoplasm Metastasis; Nitrosourea Compounds; Pancreatic Neoplasms | 1998 |
Adjuvant therapy for pancreatic cancer: current status.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate | 1998 |
Chemotherapy in the treatment of cancer of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 1998 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 1999 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2000 |
[A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male | 2000 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Palliative Care; Pancreatic Neoplasms | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Therapy for regionally unresectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
506 trial(s) available for gemcitabine and Adenocarcinoma
| Article | Year |
|---|---|
Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Topics: Adenocarcinoma; Albumins; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Japan; Markov Chains; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azepines; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoplasms; Pancreatic Neoplasms; Pyrimidines | 2022 |
A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |
Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies | 2022 |
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2022 |
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Gemcitabine; Humans; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Tyrosine Kinase Inhibitors | 2023 |
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Gemcitabine; Humans; Male; Middle Aged; Mucin 5AC; Paclitaxel; Pancreatic Neoplasms | 2023 |
Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which Patients Are Suited for Additional Adjuvant Chemoradiation Therapy: From a Prospective Randomized
Topics: Adenocarcinoma; CA-19-9 Antigen; Carbohydrates; Chemotherapy, Adjuvant; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies | 2023 |
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2023 |
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparat
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Gemcitabine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Quality of Life; Radiosurgery; Randomized Controlled Trials as Topic | 2023 |
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Non-Randomized Controlled Trials as Topic; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Patient Safety; Treatment Outcome | 2020 |
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Survival Rate; Treatment Outcome | 2019 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors | 2020 |
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.
Topics: Adenocarcinoma; Aged; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunoglobulin Fc Fragments; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Proteins | 2020 |
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Topics: Adenocarcinoma; Aged; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Mucin-1; WT1 Proteins | 2020 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Care; Prognosis; Survival Rate; Young Adult | 2021 |
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-G
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; GTP-Binding Proteins; Humans; Membrane Proteins; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2021 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2017 |
Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis | 2017 |
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cisplatin; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Vaccines, Subunit; WT1 Proteins | 2018 |
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2018 |
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Receptors, Somatomedin; Survival Analysis; Treatment Outcome | 2018 |
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Cell Line, Tumor; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Receptors, Calcitriol; RNA, Messenger; Vitamin D | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Paclitaxel; Pancreatic Neoplasms; Phenylthiohydantoin; Prognosis; Survival Rate; Tissue Distribution | 2019 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cancer Vaccines; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Interferon-beta; Male; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Progression-Free Survival; Survivin; Vaccination; Vaccines, Subunit | 2019 |
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Wnt Signaling Pathway | 2020 |
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Oximes; Pancreatic Neoplasms; Piperazines; Sulfonamides | 2013 |
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; GPI-Linked Proteins; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2013 |
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Radiosurgery; Treatment Outcome | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Radiotherapy | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Prospective Studies; Survival; Young Adult | 2013 |
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Receptor, IGF Type 1; Survival Analysis | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Macrophages; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Survival; Treatment Outcome | 2013 |
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Risk Factors; Time Factors | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Helicases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nerve Tissue Proteins; Pancreatic Neoplasms; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Europe; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2014 |
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Pemetrexed; Prognosis; Prospective Studies; Quality of Life; Research Design; Survival Rate | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Survival Rate | 2014 |
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA-Binding Proteins; Female; Folate Receptor 1; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Peptide Synthases; Prognosis; Retrospective Studies; Survival Rate; Thymidylate Synthase; Tissue Array Analysis; Transcription Factors | 2013 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2015 |
First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancr
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drugs, Investigational; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Thrombocytopenia; Treatment Outcome | 2014 |
Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Treatment Outcome | 2014 |
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Survival Analysis | 2014 |
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2014 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Epitopes; Female; Follow-Up Studies; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Vaccination; WT1 Proteins | 2014 |
Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Conformal | 2014 |
Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Nausea; Organoplatinum Compounds; Ribonucleoside Diphosphate Reductase; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vault Ribonucleoprotein Particles; Vomiting | 2014 |
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2014 |
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Topics: Actins; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Stromal Cells; Survival Rate; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Time Factors; Treatment Outcome | 2015 |
Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiation Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; International Cooperation; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution | 2015 |
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Adenosquamous; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antirheumatic Agents; Autophagy; Biomarkers; CA-19-9 Antigen; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Safety; Survival Rate | 2015 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Deoxycytidine; Female; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glycine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Sulfones; Tumor Suppressor Protein p53 | 2015 |
Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Electroporation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Genetic; RecQ Helicases; Reproducibility of Results | 2016 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Biomarkers, Pharmacological; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery | 2016 |
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Research Design; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2016 |
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Pyridines; Survival Rate | 2016 |
Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Therapy, Combination; Endonucleases; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Treatment Outcome | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2017 |
Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Transplantation, Autologous | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Extracellular Matrix; Female; Gemcitabine; Humans; Immunoglobulin G; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Treatment Outcome | 2017 |
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy, Adjuvant | 2008 |
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy | 2008 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms | 2008 |
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy | 2008 |
A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2008 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Morbidity; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron-Emission Tomography; Prospective Studies | 2008 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards; Survival Analysis; Treatment Outcome | 2009 |
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2009 |
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Analysis | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pilot Projects; Salvage Therapy; Survival Analysis | 2010 |
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complementary Therapies; Deoxycytidine; Dietary Supplements; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Peptide Hydrolases; Proportional Hazards Models; Quality of Life; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphoramide Mustards; Safety; Survival Rate; Treatment Outcome | 2010 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome; Young Adult | 2010 |
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Cystine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Half-Life; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfhydryl Compounds; Tomography, X-Ray Computed | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2009 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2009 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2009 |
Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2010 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Survival Rate | 2010 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Plant Proteins; Retrospective Studies; Survival Analysis; Viscum album | 2010 |
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Blood Coagulation Factors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy; Safety; Survival Analysis | 2010 |
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cadherins; Cetuximab; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; ErbB Receptors; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Vimentin | 2011 |
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mental Health; Middle Aged; Pain; Pancreatic Neoplasms; Quality of Life | 2010 |
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Survival Rate; Treatment Outcome | 2011 |
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Missouri; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities | 2012 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2010 |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2011 |
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2010 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; France; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Fine-Needle; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatic Insufficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Pyridines; Ribonucleotide Reductases; RNA, Messenger; Survival Analysis; Thiosemicarbazones | 2011 |
Curcumin and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis | 2010 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2011 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Analysis | 2012 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Taxoids | 2011 |
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2011 |
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Maryland; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Research Design; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2011 |
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant; Remission Induction; Research Design; Smad4 Protein; Treatment Outcome | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2012 |
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Translational Research, Biomedical | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
[Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Dizziness; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2011 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotides, Antisense; Survival Rate; Thionucleotides; Treatment Outcome | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Surveys and Questionnaires; Treatment Outcome | 2013 |
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organs at Risk; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Time Factors | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome | 2012 |
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea | 2012 |
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Placebos; Receptor, IGF Type 1; Survival Rate; Treatment Outcome | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Amphibian Venoms; Animals; Antineoplastic Combined Chemotherapy Protocols; Anura; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Single-Blind Method | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Prognosis; Survival Analysis; Watchful Waiting | 2012 |
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphocyte Activation Gene 3 Protein; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2013 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Topics: Adaptive Immunity; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; CD8-Positive T-Lymphocytes; Cytotoxicity, Immunologic; Deoxycytidine; Female; Follow-Up Studies; Forkhead Transcription Factors; Gemcitabine; Glutamates; Guanine; Humans; Immunity, Innate; Immunologic Memory; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; T-Lymphocyte Subsets | 2012 |
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy, Active; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Analysis; Treatment Outcome; Trisaccharides | 2013 |
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escala
Topics: Adenocarcinoma; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Sex Factors; Tumor Burden | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Chromatography, High Pressure Liquid; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutathione; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Patient Compliance; Patient Safety; Sentinel Lymph Node Biopsy | 2013 |
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms | 2002 |
Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged | 2002 |
Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy | 2002 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Statistics, Nonparametric; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2003 |
Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2001 |
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoviridae; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; In Situ Hybridization; Injections, Intralesional; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Safety; Treatment Outcome; Ultrasonography; Viral Vaccines | 2003 |
Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uterine Cervical Neoplasms | 2003 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2003 |
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival; Treatment Outcome | 2003 |
A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Time Factors | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2003 |
Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 2003 |
Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Postoperative Care; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Quality of Life; Survival Rate; Time Factors; Vinblastine | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Failure | 2003 |
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Organic Chemicals; Pancreatic Neoplasms; Phenylbutyrates; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
[Effectiveness of Gemzar-Cisplatin therapy in stage IIIA-N2, IIIB and IV non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Survival Analysis; Treatment Outcome | 2003 |
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Kinetics; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design | 2003 |
Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2003 |
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quality of Life; Thrombocytopenia; Treatment Outcome | 2003 |
Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Prospective Studies; Treatment Outcome | 2003 |
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2003 |
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytokines; Deoxycytidine; Female; Gemcitabine; Granulocytes; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Superoxides | 2004 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Picibanil; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Cisplatin and gemcitabine in patients with metastatic cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Rate; Thrombocytopenia; Uterine Cervical Neoplasms | 2004 |
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis | 2003 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2005 |
[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2004 |
Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Adenosquamous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Uterine Cervical Neoplasms | 2005 |
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Survival Analysis | 2004 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quality of Life; Receptors, Platelet-Derived Growth Factor; Surveys and Questionnaires; Survival Rate | 2006 |
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Models, Statistical; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Analysis; Thrombocytopenia | 2005 |
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2005 |
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; International Agencies; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neurotoxicity Syndromes; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
Topics: Adenocarcinoma; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Survival Rate | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Ribonucleotide Reductases; Survival Rate | 2006 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Conformal; Taxoids | 2005 |
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radiography; Vinblastine; Vinorelbine | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Research Design; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Prognosis; Remission Induction; Survival Analysis; Vomiting, Anticipatory | 2006 |
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2006 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phenylenediamines; Prognosis; Survival Rate | 2006 |
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Respiratory Function Tests; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2007 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2006 |
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Survival Rate; Treatment Outcome | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance | 2006 |
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Home Infusion Therapy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Large Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2006 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Korea; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2006 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thrombocytopenia; Treatment Outcome | 2006 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2008 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms | 2007 |
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lactones; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Sulfones; Survival Rate | 2007 |
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Failure | 2007 |
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Female; Gemcitabine; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Survival Rate | 2007 |
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis | 2008 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2007 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Glucose; Half-Life; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards | 2008 |
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2007 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Ascitic Fluid; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Dialysis Solutions; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Dialysis; Pilot Projects; Survival Rate | 2008 |
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Infliximab; Liver Neoplasms; Male; Pancreatic Neoplasms; Placebos; Prognosis; Survival Rate | 2008 |
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukopenia; Male; Middle Aged; Mouth Mucosa; Pancreatic Neoplasms; Polymorphism, Genetic; Pyridines; Ribonucleoside Diphosphate Reductase; Survival Rate; Thiosemicarbazones; Treatment Outcome | 2008 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2008 |
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Drug Tolerance; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Radiosurgery; Radiotherapy Dosage; Survival Analysis; Survivors | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Research Design; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2008 |
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms | 2008 |
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neutropenia; Stomach Neoplasms | 1994 |
Phase II trial of gemcitabine in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Remission Induction; Stomach Neoplasms | 1994 |
Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical | 1996 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Retreatment; Survival Rate; Treatment Outcome | 1996 |
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Survival Analysis | 1997 |
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
[Phase I study of gemcitabine hydrochloride (LY 188011) combination therapy with cisplatin in the patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting, Anticipatory | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Hormones; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2000 |
Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Israel; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2000 |
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Survival Analysis | 2000 |
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis | 2000 |
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Biliary tract cancer: our experience with gemcitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2000 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2001 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyponatremia; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Nervous System Diseases; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms, Unknown Primary; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Hydroxamic Acids; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2001 |
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine Alkaloids; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Phenanthridines; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2002 |
Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vomiting | 2002 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged | 1992 |
874 other study(ies) available for gemcitabine and Adenocarcinoma
| Article | Year |
|---|---|
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Pancreas; Pancreatic Neoplasms; RNA; RNA Interference; Tumor Cells, Cultured | 2011 |
Syntheses and anti-pancreatic cancer activities of rakicidin A analogues.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combinatorial Chemistry Techniques; Humans; Lipopeptides; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides, Cyclic; Structure-Activity Relationship; Tumor Hypoxia | 2018 |
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Use of
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Gemcitabine; Granulocytes; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Analysis of the CONKO-001 trial: Is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Ferroptosis; Gemcitabine; Glutathione Peroxidase; Humans; Magnetic Resonance Imaging; Pancreatic Neoplasms; Peroxidase; Reactive Oxygen Species | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tubulin | 2022 |
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life | 2023 |
Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Diphosphates; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proteomics; Ribonucleosides; S100 Calcium-Binding Protein A4 | 2022 |
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2023 |
The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Messenger | 2022 |
Drug Interactions Causing Warfarin Overdose in a Patient with Pancreatic Cancer: A Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme System; Drug Interactions; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Plant Extracts; Warfarin | 2023 |
A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Pancreatic Neoplasms; Transcriptome | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Immunity; Insulins; Male; Metformin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2023 |
DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; In Situ Hybridization, Fluorescence; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding; Tumor Suppressor Proteins | 2022 |
Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2023 |
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Interleukin-13 Receptor alpha2 Subunit; Mice; Pancreatic Neoplasms | 2022 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin-7; RNA, Guide, CRISPR-Cas Systems; STAT5 Transcription Factor | 2023 |
Knockdown of NF-κB activating protein promotes pancreatic cancer growth and metastasis through mTOR signaling pathway.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Proliferation; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Repressor Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2023 |
Black Phosphorus as a Targeting PPAR-γ Agonist to Reverse Chemoresistance in Patient-derived Organoids, Mice, and Pancreatic Tumor Cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Organoids; Pancreatic Neoplasms; PPAR gamma; PPAR-gamma Agonists | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Macrophages; Mice; Organoids; Pancreatic Neoplasms; Plicamycin; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Tumor Microenvironment | 2023 |
Efficacy and safety of gemcitabine plus S-1
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Europe; Gemcitabine; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma".
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Targeting WEE1 in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2019 |
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Long Noncoding; Scavenger Receptors, Class E; Transcriptome; Up-Regulation | 2019 |
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Topics: Adenocarcinoma; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Mice; Nuclear Proteins; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2019 |
Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Compounding; Drug Design; ErbB Receptors; Female; Gemcitabine; Humans; Liposomes; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Polyethylene Glycols; Protein Kinase Inhibitors; Proteolysis; Xenograft Model Antitumor Assays | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Humans; Integrin alpha3; Integrin beta1; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Survival Rate; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Damage; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Naphthyridines; Pancreatic Neoplasms; RNA, Messenger; Spheroids, Cellular | 2019 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Nomograms; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2019 |
PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Stress, Physiological; Tumor Hypoxia; Up-Regulation | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Magnetite Nanoparticles; Male; Metformin; Mice, Inbred BALB C; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides | 2020 |
Gemcitabine Co-Encapsulated with Curcumin in Folate Decorated PLGA Nanoparticles; a Novel Approach to Treat Breast Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; United States | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreaticoduodenectomy; Propensity Score; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2020 |
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma.
Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin | 2020 |
De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia.
Topics: Adenocarcinoma; Allografts; Bile Duct Neoplasms; Biliary Atresia; Child; Cholangiocarcinoma; Cisplatin; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver; Liver Transplantation; Neoplasm Recurrence, Local; Postoperative Complications; Young Adult | 2020 |
Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor for Advanced Glycation End Products; Signal Transduction; Stilbenes | 2020 |
Cisplatin Plus Gemcitabine as Standard of Care for Germline
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Standard of Care | 2020 |
Reply to N. Fazio.
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas | 2020 |
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma].
Topics: Adenocarcinoma; Aged; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Urethra; Urethral Neoplasms; Urinary Bladder Neoplasms | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Nomograms; Outcome Assessment, Health Care; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reproducibility of Results | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Retrospective Studies; Treatment Outcome | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.
Topics: Adenocarcinoma; Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabine Administration: A Pilot Study.
Topics: Adenocarcinoma; Deoxycytidine; Fatty Acids, Omega-3; Gemcitabine; Humans; Pancreatic Neoplasms; Pilot Projects; Proteomics | 2021 |
Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Margins of Excision; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate | 2020 |
Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Gemcitabine; Gene Expression; Gene Knockout Techniques; Humans; Letrozole; Leuprolide; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liposomes; Multidrug Resistance-Associated Proteins; Nitric Oxide; Pancreatic Neoplasms | 2020 |
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Cohort Studies; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Lipopolysaccharides; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Translational Research, Biomedical; Treatment Outcome | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Dual Delivery of Gemcitabine and Paclitaxel by Wet-Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation.
Topics: Adenocarcinoma; Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Tumor Burden | 2020 |
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Transla
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Registries; Treatment Outcome | 2021 |
Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; ATP Binding Cassette Transporter, Subfamily B; Cell Hypoxia; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Microenvironment | 2020 |
Toxic erythema of chemotherapy secondary to gemcitabine and paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Erythema; Female; Gemcitabine; Humans; Intertrigo; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2020 |
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Transcriptome | 2021 |
Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transcriptome | 2021 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Topics: Acinar Cells; Adenocarcinoma; Animals; Antineoplastic Agents; Calcium; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Dedifferentiation; Cell Transformation, Neoplastic; Cells, Cultured; Ceruletide; Deoxycytidine; Disease Progression; Gemcitabine; GTP-Binding Proteins; Histone Deacetylase Inhibitors; Mice; Pancreatic Ducts; Pancreatic Neoplasms; Pancreatitis; Proto-Oncogene Proteins p21(ras); RGS Proteins; Signal Transduction | 2020 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Galactosyltransferases; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Neoplasm Recurrence, Local; Organoids; Transcription Factor RelA | 2021 |
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed | 2021 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
[A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbon; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway.
Topics: Adenocarcinoma; Aged; Animals; Carcinogenesis; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Pancreatic Neoplasms; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Piperidines | 2021 |
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Laminin; Male; Middle Aged; Prognosis | 2021 |
H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aging; Animals; beta-Galactosidase; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Heterografts; Histones; Humans; Mice | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Transcriptome | 2021 |
Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Deoxycytidine; Female; Gemcitabine; Humans; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2021 |
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Phenotype | 2021 |
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Allografts; Amino Acid Motifs; Animals; Apoptosis; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Synergism; Endocytosis; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Lysosomes; Mice; Microfilament Proteins; Molecular Targeted Therapy; NIMA-Interacting Peptidylprolyl Isomerase; Oncogenes; Organoids; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results.
Topics: Adenocarcinoma; Animals; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Equipment Design; Gemcitabine; Hydrogel, Polyethylene Glycol Dimethacrylate; In Vitro Techniques; Injections, Intravenous; Pancreas; Pancreatic Neoplasms; Swine; Vascular Access Devices | 2017 |
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate | 2017 |
Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; AMP-Activated Protein Kinase Kinases; Carbamoyl-Phosphate Synthase (Ammonia); Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metabolic Networks and Pathways; Metabolome; Middle Aged; Pemetrexed; Prognosis; Proportional Hazards Models; Protein Serine-Threonine Kinases; Proteome; RNA, Messenger; Signal Transduction; Survival Rate; Thiophenes; Tissue Array Analysis; Urea | 2017 |
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; NEDD8 Protein; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2017 |
Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Female; Gemcitabine; Humans; Image-Guided Biopsy; Liver Neoplasms; Lung Neoplasms; Male; Mice, Inbred Strains; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2017 |
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipoproteins, LDL; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Nanoparticles; Receptors, LDL; Squalene; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Imaging, Three-Dimensional; Mice; Mice, SCID; Pancreatic Neoplasms; Radiofrequency Therapy | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Successful pregnancy after mucinous cystic neoplasm with invasive carcinoma of the pancreas in a patient with polycystic ovarian syndrome: a case report.
Topics: Adenocarcinoma; Adult; Chemoradiotherapy; Cystadenocarcinoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Infertility, Female; Magnetic Resonance Imaging; Ovary; Ovulation; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Radiation-Sensitizing Agents; Ultrasonography | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2017 |
Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm, Residual; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron Emission Tomography Computed Tomography; Time Factors | 2017 |
Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Drug Stability; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Phospholipids; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Toxicity Tests | 2017 |
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Topics: Adenocarcinoma; AMP-Activated Protein Kinase Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mice, Nude; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Thiophenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2017 |
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gemcitabine; Humans; Lipids; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase 1 Family; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha Chains; Isoenzymes; Pancreatic Neoplasms; Prognosis; Retinal Dehydrogenase; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2017 |
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.
Topics: Adenocarcinoma; Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Hepatocyte Growth Factor; Humans; Imidazoles; Mice; Mice, Transgenic; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; Pyridines; Triazines; Tumor Microenvironment | 2017 |
Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luciferases; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fibrin Tissue Adhesive; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2017 |
Pancreatic cancer: Intra-tumour bacteria promote gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Bacteria; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2017 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gas Chromatography-Mass Spectrometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lactic Acid; Male; Metabolomics; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2018 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
Topics: Actins; Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; CA-19-9 Antigen; Cancer-Associated Fibroblasts; Collagen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Stromal Cells | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
When Lightning Strikes Twice.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; China; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
[Long-Term Survival after Resection for Repeated Abdominal Wall Recurrence of Gallbladder Cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Recurrence; Time Factors | 2017 |
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
Suppression of
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Pancreatic Neoplasms; RNA, Small Interfering | 2018 |
Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.
Topics: Acinar Cells; Adenocarcinoma; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Silencing; Genetic Loci; Mice; Neoplastic Stem Cells; Rats; Transcription Factors | 2018 |
Metastasis from pancreatic adenocarcinoma to the cheekbone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exophthalmos; Female; Gemcitabine; Humans; Middle Aged; Orbital Neoplasms; Pancreatectomy; Pancreatic Neoplasms; Plastic Surgery Procedures; Tomography, X-Ray Computed; Vinorelbine; Vision Disorders; Zygoma | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Analysis of the cytotoxic effects of combined ultrasound, microbubble and nucleoside analog combinations on pancreatic cells in vitro.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Fluorocarbons; Gemcitabine; Humans; In Vitro Techniques; Microbubbles; Pancreatic Neoplasms; Ultrasonic Therapy | 2018 |
Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Mesenteric Veins; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Indoles; Mice; Morpholines; Pyrimidines; Sulfonamides; Sulfoxides | 2018 |
Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Deoxycytidine; Diterpenes; Gemcitabine; Humans; Isodon; MAP Kinase Signaling System; Pancreatic Neoplasms; Phosphorylation; Plant Extracts; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Neoadjuvant
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Databases, Factual; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Hyperbilirubinemia; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Transfer Techniques; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Pancreatic Neoplasms; rab27 GTP-Binding Proteins; Tumor Microenvironment; Up-Regulation | 2018 |
Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Survival Rate; Transcription Factors; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2019 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
Topics: Adenocarcinoma; Animals; Antibodies; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Drug Therapy; Epithelial Cells; Female; Gemcitabine; Humans; Immunization; Immunotherapy; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligodeoxyribonucleotides; Peptides; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2018 |
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA2 Protein; Humans; Mice; Mice, Knockout; Pancreatic Neoplasms; Prognosis; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2018 |
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2018 |
The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-E2-Related Factor 2; Pancreatic Ducts; Precancerous Conditions; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2019 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Synchronous Adeno-squamous Carcinoma of Gallbladder and Adenocarcinoma of Common Bile Duct: Twin Trouble.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Common Bile Duct; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreaticojejunostomy; Treatment Outcome; Ultrasonography | 2019 |
Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Survival; Clonal Evolution; Deoxycytidine; Elafin; Gemcitabine; Glycolysis; Heterografts; Humans; Mice; Oncogene Protein v-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y2; RNA, Small Interfering; Sequence Analysis, RNA; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2019 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Topics: ADAM Proteins; Adenocarcinoma; Animals; Basement Membrane; Biocatalysis; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Lymphangiogenesis; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Signal Transduction | 2019 |
LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Long Noncoding; Up-Regulation | 2018 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2019 |
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis | 2019 |
Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide.
Topics: Adenocarcinoma; Cell Line, Tumor; Cytotoxins; Delayed-Action Preparations; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Nitric Oxide; Pancreatic Neoplasms | 2019 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Mice; Mice, Nude; Neutrophils; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Folic Acid; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Pantothenic Acid; Plant Extracts; Solutions; Vitamin B 12; Vitamin B 6; Zinc Sulfate | 2019 |
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Methylprednisolone; Paclitaxel; Pancreatic Neoplasms | 2019 |
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination.
Topics: Adenocarcinoma; Albumins; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; United States | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Standard of Care | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2020 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma in Situ; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Xenograft Model Antitumor Assays | 2013 |
Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Fluids; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Designer Drugs; Disease Models, Animal; Gemcitabine; Gold; Humans; Immunohistochemistry; Light; Male; Metal Nanoparticles; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoconjugates; Pancreatic Neoplasms; Scattering, Radiation; Static Electricity; Treatment Outcome | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Protocols; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Prosthesis Design; Sphincterotomy, Endoscopic; Stents | 2014 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Butadienes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Nitriles; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Tumor Burden | 2013 |
Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatectomy; Humans; Lymphatic Metastasis; Mutation; Neoplasm Staging; Pancreatic Ducts; Portal Vein; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Mice; Mice, Mutant Strains; NF-kappa B; Pancreatic Neoplasms; Sesquiterpenes | 2013 |
Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Drug Utilization; Female; Gemcitabine; Humans; Male; Medicare; Multivariate Analysis; Neoplasm Staging; Pancreatic Neoplasms; SEER Program; United States | 2013 |
Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Chromatin; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Gemcitabine; Hyperthermia, Induced; Inhibitory Concentration 50; Liposomes; Mice; Mice, Inbred BALB C; Temperature | 2014 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Towards a tailored therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Receptors, CXCR4 | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pyrimidines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Polymers; Xenograft Model Antitumor Assays | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery | 2013 |
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Time Factors | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Furans; Gemcitabine; Humans; Hyaluronoglucosaminidase; Lignans; Mutation; Pancreatic Neoplasms; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recombinant Proteins; RNA Interference; Treatment Outcome | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Osteonectin; Pancreatic Neoplasms; Pharmacogenetics; Transcriptome; Treatment Outcome | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Reactive Oxygen Species | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
Gemcitabine therapy-associated cutaneous vasculitis with a polyarteritis nodosa-like pattern.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Polyarteritis Nodosa; Vasculitis, Leukocytoclastic, Cutaneous | 2013 |
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Collagen; Deoxycytidine; Disease Models, Animal; Elasticity Imaging Techniques; Endosonography; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography | 2013 |
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; HEK293 Cells; Humans; Pancreatic Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptors, Glucocorticoid; Sequence Analysis, DNA; Survival Analysis; Tacrolimus Binding Proteins | 2013 |
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Mice; Mice, Knockout; Pancreatic Neoplasms; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Xenograft Model Antitumor Assays | 2014 |
Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cadherins; Carcinogenesis; Caspase 3; Cell Survival; Claudin-1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease Models, Animal; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression; Genes, Suppressor; Heterozygote; Immediate-Early Proteins; Life Expectancy; Mice; Mice, Knockout; Mucin-1; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2014 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Fusion Regulatory Protein-1; Gemcitabine; Humans; Kaplan-Meier Estimate; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Retrospective Studies; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Biomarkers, Tumor; Bronchoscopy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Multivariate Analysis; Prognosis; Receptors, Erythropoietin; Recombinant Proteins; Xenograft Model Antitumor Assays | 2013 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carbon; Cell Cycle; Cell Line, Tumor; Cell Separation; Chemoradiotherapy; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Glioblastoma; Humans; Ions; Lung Neoplasms; Paclitaxel; Pancreatic Neoplasms; Photons; Propidium; Radiotherapy; Relative Biological Effectiveness; Time Factors | 2013 |
Chin tremors associated with paroxetine in a patient with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anxiety; Chemotherapy, Adjuvant; Chin; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tremor; Withholding Treatment | 2013 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors | 2014 |
Gemcitabine-induced radiation recall myositis in a patient with dermatomyositis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dermatomyositis; Female; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Magnetic Resonance Imaging; Myositis; Neoplasms, Multiple Primary; Radiation Injuries; Treatment Outcome | 2014 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antibody Specificity; Antimetabolites, Antineoplastic; B-Lymphocytes; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin; Pancreatic Neoplasms; Peptide Fragments; Tumor Escape | 2014 |
Gemcitabine-induced myopathy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Muscle, Skeletal; Muscular Diseases; Pancreatic Neoplasms; Quadriceps Muscle; Thigh | 2014 |
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Urea | 2014 |
MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Histones; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Glycogen; Glypicans; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.
Topics: Adenocarcinoma; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Radio Waves; Xenograft Model Antitumor Assays | 2014 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Wortmannin | 2014 |
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Histones; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Proteins; ORAI1 Protein; Pancreatic Neoplasms; RNA, Small Interfering; Stromal Interaction Molecule 1 | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Topics: Adenocarcinoma; Age Factors; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2014 |
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2014 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Immunohistochemistry; Losartan; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Communication; Cell Proliferation; Connexin 43; Deoxycytidine; Drug Resistance, Neoplasm; Gap Junctions; Gemcitabine; Humans; Immunoenzyme Techniques; Isothiocyanates; Microscopy, Electron; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Spheroids, Cellular; Sulfoxides; Tumor Cells, Cultured | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; Side-Population Cells; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Models, Animal; Female; Gastrointestinal Hormones; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neuropeptides; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2014 |
The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Necrosis; Pancreatic Neoplasms; Pyrimidines; TOR Serine-Threonine Kinases | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Macrophage Colony-Stimulating Factor; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Random Allocation; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Cell Surface; Signal Transduction; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Indiana; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Universities | 2017 |
Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Murine-Derived; Antihypertensive Agents; Antimetabolites, Antineoplastic; Blood Component Transfusion; Deoxycytidine; Disease Management; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension; Kidney Failure, Chronic; Nursing Assessment; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Rituximab | 2014 |
Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzoates; Benzylamines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Liver X Receptors; Male; Microarray Analysis; Middle Aged; Neoplasm Proteins; Orphan Nuclear Receptors; Pancreatic Neoplasms; Signal Transduction | 2014 |
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Disease Progression; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Messenger; Survival Rate; Transcription Factor CHOP | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2014 |
Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Colorimetry; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Pancreatic Neoplasms; Photinia; Phytotherapy; Plants, Medicinal; Polyphenols | 2014 |
Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome | 2014 |
WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein; RNA, Messenger; Wnt Proteins; Wnt-5a Protein | 2014 |
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Tumor Suppressor Protein p53 | 2015 |
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; GPI-Linked Proteins; Male; Mesothelin; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancreatic Neoplasms | 2014 |
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Splenic Artery; Splenic Vein | 2015 |
Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diuretics; Female; Gemcitabine; Heart Failure; Humans; Paclitaxel; Pancreatic Neoplasms | 2014 |
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weight; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate | 2015 |
Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Isothiocyanates; Mice; Mice, Inbred NOD; Mice, SCID; NF-E2-Related Factor 2; NF-kappa B; Oxidation-Reduction; Pancreatic Neoplasms; Reactive Oxygen Species; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Oncogene Protein v-akt; Pancreatic Neoplasms; Reactive Oxygen Species; Ribonucleases; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2015 |
Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Cytokines; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Treatment Outcome; Vaccination; WT1 Proteins | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2015 |
A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression; Genetic Variation; Hepatocyte Nuclear Factor 1-alpha; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Coculture Techniques; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Proportional Hazards Models; Rats; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factor HES-1 | 2015 |
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clone Cells; Deoxycytidine; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lipoproteins; MAP Kinase Signaling System; Metabolic Networks and Pathways; Mice; Pancreatic Neoplasms; Phenotype; Prognosis; Receptors, LDL; Up-Regulation | 2015 |
[Long-term survivor of unresectable bile duct cancer complicated with sclerosing cholangitis treated with chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans | 2014 |
[A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2014 |
Increased expression of endoplasmic reticulum protein 29 in lung adenocarcinoma is associated with chemosensitivity to gemcitabine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Middle Aged | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
[Promotive effect and its molecular mechanism of KLF5 on gemcitabine-induced apoptosis in human lung adenocarcinoma cell line H441].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; fas Receptor; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Transfection | 2015 |
Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Databases, Factual; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Phenotype; Survival Analysis; Tissue Array Analysis | 2015 |
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Drug Resistance; Fibroblasts; Gemcitabine; Heterografts; Humans; Mice, Nude; Phosphoproteins; Somatostatin; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2015 |
pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tumor Cells, Cultured | 2015 |
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Serum; Survival Analysis; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2016 |
Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Gemcitabine; Genes, Tumor Suppressor; Humans; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Treatment Outcome | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS- Mediated Signalling Pathways.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Capillary Leak Syndrome; Cell Line, Tumor; Cell Survival; Deoxycytidine; Electric Impedance; Flavanones; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Intercellular Adhesion Molecule-1; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; rac1 GTP-Binding Protein; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53; Vascular Cell Adhesion Molecule-1 | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Biomarkers, Pharmacological; Caspases; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Humans; Lung Neoplasms; Quercetin | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthritis; Protein Kinase Inhibitors; Pyrazoles; Pyridines | 2015 |
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Survival Analysis | 2016 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcohol-Related Disorders; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Pneumonia; Retrospective Studies; Risk Factors; Severity of Illness Index; Smoking | 2016 |
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2015 |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Maytansine; Mice; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Interactions; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2016 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
[A Long-Term Survival Case of Unresectable Hilar Bile Duct Cancer Treated with Gemcitabine].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Time Factors; Treatment Outcome | 2015 |
Chemotherapy with Gemcitabine and Cisplatin for Advanced Ductal Adenocarcinoma of the Prostate: Clinical Courses of Two Patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prostatic Neoplasms | 2015 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gelatin; Gemcitabine; Humans; Mice; Mice, SCID; Nanoparticles; Pancreas; Pancreatic Neoplasms | 2016 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lectins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction | 2016 |
Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; S100 Calcium-Binding Protein A4; S100 Proteins | 2015 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2016 |
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Invasiveness; p21-Activated Kinases; Pancreatic Ducts; Pancreatic Neoplasms; Pyridones; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Recurrence; Tegafur | 2015 |
[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Thrombotic Microangiopathies; Treatment Outcome | 2016 |
CEST theranostics: label-free MR imaging of anticancer drugs.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Contrast Media; Deoxycytidine; Drug Delivery Systems; Female; Fluorescence; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Theranostic Nanomedicine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sp Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2016 |
Massive malignant pleural effusion due to lung adenocarcinoma in 13-year-old boy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Deoxycytidine; Drainage; Gemcitabine; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Tomography, X-Ray Computed | 2016 |
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Deoxycytidine; DNA Damage; Down-Regulation; Gemcitabine; Genes, Viral; Humans; Irinotecan; MRE11 Homologue Protein; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2016 |
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autoantigens; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gemcitabine; Humans; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Renal Dialysis | 2017 |
Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Immunohistochemistry; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survival Analysis; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2016 |
A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Creatinine; Deoxycytidine; Diagnosis, Differential; Erythema; Exanthema; Female; Gemcitabine; Humans; Leg; Leukocytosis; Middle Aged; Pancreatic Neoplasms; Withholding Treatment | 2017 |
Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dodecanol; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Propane; Pyridines; Signal Transduction | 2016 |
Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; China; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Janus Kinase 2; Mice; Mutation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT3 Transcription Factor | 2016 |
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2016 |
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immune Tolerance; Lectins, C-Type; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Necrosis; Pancreatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2016 |
Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle.
Topics: Adenocarcinoma; Adult; Albumins; Ampulla of Vater; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Heart Ventricles; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2016 |
Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction | 2016 |
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; p21-Activated Kinases; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2016 |
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
The combination use of 1-O-acetylbritannilactone (ABL) and gemcitabine inhibits cell growth and induces cell apoptosis in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; I-kappa B Proteins; Lactones; Lung Neoplasms; Signal Transduction | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays | 2016 |
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
Topics: Adenocarcinoma; Aged; Angiopoietin-Like Protein 4; Angiopoietins; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; ROC Curve; Sequence Analysis, RNA; Survival Analysis; Time Factors | 2016 |
P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; E1A-Associated p300 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering | 2016 |
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Macrophage-Activating Factors; Male; Pemetrexed; Treatment Outcome; Ultrasonic Therapy; Vitamin D-Binding Protein | 2016 |
Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Deoxycytidine; Electrochemotherapy; Gemcitabine; Immunocompromised Host; Mice; Mice, Nude; Pancreatic Neoplasms | 2016 |
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; Metformin; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tissue Array Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carbodiimides; Cell Line, Tumor; Chemistry Techniques, Synthetic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoglobulin G; Immunoglobulins; Lung Neoplasms; Polymerization; Receptor, IGF Type 1 | 2017 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis | 2016 |
Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2017 |
[The poor chemotherapeutic efficacy in lung adenocarcinoma overexpressing c-Src and nucleophosmin/B23(NPM1)].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cisplatin; CSK Tyrosine-Protein Kinase; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; src-Family Kinases; Treatment Outcome | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Intraoperative Care; Laparotomy; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Receptor, Notch1; Receptor, Notch3 | 2016 |
Unstable Angina: A Serious Adverse Event following Gemcitabine-Cisplatin Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Angina, Unstable; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male | 2016 |
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Pancreatic Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa | 2016 |
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Topics: Adenocarcinoma; Animals; Apoptosis; Carbolines; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; DNA Damage; Down-Regulation; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Macrophages; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Curcumin; Deoxycytidine; Diarylheptanoids; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Pancreatic Neoplasms; Prohibitins; Protein Deglycase DJ-1; Protein Interaction Maps; Repressor Proteins; RNA Interference; Signal Transduction; Transcription Factor CHOP; Transfection | 2016 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |
Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Function Tests; Male; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Treatment Outcome | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Rate | 2017 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Topics: Adenocarcinoma; Animals; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Models, Theoretical; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Transfection | 2017 |
Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreas; Pancreatic Neoplasms; Sonication; Ultrasonography | 2016 |
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Consensus Development Conferences as Topic; Deoxycytidine; Disease Management; Gemcitabine; Humans; Latin America; Pancreatic Neoplasms; Practice Guidelines as Topic | 2016 |
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Interleukin-18; L-Lactate Dehydrogenase; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2017 |
[Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Long-Term Survival in Response to Multimodality Therapy in a Patient with Invasive Pancreatic Cancer with Cyst Formation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cysts; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2016 |
[A Case of Locally Advanced Gallbladder Cancer That Developed Early Multiple Liver Metastasis after Curative Resection, and Achieved Long-TermPartial Remission Using S-1 and Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[Two Year Recurrence Free Survival after Resection of Cutaneous Metastasis from Pancreatic Cancer - A Case Report].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Recurrence; Skin Neoplasms; Thalamus; Time Factors | 2016 |
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Microdissection; MicroRNAs; Pancreatic Neoplasms; Prognosis; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
Topics: Adenocarcinoma; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chickens; Chorioallantoic Membrane; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Drug Evaluation, Preclinical; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 6; Luminescent Measurements; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Sequence Analysis, DNA; SOX9 Transcription Factor; Tumor Cells, Cultured | 2017 |
Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatic Neoplasms; Survival Analysis | 2008 |
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Genetic Vectors; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Biosynthesis; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Uridine; Xenograft Model Antitumor Assays | 2008 |
siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Pancreatic Neoplasms; Plasmids; RNA, Small Interfering; Survivin; Transfection | 2009 |
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Taxoids | 2008 |
Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2008 |
Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tegafur; Treatment Outcome | 2009 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Down-Regulation; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proteins; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Research Design | 2008 |
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin | 2008 |
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Deoxycytidine; Duodenitis; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Pancreatic Neoplasms; Radiodermatitis; Stomach Ulcer | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Europe; Fluorouracil; Gemcitabine; Humans; Incidence; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; United States | 2008 |
A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Digestive System Surgical Procedures; Drug Administration Schedule; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2009 |
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; CA-19-9 Antigen; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Immunologic Factors; Middle Aged; Pancreatic Neoplasms; Plasmapheresis; Retrospective Studies; Rituximab; Vincristine | 2009 |
Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2008 |
Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Time Factors | 2009 |
Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Topics: Adenocarcinoma; Adenoviridae; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Deletion; Genetic Therapy; Genetic Vectors; Humans; Immunoblotting; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S Phase; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
[Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tandem Mass Spectrometry | 2009 |
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Humans; Logistic Models; Male; Mass Spectrometry; Middle Aged; Neutropenia; Pancreatic Neoplasms; Phenotype; Thrombocytopenia | 2009 |
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Survivors | 2009 |
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Interphase; Ligands; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms; Receptors, sigma; Survival Analysis | 2009 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Interferons; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2009 |
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Prostatic Neoplasms; Splenic Neoplasms; Transplantation, Heterologous | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation Tolerance; tat Gene Products, Human Immunodeficiency Virus; Thiolester Hydrolases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromosome Mapping; Chromosomes, Human; Chromosomes, Human, X; Comparative Genomic Hybridization; Deoxycytidine; Drug Resistance; Gemcitabine; Genetic Variation; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome | 2009 |
Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Tumor Stem Cell Assay; Vorinostat | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positive T-Lymphocytes; Cisplatin; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-12 Subunit p40; Killer Cells, Lymphokine-Activated; Lipopolysaccharides; Liver Neoplasms; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects; Prognosis; Survival Rate; T-Lymphocytes; Treatment Outcome | 2009 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lenalidomide; Pancreatic Neoplasms; Thalidomide | 2010 |
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Taxoids | 2009 |
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Cholecystectomy; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fallopian Tubes; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Testosterone; Tomography, X-Ray Computed; Ultrasonography | 2009 |
Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Vorinostat | 2009 |
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia | 2010 |
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Proteins; Ultrasonography | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Uracil | 2009 |
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Perfusion; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Treatment Outcome | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Treatment Outcome | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Probability; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Survival Analysis | 2009 |
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
[Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Remission Induction; Survival Rate | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2009 |
Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bayes Theorem; Bevacizumab; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Models, Statistical; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Research Design | 2009 |
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; G1 Phase; Gemcitabine; Humans; MicroRNAs; Oligonucleotides, Antisense; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2009 |
Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Pancreatic Neoplasms | 2009 |
The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lectins, C-Type; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Pancreatitis-Associated Proteins | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
Topics: 5'-Nucleotidase; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Suppressor Proteins | 2010 |
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Neoplasm Metastasis | 2010 |
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Resveratrol; Stilbenes; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
A case of unresectable gallbladder cancer responding to gemcitabine after metallic biliary stent implantation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drainage; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Metals; Radiography; Stents | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura).
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Omentum; Pancreas; Peritoneal Neoplasms; Purpura, Thrombotic Thrombocytopenic | 2010 |
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Proteomics; Spectrometry, Mass, Electrospray Ionization; Survival Rate; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2010 |
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Treatment Outcome | 2010 |
[The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy | 2009 |
[A case of long-term survival for advanced gallbladder cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged | 2009 |
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Nucleoside Deaminases; Pancreatic Neoplasms; Tetrahydrouridine; Transfection; Up-Regulation | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Early Detection of Cancer; Endosonography; Fluorouracil; Gemcitabine; Humans; Jejunostomy; Laparoscopy; Magnetic Resonance Imaging; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Italy; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Gemcitabine; Histones; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2010 |
Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Division; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; G2 Phase; Gemcitabine; Gene Silencing; Humans; Integrins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2010 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2010 |
Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucin-4; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Improved survival of left-sided pancreas cancer after surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2010 |
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Microbial Sensitivity Tests; Microtubules; Molecular Chaperones; Paclitaxel; Transfection; Tubulin; Tubulin Modulators; Vinblastine; Vinorelbine | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2011 |
Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoblotting; Interleukin-8; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT3 Transcription Factor | 2010 |
First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 2010 |
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; DNA Repair; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase; Gamma Rays; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Ovarian metastasis following gallbladder carcinoma: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Incidental Findings; Lymph Node Excision; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Treatment Outcome | 2010 |
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Reversible neuropathy after chemotherapy for metastatic adenocarcinoma from an unknown primary tumor to the sural nerve.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Peripheral Nervous System Neoplasms; Polyneuropathies; Sural Nerve | 2011 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Complications; Radiotherapy, Adjuvant | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom | 2010 |
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Cisplatin plus gemcitabine for biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Neoplasms, Squamous Cell; Pemetrexed | 2010 |
Survival analysis of pancreatic and periampullary collision cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Dermatitis; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Injections, Intradermal; Liver Neoplasms; Lymphocytes; Nuclear Proteins; Palliative Care; Radiotherapy, Adjuvant; RNA Splicing Factors; Skin | 2010 |
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
[Vertigo as a symptom of psychosocial pain].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hospices; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quality of Life; Radiotherapy, Adjuvant; Sick Role; Social Isolation; Somatoform Disorders; Vertigo | 2010 |
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; Humans; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
[A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Staging; Radiography; Renal Dialysis | 2010 |
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Biomarkers, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; ELAV Proteins; ELAV-Like Protein 2; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Microarray Analysis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Finding the tumor copycat: approximating a human cancer.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Division; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Neoplasms | 2010 |
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Endothelium, Vascular; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shiga Toxins; Signal Transduction; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Adenosquamous; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy | 2010 |
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Cancer Vaccines; CD11b Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genetic Vectors; Inhibitor of Apoptosis Proteins; Interferon-gamma; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Peptide Library; Receptors, Cell Surface; Remission Induction; Repressor Proteins; Survivin; Vaccination; Vaccinia virus | 2011 |
Treatment effect or secret nature: long-term remissions in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Evaluation of the effectiveness of a chemoprevention model of pancreatic adenocarcinoma using protein chip technology.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Chemoprevention; Deoxycytidine; Diagnostic Techniques, Endocrine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2011 |
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bile; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A rare case of thyroid metastasis from pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2011 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms; Radiosurgery | 2010 |
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Tegafur; Treatment Outcome | 2010 |
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Thiocarbamates | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2011 |
The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Cyclin D1; Deoxycytidine; DNA Breaks, Double-Stranded; Drug Therapy, Combination; Gemcitabine; HIV Protease Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2011 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Young Adult | 2011 |
Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunocompromised Host; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Magnetic Resonance Imaging; Male; Tomography, X-Ray Computed | 2011 |
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2011 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Canada; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2011 |
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Connective Tissue Growth Factor; Deoxycytidine; Enzyme Inhibitors; Factor VIIa; Gemcitabine; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Treatment Outcome | 2011 |
Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies; Antigens, Neoplasm; Cancer Vaccines; Cell Adhesion Molecules; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunization; Immunotherapy, Active; Interferon-gamma; Interleukin-10; Macrophages; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Proteins; Recombinant Proteins; Survival Rate; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Vaccines, Virus-Like Particle | 2011 |
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Nanomedicine; Nanoparticles; Pancreas; Pancreatic Neoplasms; Squalene | 2011 |
Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Injections, Intravenous; Mice; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Retrospective Studies | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Cisplatin; Deoxycytidine; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
A man with a testicular mass and a colon stenosis. Diagnosis: Metastatic pancreatic adenocarcinoma to the gonads.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Colonic Diseases; Colonoscopy; Constriction, Pathologic; Deoxycytidine; Endoscopy, Digestive System; Gemcitabine; Humans; Immunohistochemistry; Intestinal Obstruction; Krukenberg Tumor; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed | 2011 |
Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; DNA, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nucleoside-Phosphate Kinase; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Flow Cytometry; Gemcitabine; Humans; Isoflavones; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; CD11b Antigen; Coculture Techniques; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Interferon gamma Receptor; Interferon Type I; Interferon-gamma; Interferons; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Knockout; Myeloid Cells; Neoplasm Proteins; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Phosphorylation; Protein Processing, Post-Translational; Receptors, Cell Surface; Receptors, Interferon; Recombinant Proteins; Spleen; STAT1 Transcription Factor; Tumor Escape | 2011 |
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2011 |
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Silencing; Humans; Irinotecan; MAP Kinase Kinase Kinases; Mice; Mice, Nude; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Radiotherapy; Thigh | 2012 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cytopathogenic Effect, Viral; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Deletion; Gene Expression Regulation, Viral; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Virus; Retinoblastoma Protein; Virus Replication; Xenograft Model Antitumor Assays | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Therapy, Combination; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines | 2011 |
Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hand; Humans; Ischemia; Middle Aged; Ovarian Neoplasms | 2011 |
Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models | 2012 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Locally advanced pancreatic cancer: where should we go from here?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2011 |
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Triazines | 2012 |
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Heat-Shock Proteins; Heat-Shock Response; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Chaperones; Multivariate Analysis; Pancreas; Prognosis; Tissue Array Analysis | 2012 |
Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Tumor Burden | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2011 |
HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Cell Line, Tumor; Deoxycytidine; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Transfection; Xenograft Model Antitumor Assays | 2012 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Pancreaticoduodenectomy with resection of the splenic artery and splenectomy for pancreatic double cancers after total gastrectomy. Preservation of the pancreatic function via the blood supply from the posterior epiploic artery: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Deoxycytidine; Gastrectomy; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Splenectomy; Splenic Artery; Stomach Neoplasms | 2012 |
Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genes, Reporter; Hedgehog Proteins; Humans; Mice; Mice, Nude; Middle Aged; Mutation; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Signal Transduction; Time Factors; Transcription Factors; Transfection; Tumor Burden; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Proportional Hazards Models; Tegafur | 2012 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Radiotherapy: the importance of local control in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Smad4 Protein | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Genome-Wide Association Study; Humans; Interleukin-17; Kaplan-Meier Estimate; Linkage Disequilibrium; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2012 |
Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Statistics, Nonparametric; Tegafur | 2012 |
Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Exodeoxyribonucleases; Gemcitabine; Humans; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RecQ Helicases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Werner Syndrome Helicase | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate | 2012 |
[An operated case of metastasis to the small intestine from lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Jejunal Neoplasms; Lung Neoplasms; Male; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Ribonucleotide Reductases | 2012 |
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2012 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Survival Rate | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Unprecedented case of tumor lysis syndrome in a patient with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Tumor Lysis Syndrome | 2012 |
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2012 |
Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Brucea; Camptothecin; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; Drugs, Chinese Herbal; Gemcitabine; Hepatocytes; Humans; Membrane Potential, Mitochondrial; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quassins; Stem Cells | 2012 |
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Membrane Transport Proteins; Middle Aged; Models, Biological; Mucin-4; Multigene Family; Pancreatic Neoplasms | 2013 |
Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Hepatectomy; Humans; Immunohistochemistry; Male; Middle Aged; Pancreaticoduodenectomy; Prognosis; Survival Analysis | 2012 |
Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasms; Prodrugs | 2012 |
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Treatment Outcome | 2012 |
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hemorrhage; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pulmonary Embolism; Retrospective Studies; Risk Factors; Survival Rate | 2012 |
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Outcome Assessment; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Symptom Assessment | 2013 |
Gemcitabine associated pseudocellulitis.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Follow-Up Studies; Gemcitabine; Humans; Lower Extremity; Male; Pancreatic Neoplasms; Risk Assessment | 2012 |
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering | 2012 |
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Paraneoplastic Raynaud's phenomenon manifesting before the diagnosis of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Raynaud Disease | 2012 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid | 2012 |
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2013 |
Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pharmacogenetics | 2012 |
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chlortetracycline; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2012 |
Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivors | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Random Allocation; Terpenes; Xenograft Model Antitumor Assays | 2013 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Survival Analysis | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cisplatin; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Translocation, Genetic | 2012 |
Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Gene Frequency; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Survival Rate | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms | 2013 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Movement; Cell Proliferation; Cyclohexanones; Deoxycytidine; Disease Models, Animal; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Interleukin-8; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survivin; Up-Regulation | 2013 |
Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
Topics: Adenocarcinoma; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Hemorrhage; Time Factors; Treatment Outcome | 2013 |
Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Humans; Immunohistochemistry; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Plasmids; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2012 |
Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Survival Rate; Young Adult | 2012 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Achieving the best of both worlds.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Quality of Life | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gem
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Observation; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Prospective Studies; Treatment Outcome | 2013 |
Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Survival Rate | 2013 |
Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Differentiation Protein 1; Kaplan-Meier Estimate; Mice; Mice, SCID; Nicotine; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcription, Genetic | 2012 |
ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with gemcitabine and cisplatin].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pneumonectomy | 2002 |
[Renal toxicity with a gemcitabine-cisplatin combination in lung cancer].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Lung Neoplasms; Male | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retreatment | 2002 |
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
[Weekly administration of gemcitabine in outpatient clinic for non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Ambulatory Care Facilities; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Palliative Care | 2003 |
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Gemcitabine; Humans; Life Tables; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2002 |
Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA, Neoplasm; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; HeLa Cells; Humans; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nucleosomes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Rats; Rats, Wistar; Tumor Virus Infections; Uterine Cervical Neoplasms | 2003 |
Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Infusions, Intravenous; Lung Neoplasms; Male; Models, Animal; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Morpholines; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2003 |
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Division; Cetuximab; Cobalt Radioisotopes; Deoxycytidine; Electrophoresis, Polyacrylamide Gel; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; GRB2 Adaptor Protein; Humans; Immunosorbent Techniques; Iodine Radioisotopes; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
[Combination therapy with vinorelbine and gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2003 |
[Effective treatment with the additional administration of UFT for refractory malignant pleural effusion secondary to adenocarcinoma of the lung after the treatment regimen of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Tegafur; Uracil; Vinblastine; Vinorelbine | 2003 |
It's what's inside that counts.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms | 2003 |
[A case of advanced pancreatic cancer treated with gemcitabine hydrochloride].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2003 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
[A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Karnofsky Performance Status; Liver Neoplasms; Pancreatic Neoplasms | 2003 |
Pharmacokinetics after pulmonary artery perfusion with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Gemcitabine; In Vitro Techniques; Lung; Lung Neoplasms; Male; Pulmonary Circulation; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2003 |
Fatal cholestatic liver failure associated with gemcitabine therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver; Liver Failure, Acute; Liver Neoplasms; Middle Aged; Necrosis | 2003 |
Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fingers; Gangrene; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Iloprost; Male; Middle Aged; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Vasodilator Agents | 2003 |
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiodermatitis | 2003 |
[Gemcitabine infusion via splenic artery for advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Pancreatic Neoplasms; Quality of Life; Remission Induction; Splenic Artery | 2003 |
A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA; RNA Interference; RNA, Small Interfering; Transfection | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Time Factors; Transplantation, Heterologous | 2004 |
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine; DNA Methylation; Fluorouracil; Gemcitabine; Genes, p16; Genes, p53; Genes, ras; Humans; Immunophenotyping; Interferon-gamma; Karyotyping; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Ploidies; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Flow Cytometry; Gemcitabine; Lipopeptides; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligopeptides; Pancreas; Pancreatic Neoplasms; Spleen; Survival Analysis; Ultrasonography | 2004 |
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
Right pneumonectomy for adenocarcinoma stage IIIA-N2 in a heart transplant patient after induction chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Heart Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Ribonucleotide Reductases | 2004 |
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Cell Line, Tumor; Clusterin; Coloring Agents; Deoxycytidine; DNA; DNA Fragmentation; Dose-Response Relationship, Drug; Gemcitabine; Glycoproteins; Humans; Immunohistochemistry; In Vitro Techniques; Lung Neoplasms; Mice; Molecular Chaperones; Nucleotides; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Double-Stranded; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Ribonucleoside Diphosphate Reductase; src-Family Kinases; Transcription Factors; Tyrosine | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Pancreatic Neoplasms; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Heart Neoplasms; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction | 2004 |
A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Caspase 3; Caspases; Cell Adhesion Molecules; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Cytochromes c; Deoxycytidine; Drug Resistance, Viral; Enzyme Activation; Gemcitabine; Gene Silencing; GPI-Linked Proteins; Humans; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; src-Family Kinases; Transfection | 2004 |
[Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Vincristine | 2004 |
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Small Interfering; src-Family Kinases; Tumor Cells, Cultured | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms | 2004 |
Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Tumor Cells, Cultured; Vesicular stomatitis Indiana virus | 2004 |
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Incidence; Lymphoma; Male; Middle Aged | 2005 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fibrosis; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2003 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Dipyridamole; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2004 |
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Retrospective Studies; Survival Analysis; Time Factors | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gemcitabine; Genes, erbB; Humans; Immunoblotting; Mice; Pancreatic Neoplasms; Phosphorylation; Rabbits; Radiation-Sensitizing Agents; Receptor, ErbB-4; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Coronary Artery Disease; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Failure; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema | 2004 |
[Cisplatin schedule in combination with gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Length of Stay; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia | 2005 |
[A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Survivors | 2005 |
[Local recurrence of pancreatic cancer successfully treated with gemcitabine].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antimetabolites, Antineoplastic; B-Lymphocytes; CD4-CD8 Ratio; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; T-Lymphocytes | 2005 |
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Topics: Adenocarcinoma; Adenovirus E1A Proteins; Adenoviruses, Human; Animals; Antiviral Agents; Bone Marrow Cells; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genetic Therapy; Liver; Mice; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Virus Replication | 2005 |
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinases; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Serine; Transfection | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enkephalin, Methionine; Fluorouracil; Gemcitabine; Growth Substances; Humans; Male; Mice; Mice, Nude; Naloxone; Narcotics; Pancreatic Neoplasms; Receptors, Opioid; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiotherapy; Smoking; Tomography, X-Ray Computed | 2005 |
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Male; Melphalan; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2005 |
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; beta-Galactosidase; Colorimetry; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2005 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Protein Subunits; Ribonucleotide Reductases; Up-Regulation | 2005 |
Predictive value of heparanase expression in the palliative therapy of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Biomarkers; Deoxycytidine; Female; Gemcitabine; Germany; Glucuronidase; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2005 |
[An orbital metastasis as the presentation of lung adenocarcinoma].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gadolinium; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Orbit; Orbital Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
[Experience of gemcitabine therapy after non-curative resection for biliary tract cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Edema; Furosemide; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisolone; Spironolactone | 2005 |
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinases; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2006 |
[An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatic Neoplasms | 2005 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
[Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Survivors | 2006 |
Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Lung; Lung Neoplasms; Male; Random Allocation; Rats; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
Topics: Adenocarcinoma; Animals; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Targeting oncogenes to improve breast cancer chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Gene Expression; Genes, myc; Humans; Molecular Sequence Data; Oligonucleotides; Transcription, Genetic | 2006 |
Primary carcinoid tumour of the pancreas.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diagnostic Errors; Gemcitabine; Humans; Liver Neoplasms; Liver Transplantation; Male; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction | 2006 |
Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cerebellar Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2006 |
Intramedullary metastases due to non microcytic lung carcinoma.
Topics: Adenocarcinoma; Bone Marrow Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Docetaxel; Frontal Lobe; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Taxoids; Thoracic Vertebrae; Vinblastine; Vinorelbine | 2006 |
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Deoxycytidine; DNA Topoisomerases; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Topoisomerase Inhibitors; Treatment Outcome | 2006 |
Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brain Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin | 2006 |
Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Staging; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Malignant acanthosis nigricans and tripe palms associated with pancreatic adenocarcinoma.
Topics: Acanthosis Nigricans; Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Hand Dermatoses; Humans; Pancreatic Neoplasms | 2006 |
Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion.
Topics: Adenocarcinoma; Antineoplastic Agents; Cardiac Tamponade; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Instillation, Drug; Lung Neoplasms; Middle Aged; Mitomycin; Pericardial Effusion; Recurrence | 2006 |
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9 | 2006 |
Combined gemcitabine and alpha-interferon therapy for pancreatic cancer: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Interferon-alpha; Liver Neoplasms; Male; Pancreatic Neoplasms | 2006 |
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; O-(Chloroacetylcarbamoyl)fumagillol; Protein Structure, Tertiary; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
[A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pleural Effusion, Malignant; Tomography, X-Ray Computed | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning.
Topics: Adenocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Imaging, Three-Dimensional; Lymph Nodes; Lymphatic Vessels; Male; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiography, Abdominal; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms | 2006 |
[A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survivors; Tegafur; Uracil | 2006 |
An unusual case of gemcitabine-induced radiation recall.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiodermatitis | 2006 |
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity Syndromes; Pleural Neoplasms | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Choroid Neoplasms; Deoxycytidine; Drug Resistance; Eye Enucleation; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Orbital Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Sclera | 2007 |
Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Medicine, Chinese Traditional; Middle Aged | 2007 |
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
[A case of lung adenocarcinoma with Marie-Bamberger syndrome that improved by chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthropathy, Secondary Hypertrophic; Remission Induction | 2007 |
Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2007 |
Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cancer Vaccines; Cell Proliferation; Chickens; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 1; Gemcitabine; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Recombinant Proteins; Survival Rate | 2007 |
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Reactive Oxygen Species | 2007 |
Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2007 |
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Deoxycytidine; Dioxolanes; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Treatment Outcome; Tritium; Tumor Cells, Cultured; Uridine; Xenograft Model Antitumor Assays | 2007 |
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Microscopy, Electron; Vinblastine | 2007 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2007 |
Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Deoxycytidine; Drug Synergism; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Mycophenolic Acid; Pancreatic Neoplasms; Sirolimus | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: a case treated with gemcitabine.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Skin Neoplasms | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2008 |
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Calcium Gluconate; Deoxycytidine; Diphenhydramine; Female; gamma-Aminobutyric Acid; Gemcitabine; Histamine H1 Antagonists; Humans; Magnesium Sulfate; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pregabalin; Psychomotor Agitation | 2008 |
Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms | 2007 |
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fatty Acids, Omega-3; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured | 2007 |
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gastrins; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Cholecystokinin B; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Mice; Mice, SCID; Oncolytic Virotherapy; Ovarian Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
[A long-term survivor case with good quality of life due to biliary bypass and gemcitabine for advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survivors | 2007 |
Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Agents; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Middle Aged; Prostatic Neoplasms | 2007 |
Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromones; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Gemcitabine; Humans; MAP Kinase Signaling System; Morpholines; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2008 |
[A case undergoing repeated anaphylactic shock after systemic administration of vinorelbine].
Topics: Adenocarcinoma; Anaphylaxis; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Food Hypersensitivity; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pistacia; Vinblastine; Vinorelbine | 2007 |
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2008 |
[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Deoxycytidine; Edema; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2007 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Platinum Compounds; Tomography, X-Ray Computed | 2007 |
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Enzyme Activation; Fibroblasts; Gemcitabine; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Stromal Cells | 2008 |
Recombinant human endostatin-associated acute left heart failure.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Dyspnea; Endostatins; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Receptor, ErbB-2; Recombinant Proteins | 2008 |
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Genetic Vectors; Humans; Inverted Repeat Sequences; Mice; Mice, Nude; Molecular Sequence Data; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Specific Pathogen-Free Organisms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
An iatrogenic hepatic subcapsular biloma successfully treated by percutaneous drainage and endoscopic biliary stenting.
Topics: Adenocarcinoma; Aged; Bile; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drainage; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Iatrogenic Disease; Magnetic Resonance Imaging; Male; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy | 2008 |
Gemcitabine resistance in pancreatic cancer: picking the key players.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms | 2008 |
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; HMGA1a Protein; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Tumor Cells, Cultured | 2008 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Weight Loss | 2007 |
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Gold; Humans; Immunoconjugates; Metal Nanoparticles; Pancreatic Neoplasms | 2008 |
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Nitrobenzenes; Sulfonamides; Up-Regulation | 2008 |
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Tegafur | 2008 |
Protein kinase C: a target for therapy in pancreatic cancer.
Topics: Adenocarcinoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Pancreatic Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Reference Values | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyglucose; Fluorodeoxyglucose F18; Gemcitabine; In Vitro Techniques; Male; Prostatic Neoplasms; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured | 1994 |
Gemcitabine for treatment of pancreatic cancer.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 1996 |
PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Deoxyglucose; DNA, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Male; Neoplasm Transplantation; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Ribonucleotide Reductases; Thymidine; Tomography, Emission-Computed; Tritium; Tumor Cells, Cultured | 1997 |
[Disseminated intravascular coagulation (DIG) with massive hyperfibrinolysis in metastatic uterine cancer. Observations on the effects on the coagulopathy of various treatments (a case report)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Disseminated Intravascular Coagulation; Endometrial Neoplasms; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Gemcitabine; Humans; Middle Aged; Thrombolytic Therapy; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1998 |
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, Inbred ICR; Mice, SCID; Oligopeptides; Pancreatic Neoplasms; Transplantation, Heterologous | 1998 |
Unresectable pancreatic adenocarcinoma treated with palladium-103 implant and chemoradiation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Brachytherapy; Deoxycytidine; Fatal Outcome; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palladium; Pancreatic Neoplasms; Radioisotopes; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1998 |
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Middle Aged; Pleural Neoplasms; Prednisolone; Ribonucleotide Reductases; Treatment Outcome | 1998 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Oligopeptides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Heart; Humans; Liver Neoplasms; Lung; Male; Pancreatic Neoplasms; Respiratory Distress Syndrome; Ventricular Fibrillation | 1999 |
Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Topics: 3T3 Cells; Adenocarcinoma; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Division; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Farnesyltranstransferase; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Structure; Oligopeptides; Paclitaxel; rap1 GTP-Binding Proteins; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Bryostatins; Deoxycytidine; DNA Mutational Analysis; Ethers, Cyclic; Gemcitabine; Genes, p53; Genes, ras; Humans; Karyotyping; Lactones; Macrolides; Male; Mice; Mice, SCID; Neoplasm Transplantation; Oligopeptides; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Needle; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis; Ribonucleotide Reductases | 1999 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Incidence; Liver; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Retrospective Studies; Stents | 2000 |
Gemcitabine and the blood brain barrier.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1999 |
Severe acute lung injury induced by gemcitabine.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung; Lung Injury; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema; Severity of Illness Index | 2000 |
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
Solitary cutaneous metastasis on the buttock: a disclosing sign of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Buttocks; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Skin Neoplasms | 2000 |
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Atrial Fibrillation; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2000 |
[Splenic vascular occlusion in the course of pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Infarction; Middle Aged; Pancreatic Neoplasms; Spleen; Tomography, X-Ray Computed | 2000 |
Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Nude; Mitomycin; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Paclitaxel; Statistics, Nonparametric | 2000 |
Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contracture; Deoxycytidine; Drug Interactions; Edema; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisone; Ribonucleotide Reductases | 2000 |
Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Arabinonucleosides; Bromodeoxyuridine; Catalysis; Cell Division; Cell Nucleus; Cladribine; Cytarabine; Deoxycytidine; Drosophila melanogaster; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Osteosarcoma; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Promoter Regions, Genetic; Retroviridae; Substrate Specificity; Thymidine; Thymidine Kinase; Transduction, Genetic; Tumor Cells, Cultured | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Urinary Tract Infections | 2000 |
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Adenocarcinoma; Androstadienes; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Wortmannin | 2000 |
[A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Fatal pulmonary veno-occlusive disease possibly related to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Veno-Occlusive Disease | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Neoadjuvant chemoradiation treatment of locally advanced adenocarcinoma of the duodenum.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Duodenal Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
[Efficacy of gemcitabine in the gallbladder cancer. Initial experience in 4 cases].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
[Non-small cell lung cancer with liver metastasis responsive to gemcitabine--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Arabidopsis Proteins; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspases; Computer Systems; Deoxycytidine; Fas Ligand Protein; fas Receptor; Fatty Acid Desaturases; Flow Cytometry; Gemcitabine; GPI-Linked Proteins; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Receptors, Tumor Necrosis Factor, Member 6b; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis | 2001 |
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Nude; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2001 |
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Alitretinoin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Tretinoin; Tumor Cells, Cultured | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Gemcitabine; Infusions, Parenteral; Intraoperative Care; Male; Neoplasm Seeding; Peritoneal Neoplasms; Postoperative Care; Rats; Rats, Wistar | 2002 |
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2002 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Selection; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2001 |
In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flow Cytometry; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; In Situ Nick-End Labeling; Pemetrexed; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; DNA Replication; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; G1 Phase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, Dominant; Genes, p53; Humans; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
[Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quality of Life; Vinblastine; Vinorelbine | 2002 |
Severe pulmonary toxicity in a patient treated with gemcitabine.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male | 2002 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |